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                                                                                                ABSTRACT 
 
 
 
Cholesterol has a crucial role in central nervous system physiology and cell 
signaling, and many studies correlate alterations in brain cholesterol homeostasis with 
neurodegenerative diseases. The CYP46A1 gene codes for the cholesterol 24-
hydroxylase (CYP46A1), a cytochrome P450 specifically expressed in neurons, that is 
responsible for the majority of brain cholesterol turnover. However, despite its 
physiological importance, the molecular mechanisms underlying the human CYP46A1 
expression had not been characterized. Therefore, our work aimed to identify regulatory 
elements and factors involved the CYP46A1 brain-specific expression, and further 
assess if CYP46A1 transcription is regulated by epigenetic modifications, such as DNA 
methylation. Moreover, we aimed to identify a human cell model that could be a 
valuable tool for the study of cholesterol homeostasis in human neurons.  
In our initial studies, we cloned and characterized the human CYP46A1 promoter. 
Functional deletion analysis, over-expression studies, site-directed mutagenesis and gel-
shift assays identified that not only Sp transcription factors control CYP46A1 
transcription, but are most probably responsible for cell type specificity. To test our 
hypothesis that an increase in the (Sp3+Sp4)/ Sp1 ratio would result in CYP46A1 
transcriptional activation, we differentiated Ntera2/clone D1 (NT2) human 
teratocarcinoma cells into post-mitotic neurons (NT2N). We demonstrated for the first 
time a significant increase in CYP46A1 mRNA and protein levels in a human cell 
culture, and identified a concomitant decrease in the levels of Sp1 associated with the 
proximal promoter of this gene. Nevertheless, we did not observe any conserved pattern 
in Sp protein binding to other Sp-regulated gene promoters, suggesting that Sp-DNA 
binding and transcriptional activity is highly dependent on the neuronal chromatin 
context. Moreover, we showed that throughout NT2 differentiation, HMG-CoA 
Abstract 
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synthase, HMG-CoA reductase, SREBP2 and LDLr, key players in brain cholesterol 
homeostasis, present expression profiles that mimic what is thought to occur in vivo. 
Our results also suggest that progenitor cells eliminate cholesterol in the form of 27-
hydroxycholesterol while neurogenesis induces a shift to the 24-hydroxylase-dependent 
elimination pathway. Finally, we showed that the demethylating agent 5’-Aza-2’-
deoxycytidine (DAC) is a CYP46A1 inducer. Surprisingly, bisulfite sequencing analysis 
revealed that the CYP46A1 core promoter is completely unmethylated in both human 
brain and non-neuronal human tissues where CYP46A1 is not expressed. We 
demonstrated that DAC induces CYP46A1 expression, in a DNA methylation- 
independent mechanism, by decreasing Sp3/HDAC binding to the proximal promoter.  
Collectively, our results provide new insights on the regulatory circuits that control 
CYP46A1 transcription, and contribute to the identification of potential therapeutic 
approaches that can modulate CYP46A1 expression.  
 
Keywords: CYP46A1 - Gene regulation - Sp proteins - Brain cholesterol - Alzheimer’s 
disease 
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                                                                                                     RESUMO 
 
 
 
O colesterol é o principal constituinte da mielina, sendo essencial para a estrutura e 
função do sistema nervoso central (CNS). Devido à eficiência da barreira hemato-
encefálica, não existem trocas de colesterol entre as células do encéfalo e a circulação 
sistémica, sendo o metabolismo do colesterol no CNS independente do metabolismo 
deste esterol no resto do organismo. O colesterol necessário ao bom funcionamento do 
CNS é assim produzido in situ, e a sua homeostasia é mantida por um conjunto de 
processos interdependentes, como a síntese, utilização e armazenamento, transporte e 
excreção. 
Recentemente, foi descrita a principal via de eliminação do colesterol do encéfalo, 
que consiste na sua conversão no derivado 24(S)-hidroxicolesterol (24OHC), um 
metabolito mais polar que, ao contrário do colesterol, tem a capacidade de atravessar a 
barreira hemato-encefálica. Uma vez na corrente sanguínea este esterol é transportado 
para o fígado, onde pode ser novamente metabolizado, e finalmente eliminado do 
organismo. Estima-se que esta via de eliminação seja responsável por cerca de dois 
terços da excreção do colesterol em excesso do encéfalo. O enzima responsável pela 
conversão do colesterol em 24OHC, o CYP46A1, pertence à superfamília dos 
citocromos P450 e é exclusivamente expresso nos neurónios. Apesar da sua 
importância, os mecanismos moleculares subjacentes à expressão específica de tecido 
do CYP46A1 ainda estão pouco explorados, desconhecendo-se se a transcrição deste 
gene é modulada por sinais endógenos ou exógenos. Como tal, o trabalho aqui 
apresentado teve como objectivos a identificação dos elementos e factores de 
transcrição envolvidos na expressão basal e específica de tecido do CYP46A1, 
nomeadamente o papel específico da família de factores de transcrição Sp, bem como a 
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identificação de um modelo celular humano que permitisse, em particular, estudos de 
regulação da expressão do CYP46A1, e de um modo mais geral, a compreensão dos 
mecanismos celulares de regulação da homeostasia do colesterol em neurónios pós-
mitóticos. Finalmente caracterizámos igualmente o papel da metilação do DNA, na 
expressão específica de neurónios do CYP46A1. 
Na primeira fase do trabalho clonámos e caracterizámos a região 5’ adjacente do 
gene CYP46A1 humano. A análise funcional do promotor permitiu identificar a região 
-236/-64, como sendo indispensável para a expressão basal deste gene. Uma vez que 
uma análise bioinformática revelou a presença, no promotor, de dez potenciais sítios de 
ligação para os factores de transcrição da família Sp, fomos investigar o papel destas 
proteínas na regulação da transcrição do CYP46A1. Ensaios de sobre-expressão, 
mutagénese dirigida e ensaios do desvio de mobilidade electroforética (EMSA), 
permitiram não só identificar os factores de transcrição da família Sp, como 
responsáveis pela actividade basal do promotor CYP46A1, bem como sugerir que a 
ligação preferencial das proteínas Sp3 e Sp4 seria responsável pela expressão específica 
nos neurónios. De facto, a cotransfecção de vectores de expressão que codificam para 
Sp3 e Sp4 promovem uma transactivação elevada do promotor, sendo igualmente estas 
proteínas que se ligam aos elementos de resposta Sp presentes no promotor próximo do 
CYP46A1, quando são usados, em ensaios de EMSA, extractos nucleares preparados a 
partir de neurónios corticais de rato. Estes resultados reforçaram o papel destas 
proteínas na regulação do CYP46A1, e levaram-nos a colocar a hipótese de que um 
aumento na razão das proteínas (Sp3+Sp4)/ Sp1 ligadas ao promotor próximo do gene 
poderia ser responsável pela expressão específica de tecido.  
Na tentativa de identificar um bom modelo celular humano para estudos de 
regulação da expressão do CYP46A1, procedemos à diferenciação de células de 
teratocarcinoma embrionário, Ntera2/clone D1 (NT2). Após tratamento de longa 
duração com ácido retinóico, estas células têm capacidade de diferenciar em neurónios 
pós-mitóticos. Verificámos uma indução significativa nos níveis de mRNA e proteína 
CYP46A1 nas fases finais da diferenciação, concomitante com uma diminuição nos 
níveis proteicos de Sp1. Através de ensaios de imunoprecipitação da cromatina (ChIP) 
pudemos avaliar o recrutamento das proteínas Sp para o promotor próximo do 
CYP46A1, tendo sido detectada uma diminuição da ligação do factor de transcrição Sp1, 
após a diferenciação, mantendo-se associados ao promotor níveis idênticos de Sp3 e 
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Sp4. Assim, com este modelo celular foi-nos possível confirmar os resultados obtidos in 
vitro, de que as proteínas Sp3 e Sp4 são os principais factores de transcrição ligados ao 
promotor próximo do CYP46A1, em neurónios pós-mitóticos. Estudámos ainda a 
ligação das proteínas Sp às regiões promotoras dos genes reelina, MOR, GRIN1 e 
GRIN2, que se exprimem em neurónios, e que previamente foram descritos como sendo 
regulados por estes factores de transcrição. Estes estudos permitiram-nos aferir que não 
parece existir um padrão na alteração da ligação das proteínas Sp às regiões promotoras 
de genes de expressão neuronal, sugerindo que, tal como descrito para outros tipos 
celulares, a ligação das proteínas Sp ao DNA depende do contexto estrutural da 
cromatina em cada  região promotora específica.  
Alterações na homeostasia do colesterol no CNS têm sido associadas a diversas 
doenças neurodegenerativas, nomeadamente à doença de Alzheimer. No entanto, pouco 
se sabe sobre os mecanismos que regulam a metabolização do colesterol nos neurónios. 
Isto deve-se em parte ao facto de, até à data, não se conhecer um modelo celular em que 
o gene CYP46A1 fosse expresso em níveis elevados. Como tal, fomos caracterizar o 
perfil de expressão de genes que codificam para proteínas envolvidas na síntese, 
transporte e catabolismo do colesterol, bem como medir os níveis de oxisterois, 
produtos do catabolismo do colesterol, ao longo da diferenciação das células NT2. Os 
nossos resultados demonstraram que os principais intervenientes na manutenção da 
homeostasia do colesterol no encéfalo são expressos nas NT2 diferenciadas, exibindo 
um perfil semelhante ao que se pensa existir in vivo, nomeadamente, verificámos uma 
diminuição dos níveis de expressão dos enzimas HMG-CoA sintase e HMG-CoA 
reductase. Para além disso, pudemos verificar que parece existir nos neurónios pós-
mitóticos uma substituição da via de catabolismo dependente do enzima CYP27A1, 
responsável pela hidroxilação do colesterol na posição 27, para a via da hidroxilação do 
colesterol na posição 24. Os nossos resultados vieram realçar a importância deste 
modelo celular para estudos futuros sobre a homeostasia do colesterol em neurónios 
pós-mitóticos. 
Uma vez que inicialmente verificámos que o promotor do CYP46A1 é muito rico 
em dinucleótidos guanina-citosina (CpG) e está localizado numa ilha CpG, na parte 
final deste trabalho, investigámos o papel da metilação do DNA na regulação da 
expressão deste gene. Estes estudos demonstraram que o fármaco hipometilante 
5’-aza-2’deoxicitidina (DAC) leva a um aumento na expressão do CYP46A1, de um 
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modo independente da desmetilação do promotor próximo, e que o pré-tratamento de 
células de neuroblastoma humano, SH-SY5Y, com este fármaco, potencia o efeito 
activador da expressão do CYP46A1, induzido pelo inibidor das desacetilases de 
histonas – tricostatina A. De facto, após tratamento do DNA genómico com bissulfito 
de sódio, verificámos por sequenciação, que o promotor próximo deste gene se 
apresenta totalmente desmetilado, tanto em tecidos onde este se exprime a níveis 
elevados, como em tecidos onde o mRNA CYP46A1 não é detectado. Através da 
utilização de ensaios de western blot, EMSA e ChIP, pudemos identificar que o 
tratamento com DAC induz uma diminuição dos níveis das proteínas Sp1 e Sp3, e uma 
consequente dissociação das proteínas Sp3 e das desacetilases de histonas 1 e 2 do 
promotor próximo do CYP46A1, concomitante com o aumento da expressão deste gene.  
Em suma, com a realização deste trabalho contribuímos para a caracterização de 
importantes mecanismos moleculares que controlam a expressão do CYP46A1, através 
da identificação da relevância dos factores de transcrição da família Sp, tanto na 
regulação basal deste gene como na resposta ao agente desmetilante DAC. Por outro 
lado, este trabalho possibilitou ainda a identificação de um modelo celular humano para 
o estudo, não só da regulação da transcrição do CYP46A1, mas também do metabolismo 
do colesterol nos neurónios. A descoberta recente de que a sobre-expressão do 
CYP46A1 pode modular os níveis do péptido β-amilóide, aliada ao conhecimento de 
que o aumento dos níveis de 24OHC favorece o processamento não amiloidogénico da 
proteína percursora do péptido β-amilóide, pode ter implicações importantes em 
estratégias terapêuticas futuras que minimizem os danos e a progressão da doença de 
Alzheimer. A caracterização dos mecanismos de regulação do CYP46A1 possibilitam 
ainda o desenvolvimento de possíveis abordagens terapêuticas que possam igualmente 
modular a expressão deste importante enzima do catabolismo do colesterol noutras 
patologias neurodegenerativas.  
 
Palavras-chave: Metabolismo do colesterol no encéfalo - CYP46A1 - Regulação da 
transcrição - Factores de transcrição Sp - Metilação do DNA 
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1.1 Brain Cholesterol 
Cholesterol is essential for the proper functioning of eukaryotic cells, and in the 
central nervous system (CNS) it plays an essential role in myelination (Saher et al. 2005), 
stabilization and organization of axonal microtubules (Fan et al. 2001), dendritic 
differentiation (Fan et al. 2002) and synaptic plasticity (Mauch et al. 2001). Since 
cholesterol plays a pivotal role, there seems to be a physiological imperative to maintain 
constant levels of this important molecule in the CNS (Bjorkhem et al. 2009). 
Outside the CNS, cholesterol homeostasis is maintained by extremely precise 
regulation and coordination of uptake, synthesis and esterification. The cellular 
requirements for this sterol are covered by de novo synthesis and by the uptake of dietary 
cholesterol under the form of lipoprotein-cholesterol complexes from blood circulation 
(Martin et al. 2010). However, cholesterol metabolism in the CNS is distinct from that in 
other tissues (Dietschy & Turley 2004). No uptake of cholesterol from the plasma to the 
brain occurs, as the blood-brain barrier (BBB) prevents the diffusion of large molecules at 
the tight junctions between brain capillary endothelial cells (Bjorkhem & Meaney 2004). 
Two recent studies suggest the existence of mechanisms that can facilitate cholesterol 
uptake from the plasma to the brain, which raises the possibility that brain cholesterol 
metabolism is not completely isolated from the rest of the organism (Karasinska et al. 
2009, Saito et al. 2009). However, these two studies rely on the brain-specific ablation of 
key enzymes in cholesterol synthesis (squalene synthase) and transport (ATP-Binding 
cassette A1 - ABCA1), not reflecting normal brain metabolism. Therefore, virtually all 
the cholesterol necessary to the good functioning of the CNS is thought to be synthesized 
in situ (Dietschy & Turley 2004).  
 
1.1.1 Brain cholesterol synthesis  
The CNS cholesterol is believed to reside in two different pools, the plasma 
membranes of neurons and glial cells and the myelin sheaths. Myelin represents up to half 
of the white matter and since it has been estimated that approximately 70% of all the 
cholesterol in the brain is associated with myelin, it is not surprising that the brain is the 
most cholesterol rich organ in the body (Bjorkhem & Meaney 2004).  
During brain development, it is thought that most of the cholesterol synthesis occurs 
in oligodendrocytes associated with myelin production. As the CNS matures and myelin 
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production decreases, the pool of cholesterol in the CNS reaches a constant value. The 
rate of cholesterol synthesis declines and mainly reflects synthesis in the glial cell and 
neuron compartments (Dietschy & Turley 2004). The cholesterol biosynthetic pathway 
requires more than 20 dedicated enzymes distributed in different organelles, of which the 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, that catalyzes the 
formation of mevalonate, is the major rate-limiting enzyme of this pathway (Brown & 
Goldstein 1980). HMG-CoA reductase activity, which is inhibited by statins, is subject to 
complex regulation, such as the feedback inhibition by high cholesterol through 
transcriptional control via the sterol-regulated element binding protein (SREBP) 
(Goldstein & Brown 1990). This is an energetically expensive and complex pathway that 
has a very elevated cost to the cell (Figure 1.1). 
  
 
 
 
 
 
 
 
 
Supported by the knowledge that astrocytes play important roles in the CNS, such as 
metabolic support for neurons, neuronal survival and differentiation, neuronal guidance, 
neurite outgrowth and synaptogenesis (Verkhratsky & Parpura 2010), and the fact that 
neurons are highly specialized cells responsible for the generation and exchange of 
chemical and electrical signals, Frank Pfrieger (2003) has put forward the hypothesis of a 
cholesterol shuttle between astrocytes and neurons. This hypothesis states that mature 
neurons rely mostly on cholesterol produced by astrocytes, which allows neurons to 
Figure 1.1. Cholesterol pathways in the brain. An abbreviated cholesterol biosynthetic pathway is 
shown where the key enzymes and intermediates are depicted. Double arrows imply multiple reactions. 
Statins reduce the flow of intermediates through the biosynthetic pathway by inhibiting HMG-CoA 
reductase, which is also inhibited by a negative feedback pathway activated by cholesterol. Farnesyl 
diphosphates (farnesyl-PP) are polyisoprenoid end products of the pathway. Catabolism of brain 
cholesterol is mediated by CYP46A1, which converts excess cholesterol into 24S-hydroxycholesterol 
(24OHC). Adapted from Russell et al. 2009. 
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dispense the energetically expensive cholesterol synthesis and focus on chemical 
signaling and the generation of electrical activity (Pfrieger 2003). 
Several studies support the cholesterol shuttle hypothesis. It has been demonstrated 
that purified retinal ganglion cells exhibit little synaptic activity, unless they are co-
cultured with astrocytes (Pfrieger & Barres 1997). Furthermore, two studies showed that 
astrocytes increase the number of mature and functional synapses of neurons by sevenfold 
and are required for synaptic maintenance in vitro (Nagler et al. 2001, Ullian et al. 2001). 
In these studies, a soluble glia-derived signal was found to induce synapse formation, and 
this was later identified as the apolipoprotein E (apoE). However, recombinant apoE 
failed to induce synapse formation in neurons. Since apoE containing lipoproteins are 
cholesterol carriers, Mauch and co-workers (2001) added cholesterol to the cultured 
neurons and demonstrated that cholesterol by itself induced almost the same number of 
synapses as those induced by astrocyte-conditioned medium. These results demonstrated 
that, astrocytes provide neurons with cholesterol in the form of apoE containing 
lipoproteins (Mauch et al. 2001). Furthermore, Fünfschilling and co-workers (2007) have 
disrupted the mouse squalene synthase gene, that codes for an enzyme critical for 
cholesterol synthesis, in cerebellar granule cells and in precerebellar nuclei in the adult 
mice brain. These mice had no histological signs of neuronal degeneration, displayed 
normal synapses ultrastructures, and exhibited normal motor coordination. These data 
imply that at least some populations of adult neurons do not require autonomous 
cholesterol synthesis for survival or function (Funfschilling et al. 2007). More recently, 
the Pfrieger laboratory has demonstrated that neurons show distinct profiles of 
biosynthetic enzymes, precursors and cholesterol metabolites when compared with 
astrocytes. Moreover, neurons have a less efficient cholesterol synthesis than astrocytes 
and there is massive down-regulation in the levels of neuronal intermediaries of the 
cholesterol biosynthetic pathway when neurons are maintained in co-culture with glial 
cells (Nieweg et al. 2009). These studies support the hypothesis that neurons reduce 
cholesterol synthesis and rely on delivery by astrocytes. 
In contrast, there are also several evidences of cholesterol production in specific 
neuronal populations throughout the adult brain. Indeed, the first and last enzymes in the 
cholesterol biosynthetic pathway, HMG-CoA reductase and 7- dehydrocholesterol 
reductase, respectively, are expressed in neurons throughout the adult mouse brain and 
are particularly prominent in cortical, hippocampal, and cholinergic neurons (Korade et 
al. 2007). The analysis of 25 genes involved in cholesterol homeostasis from in situ data 
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provided by the Allen Brain Mouse Atlas, has revealed that the expression of cholesterol 
homeostasis genes is preferentially targeted to neuronal hippocampal pyramidal and 
granule layers (Valdez et al. 2010). In addition, the sterol-sensing transcription factors 
SREBP-1 and SREBP-2 are expressed in cortical and hippocampal neurons in the normal 
brain (Ong et al. 2000, Kim & Ong 2009). Furthermore, it has been shown that the brain-
derived neurotrophic factor (BDNF) elicits transcription of enzymes in the cholesterol 
biosynthetic pathway in cultured cortical and hippocampal neurons, but not glial cells 
(Suzuki et al. 2007). Moreover, it has been shown that important intermediaries of the 
cholesterol biosynthetic pathway, like isoprenoids and ubiquinone are crucial for proper 
neuronal functioning (Maltese 1990, Crane 2001). These studies show that at least some 
cholesterol synthesis can occur in specific neuron populations. 
Taken together, current data suggest that due to the structural and functional 
specialization of the different brain regions it is likely that some neurons may be 
autonomous while others may depend entirely on an external cholesterol supply (Pfrieger 
2003). 
 
1.1.2 Brain cholesterol transport, utilization and storage  
Cholesterol metabolism and distribution are not uniform across all cell types present 
in the brain, thus an efficient system is necessary for the transport of cholesterol between 
the different cells of the CNS.  
ApoE is present in the CNS at high levels and throughout development this 
apolipoprotein is responsible for the mobilization and redistribution of cholesterol in 
myelin sheaths and neuronal membranes, during growth, maintenance and repair (Leduc 
et al. 2010). ApoE is required for the uptake of lipoproteins into cells via low-density 
lipoprotein receptors (LDLr) under non-pathological conditions. Other lipoproteins, such 
as apoD and apoJ, and several receptors from the LDLr family are also expressed in the 
CNS (Martins et al. 2009), as well as some members of the ABC transporter family, like 
ABCA1 and ABCG1. These transporters are responsible for the lipid efflux from cells to 
apolipoproteins, and it has been shown that ABCG1 mediates the efflux of cholesterol 
from glial cells to partially lipidated apoE (Karten et al. 2006). It is also known that 
ligand activation of the liver X receptors (LXRs) by oxysterols, can elicit the expression 
of both APOE and ABCA1 (Vaya & Schipper 2007), therefore promoting cholesterol 
transport between different cells in the brain. Indeed, the cholesterol transporter ABCA1 
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was recently shown to be a key regulator of cholesterol metabolism, since its ablation not 
only reduced the number of synapses and synaptic vesicles, but it also led to an increase 
in cholesterol uptake from the plasma to the brain, via a yet unknown mechanism, in 
order to compensate for the reduced brain cholesterol levels in these animals (Karasinska 
et al. 2009, Saito et al. 2009). However, the role of all of these lipoproteins and receptors/ 
transporters in the CNS is not well established, although they have been implicated in 
brain cholesterol homeostasis. 
When a cell is not capable of autonomous cholesterol production, it relies on the 
uptake of cholesterol from the extracellular milieu. After internalization of the apoE 
containing lipoproteins, endossomes are formed and subsequently fused with lysosomes. 
Here the apoE-phospholipid-complexed cholesterol is released intracellularly as 
unesterified (free) cholesterol (Poirier 2003). In fact, most brain cholesterol is unesterified 
and is found within the myelin sheaths, whereas the remaining unesterified cholesterol is 
found in neurons, glial cells and extracellular lipoproteins (Puglielli et al. 2003). Free 
cholesterol can serve as a signaling molecule, for example inhibiting HMG-CoA 
reductase activity (Nakanishi et al. 1988), can be a precursor of steroid hormones 
(Baulieu 1998), can be incorporated into different cellular compartments and, together 
with sphingolipids, can form lipid rafts (Simons & Gerl 2010). Furthermore, cholesterol 
can be esterified by acyl-coenzyme A: cholesterol O-acyltransferase  (ACAT) to be 
efficiently stored in the form of cholesterol esters (Shobab et al. 2005). This intracellular 
cholesterol reservoir serves as a readily available source of this sterol to be used in 
membrane remodeling associated with synaptic turnover and dentritic reorganization 
(Mauch et al. 2001).  
 
1.1.3 Brain cholesterol efflux 
As previously mentioned, cholesterol synthesis is very low in the adult state and this 
can be explained by a very efficient recycling of cholesterol in the CNS. In fact, brain 
cholesterol has an extremely long half-life that has been estimated to be of at least 5 years 
(Bjorkhem et al. 1998), whereas in plasma the cholesterol half-life has been estimated to 
be of approximately 2 to 4 months (Chobanian et al. 1962). Cholesterol homeostasis is a 
dynamic process and the continuous turnover of cholesterol in neurons may account for 
their ability to efficiently and quickly balance cholesterol levels required for dynamic 
structural changes such as neurite extension and synapse formation (Pfrieger 2003). 
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Although the brain cholesterol recycling processes are highly effective, there is some 
excretion of excess cholesterol. To date two different mechanisms of cholesterol 
excretion from the brain have been identified. The first mechanism described relies on a 
reverse cholesterol pathway. Through this pathway, cholesterol-laden apoE-containing 
lipoproteins pass into the cerebrospinal fluid (CSF) and from here into the plasma, thus 
transporting excess cholesterol from the brain into circulation (Pitas et al. 1987). 
However, this mechanism accounts for only a small percentage of cholesterol export from 
the brain, having been calculated to correspond to a flux of approximately 1 mg/ 24 h 
(Bjorkhem 2006).  
If the apoE-dependent excretion was the only mechanism of elimination from the 
brain, cholesterol half-life would be of about 50 years (Bjorkhem 2006). In fact, the major 
pathway by which excess cholesterol is eliminated from the brain involves the conversion 
of cholesterol into 24(S)-hydroxycholesterol (24OHC). The enzyme responsible for this 
conversion was found to be a brain-specific cytochrome P450, the cholesterol 24-
hydroxylase (CYP46A1) (Lund et al. 1999).  
Lütjohann and co-workers determined that the brain contains about 80% of all 
24OHC in the body (Lütjohann et al. 1996). By measuring the levels of this oxysterol in 
serum samples from the internal jugular vein and the brachial artery of several healthy 
volunteers, Bjorkhem and co-workers (1998) demonstrated that 24OHC is the major 
oxysterol transported from the brain into circulation. Furthermore, this study 
demonstrated that most of the 24OHC present in human circulation is of cerebral origin 
and that there is a net flux of this oxysterol of about 6.4 mg/ 24 h from the brain into the 
circulation (Bjorkhem et al. 1998).  
Less than 1% of the total 24OHC present in circulation corresponds to a primary 
secretion of this oxysterol into the CSF (Leoni et al. 2004). More than 99% of 24OHC 
leaves the brain directly through the BBB, which implies an efficient transport of 24OHC 
through the BBB. In fact, 24OHC is a more polar molecule than cholesterol, which 
should make it less able to pass a lipophilic barrier, however the hydroxyl group added to 
the side-chain of the cholesterol molecule leads to a reordering of membrane 
phospholipids such that it is more favorable to exclude the oxysterol molecule 
(Theunissen et al. 1986, Meaney et al. 2002). In addition, it has been demonstrated that 
24OHC passes the BBB at a much faster rate than cholesterol (Lütjohann et al. 1996, 
Bjorkhem et al. 1997).  
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The conversion of cholesterol into 24OHC has been calculated to be responsible for 
the excretion of approximately two thirds of all the cholesterol secreted from the brain. 
After entering circulation, 24OHC is metabolized in the liver, and finally eliminated from 
the organism (Bjorkhem et al. 2001).  
It is thus evident that cholesterol homeostasis in the brain is maintained by a cycle of 
interdependent processes that include synthesis, utilization/ storage, transport and 
excretion (Figure 1.2). 
 
 
 
 
 
 
 
 
 
1.1.4 Oxysterols in the brain  
As previously mentioned, cholesterol destined to be eliminated from the brain is 
mainly oxidized at the 24 position to produce 24OHC. However, in a number of extra-
Figure 1.2. Cholesterol shuttle from astrocytes to neurons. It is hypothesized that, in the adult brain, 
neurons rely on delivery of cholesterol produced by astrocytes. Cholesterol is synthesized in astrocytes, 
delivered by lipoprotein particles to neurons, where it can be integrated in lipid rafts and can be 
incorporated into synaptic vesicles. Excess cholesterol in neurons is disposed of by conversion into 
24OHC, this and other oxysterols can cross the blood–brain barrier, these sterols are important ligands of 
LXR, which translocate to the nucleus and induce expression of several genes important for cholesterol 
homeostasis in astrocytes. Adapted from Benarroch 2008. (Benarroch 2008). 
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hepatic organs and tissues excess cellular cholesterol is oxidized at the 27 position 
originating 27-hydroxycholesterol (27OHC), transported in the circulation and eliminated 
(Heverin et al. 2005). Due to the fact that 27OHC is structurally very similar to 24OHC, 
it can pass the BBB and enter the brain, where it is rapidly metabolized having low 
steady-state levels (Heverin et al. 2005, Meaney et al. 2007). Interestingly, there is a flux 
of 27OHC from the plasma to the brain, in the opposite route to the flux of 24OHC. The 
implications of such a flux will be discussed in section 1.1.5.4. 
Both 24OHC and 27OHC are ligands for LXRs (Lehmann et al. 1997, Fu et al. 
2001). LXRs are nuclear hormone receptors activated by oxysterols that act as cholesterol 
sensors and respond to elevated sterol levels, modulating the expression of their target 
genes. Ligand activation of LXRs promotes cholesterol efflux from glia and primary 
neurons (Whitney et al. 2002, Koldamova et al. 2003, Abildayeva et al. 2006), and 
ablation of either LXRα or LXRβ in a mouse model of Alzheimer’s Disease (AD) results 
in increased senile plaque load (Zelcer et al. 2007). Furthermore, activated LXRs have 
been shown to increase the expression of several genes involved in brain cholesterol 
homeostasis, such as APOE (Abildayeva et al. 2006), ABCA1 (Liang et al. 2004) and the 
LXRα gene itself (Laffitte et al. 2001). These data point to the importance of both 24OHC 
and 27OHC in the maintenance of brain cholesterol homeostasis by acting as ligands for 
LXRs. 
  
1.1.5 Brain cholesterol homeostasis disruption  
The interdependent processes that regulate brain cholesterol homeostasis have to be 
precisely regulated for the good functioning of the brain. Actually, several studies point to 
a link between disruption of brain cholesterol homeostasis and the development of several 
neurological diseases, including AD, Huntington’s and Parkinson’s disease and 
Niemman-Pick type C disease (Martin et al. 2010, Karten et al. 2009, Liu et al. 2010, 
Block et al. 2010).  
Several studies have already provided links between altered cholesterol homeostasis 
and AD. Indeed, epidemiological studies have revealed that the APOE 4 allele is the 
major genetic risk factor in sporadic AD (Corder et al. 1993). Moreover, Notkola and co-
workers evaluated the relation between APOE 4 allele and plasma cholesterol levels on 
the risk of developing AD and firstly pointed to the possibility that high levels of serum 
total cholesterol could be an independent risk factor for this disease (Notkola et al. 1998). 
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Later that year, this hypothesis was corroborated by another group that demonstrated for 
the first time that high levels of total serum cholesterol predominantly in the form of LDL 
influence the AD-related pathology (Kuo et al. 1998). A significant number of studies 
point to a decreased susceptibility to AD in patients treated with statins, a class of 
cholesterol lowering drugs that inhibit HMG-CoA reductase (Jick et al. 2000, Hajjar et al. 
2002). In the last years an effort has been made to understand how high plasma 
cholesterol, which is independent of brain cholesterol metabolism, can increase the risk to 
develop AD. Moreover, several studies endeavored to elucidate the molecular 
mechanisms by which disruption of brain cholesterol homeostasis alters the risk 
associated with AD.  
AD is the most common neurodegenerative disease, defined clinically as a slow 
progressive loss of cognitive functions that leads to dementia and death. It is 
characterized by the aggregation and deposition of misfolded proteins, in particular 
aggregated amyloid β peptide (Aβ) in the form of extracellular senile plaques, and 
hyperphosphorlylated tau protein in the form of intracellular neurofibrillary tangles, 
which ultimately result in massive neuronal death and cognitive impairment (Bertram et 
al. 2010). 
The amyloid cascade hypothesis states that deposition of Aβ, the main component of 
the senile plaques, is the causative agent of AD and that the neurofibrillary tangles, cell 
loss, vascular damage, and dementia follow as a direct result of this deposition (Hardy & 
Higgins 1992). This hypothesis has been updated to include the knowledge that senile 
plaques serve as a deposit for the toxic Aβ and are not the toxic agents themselves (Hardy 
2006). Although several studies contradict the specific sequence of events leading to the 
production of Aβ, as critical in the initiation of AD pathogenesis (reviewed in Korczyn 
2008) there is indisputable evidence that amyloid precursor protein (APP) processing is 
clearly an important event in AD. 
 
1.1.5.1 Cholesterol and APP processing 
The α-, β- and γ- secretases are responsible for the proteolytic cleavage of APP. Two 
major pathways of APP cleavage have been characterized (Figure 1.3): the protein may 
be cleaved by the α- secretase, which prevents the formation of Aβ and results in the 
production of a secreted fragment (αAPP) and a shorter COOH-terminal fragment (αCTF 
- C83) that is further cleaved by γ- secretase, giving rise to the p3 peptide and to the APP 
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intracellular domain (AICD). Alternatively, APP can be proteolysed by β- secretase, 
giving rise to a secreted fragment (βAPP) and a βCTF (C99), this then is cleaved by γ- 
secretase originating the AICD and the deleterious Aβ, which is released to the 
extracellular milieu (Selkoe 2001). 
 
 
 
 
 
 
 
Several studies have been carried out to understand how altered cholesterol 
metabolism may affect APP processing. Changes in the subcellular distribution of 
cholesterol have been found to modulate APP processing, both in vitro and in vivo 
(reviewed in Vetrivel & Thinakaran, 2010). Indeed, Bodovitz and Klein (1996) have 
shown that increasing cholesterol impeded membrane fluidity and lowered soluble APP 
production, by hampering the protease interaction with its substrate. It was demonstrated, 
using different means to deliver cholesterol to cultured cells, that increasing cellular 
cholesterol impairs the association of APP with the membrane, which is known to be a 
prerequisite for α- secretase activity (Sisodia 1992), thereby dramatically inhibiting this 
activity (Bodovitz & Klein 1996).  
Furthermore, two independent groups have demonstrated that depletion of cholesterol 
and disruption of lipid rafts affects the amyloidogenic processing of APP, while favoring 
the non-amyloidogenic pathway (Simons et al. 1998, Kojro et al. 2001). On the other 
Figure 1.3. APP processing. APP is first cleaved by α- or β- secretase, resulting in the shedding of 
nearly the entire ectodomain (αAPP and βAPP) and the generation of membrane bound α-CTF (C83) or 
β-CTF (C99). These are subsequently cleaved by γ- secretase to release p3 or Aβ peptides, respectively. 
γ- secretase also generates a cytoplasmic polypeptide, the AICD. The levels of cholesterol, 24OHC and 
27OHC and their effects on APP processing are also depicted. Adapted from Bjorkhem and Meaney 2004 
and Chow et al. 2009. 
 
 (Chow et al. 2009)  (Vetrivel & Thinakaran 2010) 
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hand, Kalvodova and co-workers have demonstrated that, not only β- secretase is located 
at the lipid rafts, but cholesterol increases its activity as well (Kalvodova et al. 2005).  
Grimm and co-workers have also shown that β- secretase activity is modulated by 
cholesterol levels and showed for the first time that γ- secretase activity, which can only 
cleave APP after α- or β- secretase cleavage, is also affected by cholesterol levels. These 
authors demonstrated that cholesterol depletion results in a parallel and additive inhibition 
of both secretases, although the inhibition mechanism seem to be different (Grimm et al. 
2008).  
 
1.1.5.2 ApoE and AD 
As above mentioned, apoE is a key cholesterol transporter that is expressed in the 
brain and plays an important part in the redistribution of lipids that follows 
neurodegeneration (Poirier et al. 1993, Strittmatter et al. 1993). The APOE gene presents 
three allelic variants: 2, 3 and 4. The APOE 3 is the most common allele in the 
general population, followed by APOE 4 (Strittmatter & Roses 1995). The latter has a 
dose effect on the distribution of the age of onset in familial AD and has been identified 
has a major risk factor for both the familial and the sporadic form of AD (Corder et al. 
1993). Each APOE 4 allele inherited lowers the distribution of the age of onset and 
increases the risk of developing the disease (Corder et al. 1993). In contrast, it has been 
shown that the inheritance of an APOE 2 allele decreases the risk and increases the mean 
age of onset of AD (Corder et al. 1994).  
ApoE co-localizes with senile plaques (Namba et al. 1991) and Aβ levels are 
increased in the brains of AD patients carriers of the APOE 4 allele (Schmechel et al. 
1993). Furthermore, it has been shown that apoE is capable of reducing potentially toxic 
extracellular Aβ (Beffert et al. 1999). It has been demonstrated that both APOE 2 and 3, 
but not 4, play important roles in the clearance of Aβ from the extracellular space via the 
low-density lipoprotein receptor-related protein (LRP) (Yang et al. 1999).  
Other authors have also shown that apoE4 appears to modulate APP processing and 
Aβ production through the LRP pathway. By stably transfecting cells with human APP, 
Ye and co-workers (2005), showed that both apoE3 and apoE4 increase Aβ production. 
However, they have also demonstrated that the stimulatory effect of apoE4 on Aβ 
production was linked to an intramolecular interaction between two structural domains of 
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apoE4, which does not happen in the apoE3. Therefore, there is an isoform-specific effect 
of apoE4 on the LRP pathway-dependent increase of Aβ production (Ye et al. 2005). 
A more recent study demonstrates a cross-talk between APP processing, apoE 
expression and cholesterol metabolism (Liu et al. 2007). Using conditional knockout 
mice, it was demonstrated that AICD, resulting from the two pathways of APP cleavage, 
can down-regulate LRP1 expression, which in turn modulates apoE and cholesterol levels 
within the CNS. In fact, not only cholesterol levels seem to regulate APP processing, but 
also AICD, a proteolytic fragment of APP, can alter the redistribution of cholesterol in the 
CNS. 
 
1.1.5.3 Statins in AD 
As mentioned above, statins are cholesterol lowering drugs that inhibit HMG-CoA 
reductase. It is known that different statins can traverse the BBB in varying degrees, 
giving rise to pleiotropic effects, namely decreasing the Aβ load, although the mechanism 
by which these compounds act is not currently well known (Vega et al. 2003). 
The Hartmann laboratory was the first to try to dissect the mechanisms underlying 
the effect of statins on AD. It was shown that simvastatin can have a beneficial effect in 
AD, since this cholesterol-lowering drug and a cholesterol-extracting toxin strongly 
reduced neuronal Aβ levels in vitro. Moreover, guinea pigs treated with simvastatin also 
had reduced levels of cerebral Aβ (Fassbender et al. 2001). Several other studies sustain 
the idea that statins may have a beneficial effect in AD by affecting the cholesterol 
content, both intracellularly and at the membrane level (Kirsch et al. 2003, Urano et al. 
2005, Burns et al. 2006), which could in turn affect APP processing. On the other hand, 
several other studies support the hypothesis that statins have a positive effect in AD, due 
to their anti-inflammatory properties (Cordle & Landreth 2005, Chauhan et al. 2004, 
Tong et al. 2009). Moreover, Sun and co-workers have shown that pre-treatment of 
human glioma cells with pravastatin decreases Aβ dependent pro-inflammatory markers 
(Sun et al. 2003). 
Isoprenoid intermediates of the mevalonate pathway are important for prenylation of 
small guanosine triphosphate binding proteins, which regulate vesicular transport and 
cytoskeletal membrane interactions (Sinensky 2000). It has been postulated that one or 
more of these intermediates are crucial for long-term potentiation (LTP), at least in a 
subset of neurons (Kotti et al. 2006). Several recent studies have shown that statins, by 
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altering the levels of isoprenoid intermediates, affect neurite outgrowth (Pooler et al. 
2006), inhibit vesicular trafficking and impair Aβ secretion (Ostrowski et al. 2007). 
The beneficial effect of statins in AD still remains controversial as several 
epidemiological studies show that the use of statins is correlated with amelioration of AD 
symptoms (Fassbender et al. 2002, Sjogren et al. 2003, Hoglund et al. 2005), while others 
fail to show any improvement (Tokuda et al. 2001, Ishii et al. 2003, Hoglund et al. 2004). 
 
1.1.5.4 Oxysterols and AD 
Several studies have described changes in the levels of 24OHC and 27OHC in AD. 
Indeed, the plasma levels of 24OHC were shown to be significantly lower in the brain of 
AD patients when compared with controls, whereas the levels of 27OHC were increased 
(Heverin et al. 2004).  
Based on a comprehensive examination of total cholesterol, cholesterol precursors 
and oxysterols from brain samples of a large number of subjects, Hascalovici and co-
workers (2009) have provided direct evidence of cholesterol homeostasis disruption in the 
brains of AD and mild cognitive impairment patients. Among other changes, these 
authors have shown that AD subjects exhibited a decrease in 24OHC with age, relative to 
subjects with no cognitive impairment and propose that the observed decrease can be the 
result of an increase in free cholesterol, due to the destruction of myelin sheaths and cell 
membranes, which exceeds the brain’s ability to eliminate cholesterol by conversion into 
24OHC (Hascalovici et al. 2009). 
Brown III and co-workers were the first to demonstrate that 24OHC inhibited the 
formation of Aβ (Brown et al. 2004). Later, the activities involved in this effect were 
determined (Figure 1.3): it was shown that 24OHC stimulates α- secretase activity, 
inhibits β- secretase activity and also significantly increases the α-/ β- secretase activity 
ratio in neuronal cells (Famer et al. 2007). Prasanthi and co-workers not only 
corroborated these results, but they also demonstrated that 27OHC increased β- secretase 
activity and suggested that the 24OHC/ 27OHC ratio could be important in APP 
processing (Prasanthi et al. 2009). These results together with the fact that there is a flux 
of 27OHC from the plasma to the brain (Heverin et al. 2005, Meaney et al. 2007), have 
lead to the proposal that 27OHC can be the missing link between high plasma cholesterol 
and AD (Bjorkhem et al. 2006). 
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1.2. CYP46A1 
The Cytochrome P450 (CYP) mono-oxigenase constitutes a superfamily of enzymes, 
responsible for the oxidative, peroxidative and reductive metabolism of a wide range of 
endogenous compounds such as steroids, bile acids, fatty acids, prostaglandins, 
leukotrienes, biogenic amines, retinoids, lipid hydroperoxides and phytoalexins (reviewed 
in Coon 2003). Moreover, these enzymes catalyze the metabolic conversion of a striking 
number of foreign chemicals, such as drugs, environmental chemicals and pollutants, to 
polar derivatives prone to be eliminated from the organism (reviewed in Waxman 1999). 
Although, the metabolism of the exogenous compounds primarily results in 
detoxification, the action of CYPs can also lead to the formation of toxic metabolites that 
can contribute to cancer, birth defects and other toxic effects (reviewed in Nebert & 
Russell 2002). 
CYP enzymes are classified into families and subfamilies according to their amino-
acid sequence similarities (> 40% and > 55% sequence identity, respectively). The family 
is designated by an Arabic number, followed by a letter indicating the subfamily identity 
and an Arabic number indicating the individual enzyme. For human and all other species 
the gene nomenclature is an italicized root symbol “CYP” (“Cyp” for mouse and 
Drosophila). The cDNA, mRNA or enzyme are referred to in regular capital letters for all 
species, without italics or hyphens (Nelson et al. 1996). 
In humans, 57 functional CYPs have been described (Nelson 2003). CYPs from 
families 1 to 4 exhibit a broad, but overlapping, substrate and product specificity. These 
enzymes are primarily responsible for the metabolism of xenobiotics, while also being 
capable of metabolizing endogenous compounds. The CYPs belonging to the other 
families play a key role in biosynthetic pathways, being mainly involved in endogenous 
compounds metabolism. These enzymes participate in thromboxane and prostacyclin 
synthesis (CYP 5 and 8A), mediate steroid-hormone biosynthesis (CYP 11, 17, 19, and 
21), catalyse reactions in the biosynthetic pathways of bile acids, vitamin D3 and 
cholesterol (CYP 7, 8B, 24, 27, 46 and 51) and, particularly, CYP26 is involved in 
retinoid metabolism (Waxman 1999, Lund et al. 1999).  
The expression of different CYPs can be development- and tissue-specific, regulated 
by endogenous hormones and cytokines and/ or respond to structurally diverse exogenous 
compounds, which often increase P450 protein levels by stimulating P450 gene 
transcription initiation (reviewed in Waxman 1999). Furthermore, CYP expression is 
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often induced by accumulation of the substrate (Nebert & Russell 2002). Taken together, 
these findings make cytochromes P450 genes as an attractive model for the study of gene 
regulation. 
The CYP46A1 gene codes for a highly conserved cholesterol 24-hydroxylase, that 
belongs to the CYP superfamily. This enzyme is responsible for the hydroxylation of 
cholesterol, by introducing a hydroxyl group at carbon 24 of this molecule (Russell et al. 
2009). The human CYP46A1 was found to be located at chromosome 14q32.1. Both the 
human and mouse genes were sequenced and each contain 15 exons and 14 introns, with 
all introns interrupting the human and mouse genes at the same positions. CYP46A1 from 
both species are microsomal proteins that comprise 500 amino-acids, and share a degree 
of sequence identity of 95% (Lund et al. 1999). 
This cytochrome P450 is predominately expressed in the CNS, unlike other P450 
sterol-hydroxylases that are predominantly expressed in the liver (Xie et al. 2003). Of the 
16 human tissues screened by Lund and co-workers, the CYP46A1 mRNA was only 
detectable in the brain. CYP46A1 is broadly expressed throughout the brain and its 
mRNA is detected at higher levels in the gray matter, such as the putamen, cerebral 
cortex and caudate nucleus and at lower levels in the white matter (Lund et al. 1999). 
More recently, it was shown that the cholesterol 24-hydroxylase is also expressed in 
neurons of the neural retina (Bretillon et al. 2007).  
A more detailed analysis was performed in the mouse brain, in which both 
immunohistochemistry and mRNA in situ hybridization revealed that CYP46A1 is 
expressed in all the six layers of the cerebral cortex, the hippocampus, dentate gyrus and 
thalamus, but not in support cells or the white matter of the adult brain (Lund et al. 1999). 
At the sub-cellular level, this microsomal cytochrome P450 is localized at the 
endoplasmic reticulum. Furthermore, this enzyme was shown to be distributed throughout 
the cell bodies and dendrites of several types of neurons of the mouse brain (Ramirez et 
al. 2008).  
The mouse CYP46A1 mRNA and protein are both expressed in the brain at birth, and 
24OHC is detected in the serum one day after birth. The serum levels of this oxysterol 
peak between post-natal days 12 and 15 during the time of myelination (Lund et al. 
2003). In accordance, in humans at the age of approximately 1 year, expression levels of 
cholesterol 24-hydroxylase reach a steady state that is maintained during adulthood. The 
increase in production and secretion of 24OHC during myelination may reflect a dual role 
for this oxysterol both as a vehicle for reverse cholesterol transport and as a mediator of 
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intercellular signaling between neurons and support cells (Lund et al. 1999). As 
previously stated 24OHC is a ligand for the LXR (Lehmann et al. 1997), which regulate a 
number of genes involved in fatty acid metabolism (Chawla et al. 2001). Moreover, LXR 
α/β null mice show a variety of CNS defects upon aging including lipid accumulation, 
astrocyte proliferation, and disorganized myelin sheaths (Wang et al. 2002). Furthermore, 
CYP46A1 has also been proposed to be part of a system for the removal of damaged cell 
membranes after traumatic brain injury, by the conversion of cholesterol to 24OHC, but 
also by activation of LXR-regulated gene transcription (Cartagena et al. 2008).  
 
1.2.1. Protein function 
After cloning of the CYP46A1 cDNA (Lund et al. 1999), it was possible to 
characterize this enzyme at the biochemical level. Studies from Irina Pikuleva’s 
laboratory have demonstrated that CYP46A1 has a very broad subtract specificity and 
that besides metabolizing cholesterol it is able to metabolize several endogenous and 
exogenous compounds (Mast et al. 2003). Firstly, by transfecting human embryonic 
kidney 293 cells with a CYP46A1 cDNA expression vector, the authors demonstrated 
that CYP46A1 had affinity towards cholesterol but also indicated that 24-hydroxylation 
of the cholesterol molecule was not the only activity of this enzyme. To further 
characterize the CYP46A1 activities, the same authors developed an E. coli expression 
system and partially purified the recombinant enzyme. This lead to the discovery that 
CYP46A1, not only metabolizes cholesterol into 24OHC but it also further metabolizes 
this oxysterol originating 24,25- and 24,27- dihydroxycholesterols. It was demonstrated 
that the enzyme has 80-fold more affinity for 24OHC than for cholesterol, with the 
oxysterol being hydroxylated 30 times faster than cholesterol. Moreover, CYP46A1 was 
found to hydroxylate diverse endogenous steroids, such as 7α-hydroxycholesterol, 
cholestanol, cortisol, testosterone and progesterone (Mast et al. 2003). This activity 
towards endogenous steroids may have physiological significance since the brain is a 
steroidogenic organ, in which steroid hormones are synthesized either de novo from 
cholesterol or from blood-born steroidal precursors. However, the possible involvement 
of CYP46A1 in the neurosteroidogenesis and degradation pathways and are not 
completely understood.  
Several xenobiotics are also metabolized by this enzyme, namely bufuralol an 
adrenoceptor antagonist; dextromethorphan an antitussive drug; diclofenac a non-
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steroidal anti-inflammatory drug; and phenacetin an analgesic drug; all of which are 
structurally diverse compounds, pointing to a wide range of substrate specificity (Mast et 
al. 2003). In order to further elucidated the physiological importance of CYP46A1 in 
xenobiotic metabolism, the same authors have engineered the CYP46A1, truncating the 
N-terminal amino-acid residues, and making the enzyme more soluble (Mast et al. 2004). 
Using this engineered protein, it was shown that structurally distinct compounds can bind 
to the enzyme active site and identified several strong inhibitors and mild activators, 
hypothesizing that CYP46A1 activity could be altered by exposure to some therapeutic 
drugs and potentially other xenobiotics (Mast et al. 2008). In fact, the effect of 
voriconazole, an antifungal drug, was further assessed. This drug was shown to inhibit 
CYP46A1 activity. Both in vitro, and in vivo studies, have demonstrated that this drug not 
only passes the BBB, but also decreases 24OHC and other intermediaries of the 
cholesterol biosynthetic pathway (Shafaati et al. 2010). The same authors have also 
demonstrated that dietary intake of n-3 polyunsaturated fatty acids increase the CYP46A1 
mRNA levels in the brains of hamsters, although they failed to demonstrate an increase in 
the activity of the enzyme or in 24OHC levels (Mast et al. 2010). 
To further understand the role of this key enzyme in cholesterol turnover in the brain, 
knockout mice for Cyp46a1 were produced by David Russell’s group. These mice look 
outwardly normal and have no differences in the growth rates and body weight when 
compared to the wild-type. However, Cyp46a1
-/-
 mice have an approximately 65% 
reduction in brain cholesterol excretion. This decrease is compensated for by a reduction 
of approximately 60% in the de novo synthesis (Figure 1.4), in brain regions that 
normally express high levels of CYP46A1, whereas in parts of the brain where CYP46A1 
is expressed at low levels there is a reduction of the synthesis of about 20-30%, such as 
the steady-state levels of cholesterol remain constant (Lund et al. 2003, Russell et al. 
2009). Whole body cholesterol synthesis was not significantly different between the wild-
type and the knockout mice (Lund et al. 2003). 
Further characterization using learning tests and electrophysiological studies, showed 
that Cyp46a1 null mice exhibit severe deficiencies in spatial, associative and motor 
learning and hippocampal LTP. The incubation of wild-type hippocampal slices with 
compactin, a HMG-CoA reductase inhibitor, also impaired LTP. Furthermore, LTP was 
restored by the addition of geranyl-geraniol, an isoprenoid intermediate that cannot be 
converted to cholesterol (Kotti et al. 2006). These data point to an important role of 
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cholesterol turnover in the production of isoprenoid intermediates that are essential in 
LTP and learning. 
 
 
 
 
 
 
 
 
1.2.3. CYP46A1 and AD 
In the last years, several epidemiological studies have reported that genetic variants 
of CYP46A1 might act as risk factor for AD. Different intronic polymorphisms in 
CYP46A1 have been described to influence AD risk and cholesterol levels or Aβ load 
(Kolsch et al. 2002, Papassotiropoulos et al. 2003, Combarros et al. 2004, Borroni et al. 
2004, Wang et al. 2004, Golanska et al. 2005, Helisalmi et al. 2006, Fernandez Del Pozo 
et al. 2006, Li et al. 2006, Ma et al. 2006, Kolsch et al. 2009). These results are 
nonetheless controversial, since in other studies, no such association was found (Desai et 
al. 2002, Johansson et al. 2004, Chalmers et al. 2004, Kabbara et al. 2004, Ingelsson et 
al. 2004, Juhasz et al. 2005, Shibata et al. 2006, Tedde et al. 2006, Wang & Jia 2007, 
Llorca et al. 2008, Golanska et al. 2009). A list of all the published association studies for 
CYP46A1 genetic variants and AD is summarized in Table 1.1. 
 
Figure 1.4. Cholesterol turnover in wild-type and Cyp46a1 knockout mouse. Knockout mice lacking 
Cyp46a1 have an approximately 65% reduction in brain cholesterol excretion, but this decrease is 
compensated for by a reduction in the de novo synthesis, so that the steady-state levels of cholesterol 
remain constant. Adapted from Russell et al. 2009.  
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Table 1.1. Overview of published association studies for CYP46A1 genetic variants and 
AD 
SNP Association Population Reference 
rs754203 and rs4900442 Positive Germany (Kolsch et al. 2002) 
rs754203 Negative USA (Desai et al. 2002) 
rs754203 Positive Switzerland, Greece 
and Italy 
(Papassotiropoulos et al. 
2003) 
rs754203 and rs4900442 Negative Sweden and Scotland (Johansson et al. 2004) 
rs754203 Positive Spain (Combarros et al. 2004) 
rs754203 Negative United Kingdom (Chalmers et al. 2004) 
rs754203 Positive Italy (Borroni et al. 2004) 
rs754203 Negative France (Kabbara et al. 2004) 
rs754203 Positive China (Wang et al. 2004) 
rs754203 Negative USA (Ingelsson et al. 2004) 
rs754203 Positive Poland (Golanska et al. 2005) 
rs754203 Negative Hungary (Juhasz et al. 2005) 
rs754203 Positive Finland (Helisalmi et al. 2006) 
rs754203 and rs4900442 Negative USA and Canada (Shibata et al. 2006) 
rs754203 Positive Spain (Fernandez Del Pozo et al. 
2006) 
rs754203 Negative Italy (Tedde et al. 2006) 
rs754203 and rs4900442 Positive China (Li et al. 2006) 
rs754203, rs3742375, 
rs3742376 and rs3742377 
Positive China (Ma et al. 2006) 
rs754203 Negative China (Wang & Jia 2007) 
rs754203 and rs4900442 Negative Mixed (Llorca et al. 2008) 
16 different SNPs Positive 
(rs754203 and 
rs4900442) 
Germany (Kolsch et al. 2009) 
rs754203 Negative Sweden (Golanska et al. 2009) 
Adapted from www.alzforum.org. (Bertram et al. 2010) 
 
Moreover, the functional significance of these polymorphisms is not known, since 
none of the studied polymorphisms is located in CYP46A1 exonic regions, and only 4 of 
the polymorphisms studied by Llorca and co-workers are predicted to be near an exon/ 
intron boundary (Llorca et al. 2008). 
In a recent study, two promoter polymorphisms were identified and associated with 
AD in a Chinese population. These two polymorphisms could putatively impair the 
binding of several transcription factors to the CYP46A1 proximal promoter, since directed 
mutagenesis analysis revealed a decrease in reporter promoter activity (Li et al. 2010). 
Nevertheless, only in silico predictions of the potential transcriptional regulators were 
made, and the functionality of the putative binding sites should be further assessed. 
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Although the molecular epidemiology studies do not reveal a clear association of 
particular CYP46A1 polymorphisms with AD incidence, other significant evidences 
suggest that CYP46A1 could affect the pathophysiology of AD. In vitro studies have 
shown that overexpression of CYP46A1 and/ or treatment with 24OHC can reduce 
membrane cholesterol levels, that can lead to the dissociation of several proteins from 
lipid rafts impairing their function, and can increase α-secretase activity as well as α/ β-
secretase activity ratio, by further inhibiting β- secretase activity (Famer et al. 2007, 
Prasanthi et al. 2009, Hudry et al. 2009, Tian et al. 2010).  
Hudry et al. (2009) published a study where two different transgenic mouse strains 
that develop Aβ plaques and memory deficits with different timings were used: APP23 
mice that develop memory deficits at 3 months and amyloid plaques at 6 months; and 
APP/ PS1 mice that develop amyloid plaques at 10 weeks and are characterized by a 
more severe phenotype. These authors have showed that overexpression of CYP46A1 in 
hippocampal and cortical neurons with an adeno-associated expression vector improved 
spatial memory before the onset of the Aβ plaques and reduced APP amyloidogenic 
processing before and after Aβ plaque onset. Furthermore, they have shown that 
cholesterol 24-hydroxylase overexpression led to a decrease in cholesterol content at the 
level of lipid rafts and a decreased in APP and components of the γ -secretase in these 
microdomains (Hudry et al. 2009). 
In a related study, the ablation of ACAT-1 in triple transgenic mice of AD (3xTgAD) 
ameliorated cognitive deficits (Bryleva et al. 2010). Furthermore, lack of ACAT-1 
activity increased the content of 24OHC in the brain of these animals, decreased 
cholesterol synthesis and lead to more than 60% reduction in full-length human APP as 
well as its proteolytic fragments. Moreover, treatment of primary neurons with 24OHC 
caused a rapid decline in APP and in HMG-CoA reductase protein levels. The authors 
propose an explanatory model of the cross-talk between ACAT-1, cholesterol metabolism 
and APP processing (Figure 1.5) (Bryleva et al. 2010). 
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It was also shown that up-regulation of CYP46A1 leads to the activation of tyrosine 
kinase (Trk) B receptor in immature neurons in the absence of its cognate ligand - BDNF 
(Martin et al. 2008). This auto-activation is possibly triggered by an alteration in the 
cholesterol content in membrane lipid rafts and leads to the activation of survival 
pathways. In subsequent studies the same authors have shown that knockdown of 
CYP46A1 in hipoccampal neurons leads to a significant increase in apoptosis (Martin et 
al. 2009). Interestingly, TrkB receptor activation by BDNF modulates the expression of 
several genes of the cholesterol biosynthetic pathway in neurons but not in glial cells 
(Suzuki et al. 2007).  
Although the latter studies suggest that induction of CYP46A1 can have a therapeutic 
value in the management of AD progression, this upregulation seems to be beneficial only 
if specifically targeted to neuronal cells. Indeed, it has been shown that overexpression of 
CYP46A1 in primary cultures of astrocytes decreases the cholesterol content of lipid 
rafts, and consequently results in a dissociation of the excitatory amino-acid transporter 2 
(EAAT2) from these microdomains, and the loss of EAAT2 and associated glutamate 
uptake function, which is deleterious to neuronal cells (Tian et al. 2010).  
Furthermore, a transgenic Cyp46a1
-/-
/AD mouse strain was developed by crossing the 
Cyp46a1 knockout mouse strain with a AD transgenic mouse strain [B6.Cg-Tg(APPswe, 
PSEN1E9)85Dbo/J] that accumulates Aβ plaques in the cortex at an early age and present 
cognitive defects (Halford & Russell 2009). These authors have shown that decreasing 
Figure 1.5. Proposed model linking ACAT1, cholesterol and APP processing. Inhibition of ACAT1 
increases free cholesterol that is converted by CYP46A1 into 24OHC. The increased content in 24OHC 
and cholesterol inhibit APP levels and processing, and HMG-CoA reductase activity at the endoplasmic 
reticulum. Adapted from Bryleva et al.(2010). 
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cholesterol de novo synthesis in the brain does not markedly influence the accumulation 
of Aβ plaques in these animals. Interestingly, it was also demonstrated that the Cyp46a1-/-
/ AD animals have a prolonged life-span when compared to the WT/AD mice, suggesting 
that reduction of de novo brain cholesterol synthesis does not seem to alter the progress of 
AD, however loss of one or both the Cyp46a1 alleles may confer a survival advantage 
(Halford & Russell 2009).  
These studies underscore the importance of CYP46A1 in the maintenance of cellular 
cholesterol levels and its importance in the activation/ repression of several important 
proteins that are related to different cell processes.  
Independently of its putative role on the onset/ progression of AD, CYP46A1 
expression profile is altered in post-mortem brains of AD patients when compared with 
the controls. Indeed, CYP46A1 was shown to be up-regulated in glial cells in the brains 
of AD patients. Oligodendrocytes showed very weak staining, whereas some astrocytes 
stained positive for CYP46A1 preferentially in the soma and partially in the fibrillar 
branching, whereas neuronal cells show a decrease in CYP46A1 (Bogdanovic et al. 
2001). These results were corroborated by another group that demonstrated that in the 
brains of AD patients CYP46A1 shows prominent expression in astrocytes and in 
degenerating neurites around senile plaques, and neurons have a less marked expression 
of CYP46A1 in the brains of AD patients, when compared to controls (Brown et al. 
2004).  
Moreover, several studies have demonstrated an upregulation of CYP46A1 in 
response to brain injury. After brain injury induced by the excitotoxin, kainic acid, He 
and co-workers were the first to demonstrate increased CYP46A1 expression in rat 
astrocytes (He et al. 2006). In this study, the levels of both cholesterol and 24OHC were 
shown to be increased after injury, due to an increase in cholesterol synthesis and the 
upregulation of CYP46A1 in the degenerating brain tissue, and not by an increase in 
plasma uptake (He et al. 2006).  
In a rat model of multiple sclerosis with a compromised BBB, the observed increased 
expression of CYP46A1 in infiltrated macrophages near a site of injury was proposed to 
facilitate metabolism of phagocytosed cholesterol from neural membranes and myelin. 
The presence of CYP46A1 in macrophages near blood vessels may allow for rapid 
excretion of cholesterol into the circulation (Teunissen et al. 2007). In addition, activated 
microglia cells expressing CYP46A1 were detected at the site of injury in a rat model of 
traumatic brain injury (Cartagena et al. 2008). These results were corroborated in a more 
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recent study, where it was demonstrated that microglial cells surrounding lesion sites 
have increased CYP46A1 expression (Smiljanic et al. 2010).  
These studies give emphasis to the importance of CYP46A1 in maintaining brain 
cholesterol homeostasis in response to CNS injury, by facilitating the elimination of 
excess cholesterol released from damaged neuronal membranes and myelin phagocytosed 
by activated microglia and astrocytes.  
 
1.2.4. Gene regulation 
Ingemar Björkhem’s group was the first to structurally and functionally characterize 
the human CYP46A1 promoter (Ohyama et al. 2006). These authors cloned 2.7 Kb of the 
CYP46A1 5´ flanking region and found that it lacks TATA or CAAT boxes. The proximal 
promoter is very GC rich, a feature often found in genes considered to have a largely 
housekeeping function.  
The functional analysis of the CYP46A1 promoter indicated that the region between 
nucleotides -659 and -510 was responsible for basal promoter activity and most likely 
silencing elements were present further upstream. Nevertheless, these authors could not 
identify in this region putative binding sites for neuron-specific transcription factors. 
Furthermore, they demonstrated that there is no substrate-dependent transcriptional 
regulation and that treatment of neuroblastoma cells with a broad spectrum of endogenous 
and exogenous compounds did not result in any significant change in CYP46A1 promoter 
activity. However, treatment with a radical generator slightly increased CYP46A1 reporter 
activity, pointing to a possible role of oxidative stress in the regulation of CYP46A1 
expression (Ohyama et al. 2006).  
In a follow-up study it was demonstrated that epigenetic mechanisms might be 
involved in the tissue-specific expression of CYP46A1. Treatment of neuroblastoma cells 
with trichostatin A (TSA) a potent inhibitor of histone deacetylases (HDAC) led to a 
marked time-dependent derepression of CYP46A1 expression. The effect of HDAC 
inhibitors was also evaluated in vivo and corroborated the in vitro findings of a dose 
dependent increase in the expression of CYP46A1 in the brain (Shafaati et al. 2009). Our 
group has also corroborated the findings by Shafaati et al. (2009) showing that inhibition 
of HDAC activity by TSA, valproic acid and sodium butyrate caused a potent induction 
of CYP46A1 expression (Nunes et al. 2010). Furthermore, our studies have shown that 
silencing the Specificity protein (Sp) transcription factors led to a significant decrease in 
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HDAC inhibitor-mediated induction. Moreover, our data showed that a decrease in Sp3 
binding at particular responsive elements, can shift the Sp1/Sp3/Sp4 ratio, and favor the 
detachment of HDAC 1 and 2 and the recruitment of transcriptional activators (Nunes et 
al. 2010). These data imply that an epigenetic program may be responsible for the tissue 
specific expression of CYP46A1.  
 
1.3 Transcriptional regulation of gene expression 
Eukaryotic organisms, especially mammals, have evolved complex gene regulatory 
mechanisms that control tissue- and development- specific gene expression. Gene 
transcription is a remarkably intricate process that is tightly regulated by the interplay 
between structural properties of DNA, chromatin dynamics, and transcription factors (TF) 
that target specific DNA sequences, which interact with components of the core initiation 
machinery leading to the activation or repression of transcription (Kadonaga 2004). 
In fact, genes contain complex arrays of specific DNA sequences such as promoters, 
enhancers, silencers and insulators that are positioned throughout the genome and that 
cooperate with epigenetic marks to define specific expression patterns (Figure 1.6) 
(Lemon & Tjian 2000).  
The core promoter plays a pivotal role in the transcription process and is defined as 
the DNA region that directs the accurate initiation of transcription by RNA polymerase II 
(RNA pol II) (Juven-Gershon & Kadonaga 2010). The conserved TATA box was the first 
eukaryotic core promoter element identified and besides the TATA box-enriched 
promoters, a second class of promoters exists, the CpG-rich promoters (Carninci et al. 
2006). Although these CpG island-associated promoters are predominant throughout the 
genome, the mechanisms and factors responsible for their function remain poorly 
identified (Baumann et al. 2010). 
In eukaryotes, the core promoter is recognized by the general transcription factor 
complexes, such as TFIID, which consists of the TATA binding protein (TBP) and 
approximately 13 or 14 TBP-associated Factors (TAFs). Multiple TFIID related 
complexes exist and function at distinct promoters through the use of tissue-specific 
TAFs and TBP-related factors (Levine & Tjian 2003). Moreover, it is known that these 
complexes function in the majority, if not all, promoters recognized by RNA pol II, 
regardless of the presence or absence of the TATA box (Goodrich & Tjian 2010). 
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The DNA motifs present at the promoter, silencers and enhancers are recognized by 
sequence-specific DNA binding regulatory proteins, which bind directly to DNA and, 
through protein–protein interactions, convey signals to the basal transcriptional 
machinery resulting in differential gene expression. These DNA binding proteins can 
recruit a number of different cofactor complexes, which can be co-activators or co-
repressors that in turn can serve as bridges between distal regulatory sequences and the 
core promoter or can induce conformational modifications important for regulating 
transcription (Levine & Tjian 2003). 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Fundamental elements of eukaryotic transcriptional control. A) Scheme representing the 
essential components involved in gene regulation, including promoter, silencer and enhancer DNA 
sequences, sequence-specific DNA-binding transcription factors (i.e. GR, NHR, Hairy, SREBP, Sp1, 
REST), components of the core initiation machinery (TFIIA, IIB, IID, IIE, IIF, IIH) required by RNA 
polimerase II for promoter recognition and basal transcription, co-activators (p300/CBP, ARC/DRIP, 
CRSP, SAGA), co-repressors (Groucho, CRSP) and chromatin modifying complexes (HDAC, SWI/SNF, 
ISWI). B) Scheme representing the epigenetic modifications involved in the control of gene expression: 
DNA methylation, histone modifications, chromatin remodeling complexes, histone variants, and non-
coding RNAs (ncRNAs). Adapted from Lemon & Tjian 2000 and Dulac 2010.  (Dulac 2010) 
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Epigenetic mechanisms are also important for gene regulation. DNA methylation is 
mainly confined to CpG dinucleotides in mammals. The methylation of cytosine 
nucleotides in DNA to form 5-methylcytosine has an important role in the silencing of 
individual genes, the constitutive silencing of chromatin regions, the inactivation of one 
of the X chromosomes in females and the imprinting of parental alleles (Bird 2007).  
Gene expression can be further regulated by modifications at the chromatin level. In 
addition to the structural role for histones, post-translational modifications (PTM) of their 
N-terminal tails give rise to changes in nucleosome–DNA interactions that are important 
for transcriptional regulation. In fact, histones can suffer a variety of modifications 
including methylation, acetylation, ubiquitination, ADP-ribosylation, small ubiquitin-like 
modifier modification (SUMOylation) and phosphorylation, and these in turn regulate 
gene expression by allowing differential binding of specific TFs, co-activators, co-
repressors and the constituents of the transcriptional machinery (Jenuwein & Allis 2001). 
Although the significance of most of these modifications is not fully understood, 
acetylation and methylation of specific lysines have been demonstrated to be key 
modulator marks for transcriptional activation or repression (Kouzarides 2007).  
Additionally, a class of recently discovered RNA molecules, the non-coding RNAs, 
was found to regulate transcription by epigenetic mechanisms. Small interfering RNAs 
can specifically target particular DNA sequences and silence gene expression in a process 
that involves histone modifications and DNA methylation (Yilmaz & Grotewold 2010). 
Moreover, long non-coding RNAs can regulate gene transcription through a diversity of 
mechanisms and their functions include roles in high-order chromosomal dynamics, 
telomere biology and sub-cellular structural organization (Mercer et al. 2009). 
The development and function of the CNS requires accurate gene transcription 
control in response to environmental signals. Epigenetic mechanisms, such as DNA 
methylation, histone modification and small-non coding RNAs, are critically important in 
controlling precise neural gene regulation. Transcription factors also operate and are 
activated in a sequential order, in particular during neural development, so that many 
changes occur in response to transcription factors, DNA methylation, small non-coding 
RNAs and modifications at the chromatin level (Buckley 2007, Ooi & Wood 2008). The 
precisely controlled interplay between all these genetic and epigenetic events in response 
to external cues is what determines accurate gene regulation. 
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1.3.1. DNA methylation  
In vertebrates, DNA methylation mainly occurs at the fifth carbon position of the 
cytosine residue in a CpG dinucleotide. Nevertheless, the eukaryotic genomes are not 
methylated uniformly but contain methylated regions interspersed with unmethylated 
domains. Non-coding regions, both intronic and intergenic are heavily methylated to 
preserve genome integrity (Wilson et al. 2007). DNA methylation at promoter regions is 
much more complex. Indeed, one of the most striking features of vertebrate DNA 
methylation patterns is the presence of CpG islands, unmethylated GC-rich regions that 
possess high relative densities of CpG and are positioned at the 5’ ends of many genes 
(reviewed in Illingworth & Bird 2009). The great majority of CpG islands are 
unmethylated at all stages of development and in all tissue types (Antequera and Bird 
1993) even when their associated gene is silent. A small but significant proportion of all 
CpG islands become methylated during development and usually the degree of 
methylation correlates with transcription repression. Inhibition of gene expression by 
DNA methylation is achieved by either directly interfering with transcription factors 
binding to DNA or by allowing the recruitment of methyl-CpG binding domain (MBD) 
proteins, which complex with other chromatin modifying proteins that alter chromatin to 
a repressive state (Feng et al. 2007, Metivier et al. 2008).  
The enzymatic activity of DNA methyltransferases (DNMTs) is responsible for the 
methylation of the cytosine residue and S-adenosyl methionine (SAM) is the methyl 
donor for this reaction (Bird 1986), which is cyclic and depends on the clearance of by-
products and the replenishment of substrates. Also essential in this process is the presence 
of specific co-factors, folate, vitamin B6 and vitamin B12 (Narayan & Dragunow 2010). 
De novo DNA methylation patterns are established by members of the DNMT3 
family and established methylation patterns are maintained by the DNMT1 
methyltransferase (Figure 1.7) (Kim et al. 2009a) and tailored by the action of different 
demethylases, although the chemical process by which these enzymes convert the 
methylated cytosines to unmethylated cytosines is not well established (Brown et al. 
2008, Day & Sweatt 2010). 
The importance of DNA methylation in gene regulation associated with brain 
function and neurological disorders was first suggested when the gene encoding Methyl-
CpG-Binding Protein 2 (MECP2) was identified as the target of mutations that cause Rett 
syndrome (Amir et al. 1999). Interestingly, it has also been demonstrated that certain 
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genes undergo rapid and specific methylation during LTP (Levenson et al. 2006). Recent 
studies indicate that DNA methylation is dynamically regulated in the adult CNS and that 
this epigenetic modification may serve as a contributing mechanism in memory formation 
and storage (reviewed in Day & Sweatt 2010).  
 
 
 
 
Epigenetic mechanisms have been shown to be altered in two degenerative disorders 
of the CNS – Huntington’s disease and AD. Abnormal DNA methylation patterns have 
been demonstrated to affect AD. The APP promoter region has been shown to be 
hypomethylated in the brains of AD patients (West et al. 1995, Tohgi et al. 1999). AD 
patients have been reported to have elevated levels of homocysteine (Seshadri et al. 
2002), which can lead to a global hypomehtylation, by the formation of the potent 
inhibitor of methylation – S-adenosylhomocystein. The genes coding for β- and γ- 
secretases, key enzymes in the processing of APP, have also been shown to be controlled 
by DNA methylation (Scarpa et al. 2003, Fuso et al. 2005). Moreover, inducing 
demethylation by vitamin B complex deprivation leads to an increase in β- and γ- 
secretase activity and in the accumulation of Aβ deposition in mice (Fuso et al. 2008). 
Nevertheless, high dose supplements of folate and vitamins B6 and B12 administered to 
AD patients, induced a decrease in the levels of homocystein, however, this did not 
reflect in a benefit in cognitive function (Aisen et al. 2003, Aisen et al. 2008). On 
contrary, Chan and co-workers employing a supplement cocktail, containing folate, 
vitamin B6, α-tocopherol, SAM, N-acetyl cystein and acetyl-L-carnitine, reported 
significant improvements in cognitive function in early-stage AD patients (Chan et al. 
2008).     
Figure 1.7. DNA methylation. A) DNA methylation occurs at cytosine bases when a methyl group 
donated by SAM is added at the 5′ position on the pyrimidine ring by a DNMT. B) De novo DNMTs 
methylate previously nonmethylated cytosines, whereas maintenance DNMTs methylate hemi-methylated 
DNA at the complementary strand. Adapted from Day & Sweatt 2010.  
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When studying the cytogenetic effect of the demethylating agent 5-azacytidine in 
peripheral lymphocyte cultures derived from AD patients and two control groups, it was 
demonstrated that epigenetic regulation may be compromised in AD patients, since the 
DNA regions that were methylated before the treatment, were more readily and rapidly 
unmethylated in AD patients cells (Payao et al. 1998). In a recent study with post-mortem 
brain tissue from AD patients it was shown that methylcytosine, DNMT1 and MBD2 
were decreased when compared with the controls (Mastroeni et al. 2010). All of these 
studies point to the importance of epigenetic mechanisms in normal brain function and 
further strengthen the hypothesis of epigenetic dysfunction in AD.  
 
1.3.2 Sequence-specific DNA binding transcription factors   
As previously mentioned, in eukaryotes transcription regulation requires precise 
spatial and temporal cooperation of a multitude of general and sequence-specific 
transcription factors at cis-regulatory elements, including promoters, enhancers, and 
silencers (Baumann et al. 2010).  
Sequence-specific DNA binding transcription factors recognize and bind to response 
elements located at cis-regulatory regions, subsequently recruiting TFs and co-factors that 
act to regulate RNA pol II transcriptional machinery at the core promoter, which in turn 
mediates the synthesis of RNA transcripts from the DNA template (Kadonaga 2004). The 
precise regulation of genes does not depend on the binding of a single sequence-specific 
DNA binding transcription factor, but of multiple factors that can act synergistically and 
robustly activate transcription in a highly specific manner (Laybourn & Kadonaga 1992).  
A significant number of transcription factors are expressed in the brain and are 
essential for development, differentiation and in regulating gene expression in response to 
neuronal activity (Ooi & Wood 2008). In fact, it has been shown that the precise timing of 
neural stem cell differentiation is critically controlled by multiple basic helix-loop-helix 
(bHLH) TFs, both repressors and activators, and that this control is fundamental for the 
correct formation of the brain (Kageyama et al. 2005). The bHLH repressor-type proteins 
from the Hes family have been shown to regulate Notch signaling, thus inhibiting 
neuronal differentiation and promoting maintenance of neural stem cells (Kageyama et al. 
2005). The bHLH activator-type proteins, which include members of the neurogenic 
differentiation (NeuroD), neurogenin and Achaete-Scute families have been shown to be 
involved in neuronal differentiation, by inducing neuronal-specific gene expression but 
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also by inhibiting glia-specific gene expression (Bertrand et al. 2002, Kageyama et al. 
2005). Furthermore, combinations of distinct bHLH proteins can induce different types of 
neurons and it has been suggested that distinct bHLH proteins acting in cascades trigger 
the sequential steps of cell determination and differentiation (Wen et al. 2009).       
Another important transcription factor that regulates the tissue-specific expression of 
several neuronal genes, by binding to the repressor element 1 (RE1) present at the 
promoter of these genes, is the RE1-silencing transcription factor (REST)/ neuron-
restrictive silencer factor (NRSF). This transcription factor was found to be a negative 
regulator rather than a transcriptional silencer of neuronal gene expression, as initially 
thought, and it is known that it interacts with positive regulators to modulate target gene 
expression in a quantitative manner in different cell types, including neurons (Ooi & 
Wood 2007, Palm et al. 1998). REST-mediated gene repression is mainly achieved by the 
recruitment of two separate co-repressor complexes, CoREST and mSin3, and with 
several complementary chromatin-modifying enzymes, such has HDACs (Huang et al. 
1999). In addition to high levels of expression in non-neuronal cells, REST is expressed 
in the brain, where it can repress but does not silence gene expression. In neurons, REST 
mRNA exists in several alternatively spliced forms, but its function in neurons is not well 
established (Ooi & Wood 2007).  
 
1.3.2.1 The specificity protein/ Krüppel-like factors transcription factor family  
Clearly transcription factors play a pivotal role in regulating gene expression and the 
specificity protein/ Krüppel-like factors (Sp/ KLF) is one of the best characterized 
families of transcription factors, especially the prototypical Sp1 (Dynan & Tjian 1983).  
This family of transcription factors has several members that share a highly 
conserved DNA binding domain (DBD) with at least 65% of sequence identity. 
Structurally, the DBD comprises three adjacent zinc fingers motifs, which allow these 
transcription factors to bind to GC and GT boxes (5’-GGGGCGGGG-3’ and 5’-
GGTGTGGGG-3’, respectively), with overlapping specificities and affinities (Suske 
1999, Suske et al. 2005). These motifs are also responsible for protein-protein interaction, 
which can modulate DNA binding activity of these transcription factors. Furthermore, the 
protein members of this family contain a nuclear localization sequence immediately 
adjacent to, or within, the zinc finger sequence (Kaczynski et al. 2003). 
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The Sp/ KLF family is subdivided into two major subfamilies, the Sp family, which 
has a greater affinity to the GC boxes and share similar N-terminal motifs, and the KLF 
family, which has greater affinity to the GT boxes (with some exceptions) and is more 
heterogeneous (Wierstra 2008). These GC and GT boxes are important both in the 
transcription of ubiquitous as well as tissue-specific genes (Suske 1999). This large 
family of TFs has at least 25 members, although some of these were discovered only 
recently and their biological functions are still not known (Suske et al. 2005).  
The inclusion of TFs to the Sp subfamily is based on their homology and 
chromosomal localization. Sp1-Sp9 genes are all adjacent to homeobox gene clusters and 
usually in pairwise combinations (Kawakami et al. 2004, Philipsen & Suske 1999, 
Bouwman & Philipsen 2002). A characteristic feature of these TFs is the presence of a 
conserved amino-acid stretch named SP box, located close to the N-terminus of the 
protein, that contains an endoproteolytic cleavage site important for proteasome-
dependent degradation (Su et al. 1999), and also the presence of the buttonhead (BTD) 
box, just N-terminal to the zinc-fingers (Suske et al. 2005). The BTD box has been shown 
to be important for the synergistic activation of target genes by Sp1 and SREBP 
(Athanikar et al. 1997).  
Within the Sp transcription factors, Sp1, Sp2, Sp3 and Sp4 form a subgroup based on 
their similar modular structure (Bouwman & Philipsen 2002), having at least one 
glutamine rich transactivation domain (TAD) critical for transcriptional activation (Figure 
1.8). In fact, Sp2 differs from the other Sp proteins of this subgroup, since it only has one 
TAD and lacks a serine/ threonine rich domain, important for PTMs that regulate the 
activity of these TFs. In fact, no functional analysis has been made, and little is known 
about the role of Sp2 (Suske 1999). Sp1, Sp3 and Sp4 all have two glutamine rich TAD 
(transactivation domains A and B), and all have the serine/ threonine rich region that 
putatively regulate their activity (Bouwman & Philipsen 2002). The high degree of 
structural conservation between these three proteins demonstrates that these proteins are 
all transcriptional regulators that bind to similar DNA elements (Hagen et al. 1994). 
Sp1 and Sp3 are ubiquitously expressed and necessary for the regulation of many 
genes that are involved in numerous cellular processes (Cawley et al. 2004). In contrast, 
Sp4 is expressed at very high levels in the adult brain and the retina and also in several 
other tissues, albeit at lower levels (Hagen et al. 1994, Supp et al. 1996, Lerner et al. 
2005). 
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Sp1 has two isoforms (that differ in the extent of the N-terminus of the proteins) with 
the longest isoform having 106 kDa and the shortest 96 kDa. Both isoforms contain 
activation domains at the glutamine rich region, as already referred, however this TF also 
has an inhibitory domain at the N-terminal end of the protein (Murata et al. 1994). The 
abundance of Spl protein is believed to be invariant in most mammalian cell types and it 
is possible that levels of active Spl are tightly controlled. The binding of different proteins 
to the N-terminal end of Sp1 may work by sequestering active Sp1 and impairing its 
ability to bind to DNA and consequently impede the activation of its target genes 
transcription (Murata et al. 1994). The interaction of Sp1 with a large co-activator 
complex called co-factor required for Sp1 activation (CRSP) has also been shown to 
stimulate Sp1-mediated transcription in vitro (Ryu et al. 1999). Thus, Sp1 can be 
responsible for transcriptional activation or repression. Furthermore, Sp1 has been shown 
to be able to synergistically activate transcription by at least two different mechanisms. 
The synergistic effect can be achieved by Sp1 binding to adjacent Sp-binding sites 
forming homotypic interactions, through a specific domain (domain D) at the carboxy-
terminal domain, leading to the formation of multimeric complexes and not by 
cooperative binding of Sp1 to adjacent response elements (Pascal & Tjian 1991). An 
alternative synergistic mechanism requires the interaction of Sp1, via the BTD domain, 
with SREBP, which may be limited to promoters that naturally contain a single SREBP 
recognition site (Athanikar et al. 1997). 
Sp3 has four isoforms, two long forms of about 116 kDa (L1-Sp3 and L2-Sp3) and 
two short isoforms of approximately 76 kDa (M1-Sp3 and M2-Sp3), which derive from 
alternative translational start sites at positions 1, 37, 856, and 907. The short isoforms 
lack the A sub-domain of the TAD and act has repressors or weak activators (Sapetschnig 
et al. 2004). Sp3 has also been shown to be responsible for the activation of certain genes 
and for the repression of others (reviewed in Li & Davie 2010). Moreover, Sp3 does not 
have the ability to bind to DNA as multimers or to synergistically activate transcription 
by binding to multiple adjacent sites and can counter-act Sp1 mediated synergistic 
transactivation (Yu et al. 2003). However, it has been shown that Sp3 can substitute Sp1 
in the synergistic mechanism, via the BTD as domain described by Athanikar and co- 
workers (Athanikar et al. 1997). 
Sp4 has only one isoform of approximately 110 kDa and can either transactivate or 
silence gene transcription (Hagen et al. 1995, Ramos et al. 2009). The D domain that is 
responsible for the ability of Sp1 to form multimeric complexes is lacking in both Sp3 
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and Sp4. These TFs are therefore thought to be unable to synergistically transactivate its 
targets. However, Sp4 has been shown to directly interact with Sp1 forming heterotypic 
interactions, which can lead to an enhancement of the Sp1 activity when mediated 
through at least two Sp-response elements (Hagen et al. 1995). 
 
 
 
 
 
 
 
 
 
Sp knockout mice have revealed overlapping but distinct functions. Knocking out 
Sp1 and Sp3 was shown to be lethal. In addition, knocking down one of these factors will 
decrease the levels of both factors (Marin et al. 1997, Bouwman et al. 2000). 
Furthermore, heterozygous Sp1
+/-
 Sp3
+/-
 mice are also not viable, which suggests that the 
right amount of both Sp1 and Sp3 transcription factors is necessary in maintaining 
appropriate gene expression programs (Kruger et al. 2007). As expected, the defects in 
Sp4 knock-out mice are more pronounced in the nervous system, furthermore two-thirds 
of the Sp4 knockout mice die within a few days of birth and the surviving animals are 
smaller in size when compared to their littermates (Supp et al. 1996; Zhou et al. 2005). 
Although nothing is known about PTMs that regulate Sp4 activity, Sp1 and Sp3 have 
been shown to be regulated by several PTMs. Sp1 can be phosphorylated by at least nine 
different kinases, it can be acetylated, glicosylated, ubiquitylated, SUMOylated and ADP-
ribosylated (reviewed in Wierstra 2008). The major determinant of Sp3 activity was 
found to be SUMOylation (Sapetschnig et al. 2004), nevertheless this protein can also 
suffer phosphorylation, glicosylation and acetylation (Li & Davie 2010). All of these 
PTMs alter Sp proteins activity and determine their role as repressors or as activators of 
gene expression.  
Figure 1.8. Schematic representation of the four human Sp-family members Sp1, Sp2, Sp3 and Sp4. 
Sp3 refers to the full length isoforms. Yellow boxes indicate regions of the proteins which are rich in 
serine/ threonine residues and red boxes regions of the proteins which are rich in glutamine. Blue boxes 
represent the BTD box. The region preceding the first zinc finger (+/−) represents a highly charged 
region. The black boxes represent the zinc fingers. Lines above Sp1 protein indicate the extent of four 
domains (A, B, C and D) which contribute to the transcriptional properties of the Sp proteins. Activation 
(AD) and inhibitory domains (ID) are indicated. Adapted from Suske 1999. 
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Despite the similarities between these TFs and the fact that they recognize the same 
response elements albeit with different affinities, it has been extensively shown that 
different genes are regulated by the different members of this family of transcription 
factors or by the different ratio between the Sp proteins present at the proximal promoters 
of target genes. This demonstrates that the Sp proteins, like other TFs, are part of intricate 
gene regulatory networks and that PTMs and protein-protein interactions play an 
important role in regulating gene expression by modulating the Sp TFs activity and 
directing their specific function.  
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                                                                                                  OBJECTIVES 
 
 
 
The body of work presented in this dissertation focuses on the characterization of the 
molecular mechanisms underlying the brain-specific expression of the human cytochrome 
P450, CYP46A1. This cholesterol 24-hydroxylase is responsible for the majority of brain 
cholesterol turnover, nevertheless, despite its physiological importance, the regulatory 
networks that govern its expression had not been characterized. 
The cloning of 5kb of the CYP46A1 5’ flanking region reveled an extremely GC-rich 
promoter lacking a consensus TATA box and rich in putative Sp binding sites. Therefore, 
we hypothesize that the Sp family of transcription factors might play an important role in 
the basal expression of this gene.  
Afterwards, we aimed to identify a human cell model that expresses high levels of 
CYP46A1, in order to confirm our results at the chromatin level and subsequently to 
validate this cell system as a valuable tool for the study of cholesterol homeostasis in 
human neurons. 
Since the bioinformatic analysis of the 5’flanking region demonstrated that the 
CYP46A1 proximal promoter region is located in a predicted CpG island, we have raised 
the question if epigenetic mechanisms, such as DNA methylation, could be involve in the 
cell-specific expression of this gene.  
 
The experimental approaches used involve a wide range of cell and molecular 
biology methods and were designed to answer the following questions:  
1. Which are the regulatory elements and factors involved the CYP46A1 brain 
specific expression?  
2. Which is the particular role of the Sp family of transcription factors in the 
regulation of the CYP46A1 gene?  
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3. Are differentiated Ntera2/clone D1 (NT2) human teratocarcinoma cells a suitable 
model to study the human CYP46A1 regulation?  
4. Are differentiated NT2 a valuable tool for the study of cholesterol homeostasis in 
human neurons?  
5. Is the role of DNA methylation important in the tissue-specific expression of 
CYP46A1?  
 
Taken together, the results presented herein are a significant contribution to the 
definition of the regulatory mechanisms that control human CYP46A1 transcription and 
may prove useful in unraveling potential therapeutic agents that can modulate this key 
enzyme gene expression and thus control brain cholesterol metabolism in 
pathophysiological situations.  
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2.1 Abstract 
Brain defective cholesterol homeostasis has been associated with neurologic diseases, 
such as Alzheimer’s and Huntington’s disease. The elimination of cholesterol from the 
brain involves its conversion into 24(S)-hydroxycholesterol by CYP46A1, and the efflux 
of this oxysterol across the blood-brain barrier. Herein, we identified the regulatory 
elements and factors involved the human CYP46A1 expression. Functional 5’deletion 
analysis mapped a region spanning from nucleotides -236/-64 that is indispensable for 
basal expression of this TATA-less gene. Treatment of SH-SY5Y cells with mithramycin 
A resulted in a significant reduction of promoter activity, suggesting a role of Sp family 
of transcription factors in CYP46A1 regulation. Combination of Sp1, Sp3, and Sp4 over-
expression studies in Drosophila SL2 cells, and systematic promoter mutagenesis 
identified Sp3 and Sp4 binding to four GC-boxes as required and sufficient for high levels 
of promoter activity. Moreover, Sp3 and Sp4 were demonstrated to be the major 
components of the protein-DNA complexes observed in primary rat cortical extracts. Our 
results suggest that the cell-type specific expression of Sp transcription factors – 
substitution of Sp1 by Sp4 in neurons – is responsible for the basal expression of the 
CYP46A1 gene. This study delineates for the first time the mechanisms underlying the 
human CYP46A1 transcription and thereby elucidates potential pathways underlying 
cholesterol homeostasis in the brain. 
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2.2 Introduction 
The brain, although composing < 5% of the total body mass contains approximately 
25% of all the unesterified body cholesterol. Cholesterol metabolism in the central 
nervous system (CNS) is distinct from that in other tissues. Indeed, because of the 
efficiency of the blood–brain barrier (BBB), the brain is unable to take-up cholesterol 
from the circulation and relies almost completely on de novo synthesis. Cholesterol in the 
adult brain is largely metabolically inert; however, a small fraction of the pool turns over 
each day. The major mechanism by which cholesterol is metabolized in the brain is by 
conversion to 24(S)-hydroxycholesterol (24OHC), a more polar sterol that can traverse 
the BBB, enter circulation, and subsequently be cleared by the liver (Bjorkhem et al. 
1998). The flux of this oxysterol is believed to be the main mechanism by which the brain 
facilitates the removal of cholesterol. The 24OHC is a ligand for the liver X receptor 
(LXR), a nuclear hormone receptor that regulates the expression of many genes involved 
in lipid metabolism. LXRα/β null mice show a variety of CNS defects upon aging 
including lipid accumulation, astrocyte proliferation, and disorganized myelin sheaths 
(Wang et al. 2002).  
The enzyme responsible for the conversion of cholesterol to 24OHC was identified as 
a brain-specific cytochrome P450, the CYP46A1 (Lund et al. 1999). Knock-out mice 
lacking Cyp46a1 have an approximately 65% reduction in brain cholesterol excretion, but 
this decrease is compensated for by a reduction in the de novo synthesis, such as steady-
state levels of cholesterol remain constant (Lund et al. 2003). On the other hand, Cyp46a1 
null mice exhibit severe deficiencies in spatial, associative, and motor learning, and 
hippocampal long-term potentiation (Kotti et al. 2006). 
Cholesterol 24-hydroxylase mRNA and protein are expressed at low levels in the liver 
and testis and at much higher levels in the adult brain. Immunohistochemical and in situ 
mRNA hybridization experiments indicate that Cyp46a1 is expressed in pyramidal 
neurons of the mouse cerebral cortex, Purkinje cells of the cerebellum, neurons of the 
thalamus, dentate gyrus, and hippocampus but not in support cells or in the white matter 
of the adult brain (Lund et al. 1999). CYP46A1 mRNA and protein are both expressed in 
the brain at birth, and 24OHC is detected in the serum on postnatal day 1. 24OHC levels 
in the serum peak between days 1 and 21 during the time of myelination, and thereafter, 
levels of this oxysterol gradually increase in the brain. In accordance, in humans, at the 
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age of about 1 year, expression levels of CYP46A1 reach a steady state, which is 
maintained during adulthood (Lund et al. 1999). 
An increasing number of studies suggest that CYP46A1 affects the pathophysiology of 
Alzheimer’s disease (AD). Indeed, while CYP46A1 expression is restricted to neurons in 
healthy brains, a relative high protein concentration has been reported in glial cells of AD 
brains (Bogdanovic et al. 2001). Moreover, several groups have described an association 
between genetic variants of CYP46A1 and AD (Johansson et al. 2004, Papassotiropoulos 
et al. 2003). Changes in the flux of 24OHC from the brain into the circulation have also 
been reported in patients with AD (Papassotiropoulos et al. 2002). The 24OHC is able to 
induce the expression of ATP binding cassette transporters (ABC) A1, G1 and apoE in 
astrocytes and to elevate apoE-mediated cholesterol efflux in astrocytoma cells 
(Abildayeva et al. 2006). Moreover, 24OHC inhibits amyloid β secretion in primary 
cultures of cortical neurons (Brown et al. 2004). 
Although significant evidences have been presented that the deregulation of 
cholesterol balance may be related to the onset of neurological diseases, the molecular 
mechanisms that underlie the brain-specific expression of the human CYP46A1 gene have 
never been described. In addition, little is known about the transcriptional modulation of 
this gene by endogenous or exogenous signals. The recently cloned CYP46A1 5’-flanking 
region was found to be rich in putative Sp binding sites (Ohyama et al. 2006). 
Transcription factors belonging to the family typified by Sp1 are involved in the 
expression of a large number of genes, including most of those known as housekeeping 
genes. Spl, Sp3 and Sp4 are closely related members of the Sp gene family encoding 
proteins with very similar structural features. Most significantly, the DNA binding 
domains of Spl, Sp3 and Sp4 are highly conserved, formed of three conserved Cys2His2 
zinc fingers (Suske 1999), that recognize the GC box (GGGGCGGGC) and the GT motif 
(GGGTGTGGC) with identical affinities (Hagen et al. 1992). 
Within this family, Sp1 and Sp3 are ubiquitously expressed in mammalian cells while 
Sp4 expression is highly enriched in the brain (Hagen et al. 1992). Although, Sp1, Sp3 
and Sp4 present structure similarities, comparison of the Sp knockout mice phenotypes 
have revealed overlapping as well as distinct functions (Bouwman et al. 2000). Indeed, 
null mutation of Sp1 in mouse is embryonic lethal (Marin et al. 1997). Similarly, Sp3 null 
mice die soon after birth (Bouwman et al. 2000). As expected, the abnormalities arising 
from Sp4 ablation are most apparent in the nervous system (Supp et al. 1996, Zhou et al. 
2005). 
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In the present study, we aimed at identifying regulatory elements and factors involved 
in basal CYP46A1 expression. Moreover, since the CYP46A1 promoter was found to 
contain multiple potential Sp binding sites, the particular role of the Sp family of 
transcription factors in the CYP46A1 brain-specific expression was evaluated. 
 
2.3 Methods 
2.3.1 Cloning of the 5’-upstream region of the human CYP46A1 gene 
The 5’-upstream region sequence of the human CYP46A1 gene was identified with the 
Basic Local Alignment Search Tool (BLAST) using the human CYP46A1 mRNA 
sequence (GenebankTM accession number NM_006668). A 4.8-kb fragment of human 
CYP46A1 promoter was cloned in pCR®-2.1TOPO® vector (Invitrogen Corporation, 
California, USA) after amplification by PCR using human genomic male DNA (Promega 
Corporation, Madison, WI, USA) as a template and the Expand Long Template PCR 
System (Roche Diagnostics GmbH, Penzberg, Germany). The primers used to amplify a 
4765 bp region between nucleotides -4828 and -64 are listed in Table 2.1 (primers 
hCYP46PromF2 and hCYP46PromR2; +1 refers to the A of the initiation methionine). 
The insert of the recombinant plasmid harboring the CYP46A1 promoter region 
encompassed by nucleotides -4828 and -64 was sequenced by primer walking and named 
promCYP46-pCR2.1.  
 
2.3.2 Plasmids 
Several different fragments derived from the 5’ flanking region of the human 
CYP46A1 gene were subcloned in the luciferase expression vector pGL2 Basic vector 
(Promega) using standard recombinant technology methods. The promCYP46-pCR2.1 
recombinant was digested with Kpn I/ Xho I (1290bp), Mlu I/ Xho I (353bp), Sac I/ Xho I 
(209bp) and each of the restriction fragment were subcloned in the pGL2 reporter 
plasmid, generating plasmids 1.2pGL2 (-1219 to -64; +1 refers to the A of the initiation 
methionine), 0.3pGL2 (-417 to -64) and 0.2pGL2 (-271 to -64). Two fragments of the 
human CYP46A1 proximal promoter were amplified with forward primers 120XmaIf and 
SP-RE-B and the reverse primer XhoIr  (Table 2.1) containing a Xho I overhang site, 
using Pfu polymerase (Stratagene, CA) and the promCYP46-pCR2.1 plasmid as template. 
The PCR amplified fragments were subcloned in pGL2 reporter plasmid into the Sma I 
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and Xho I sites, generating recombinants 0.12pGL2 (-236 to -64) and 0.09pGL2 (-152 to -
64). 
The rat CYP46A1 proximal promoter was identified as described above using the rat 
CYP46A1 mRNA sequence (GenebankTM accession number XM_343108) and a 168 
nucleotide fragment was amplified by PCR using rat genomic DNA and primers 
RatCYP46promf and RatCYP46promr (Table 2.1). The amplified fragment was 
subcloned in the pGL2 reported construct into the Sma I and Xho I sites, generating 
construct rCYP46Prom (-226 to -54; +1 refers to the A of the initiation methionine).  
 
2.3.3 Cell culture 
SH-SY5Y (human neuroblastoma) and U118 (human glioma) cell lines were 
maintained in low glucose Dulbecco’s modified Eagle’s medium (DMEM) (Sigma 
Aldrich Inc., St Louis, MO, USA), while HeLa (cervix adenocarcinoma) was cultured in 
high glucose DMEM (Sigma) at 37 ºC in humidified 5% CO2. All media were 
supplemented with 10% heat inactivated fetal bovine serum (Biochrom KG, Berlin, 
Germany), 2mM L-glutamine (Sigma), 100 units/ml penicilline and 100µg/ml 
streptomycin (Sigma), with the exception of U118 culture medium that was supplemented 
with 4 mM L-glutamine. 
Cultures of Drosophila melanogaster Schneider cell line (SL2) were maintained in 
Schneider medium (Sigma) supplemented with 10% heat inactivated fetal bovine serum, 
50 units/ml penicillin and 50 µg/ml streptomycin at 25 ºC and atmospheric CO2. 
Neurons were isolated from fetuses of 17–18 day pregnant Wistar rats, as previously 
described (Silva et al. 2002). Astrocytes were isolated from 2-day-old rats as previously 
described (Blondeau et al. 1993), with minor modifications (Silva et al. 1999). Animal 
care followed the European Legislation on Protection of Animals Used for Experimental 
and Scientific Purposes (EU directive L0065, 22/07/2003). 
 
2.3.4 Transactivation assays 
To minimize variations in transfection efficiency, replicates were transfected, in single 
batch suspension with FuGENE 6 (Roche) according to the manufacturer’s instructions. 
Plates containing 150 000 cells were co-transfected with 0.5 µg of the reporter plasmid 
and different amounts of each expression vector. Cells were inoculated in 24-well plates 
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and maintained for 48h. These cells were harvested and lysed in reporter lysis buffer 
(Promega). Cell extracts were assayed for luciferase and β-galactosidase activity (β -Gal 
Reporter Gene Assay, Roche). The SL2 cell extracts were normalized for the total amount 
of protein (BCA reagent, Pierce, Rockfort, IL) prior to performing the luciferase assay, 
since Sp expression vectors were shown to severely induce β -galactosidase expression in 
transfected cells. 
 
2.3.5 Site-directed mutagenesis 
The plasmids 0.09pGL2 and 0.12pGL2 served as the template for site-directed 
mutagenesis using the QuickChange Site Directed Mutagenesis Kit (Stratagene). All 
reactions were performed according to the protocol provided by the manufacturer. The 
MD90CYP46 oligonucleotide (Table 2.1 - mutated bases underlined) was used for site-
directed mutagenesis of the SP-RE-A and SP.RE-B binding sites, while oligonucleotide 
MDSPRE-C was used for mutagenesis of SP-RE-C and MD120SPRE-D for SP-RE-D 
site.  
 
2.3.6 CYP46A1 expression analysis 
Total cell RNA was extracted using Trizol Reagent (Invitrogen) following 
manufacturer’s instructions. RNA was finally resuspended in nuclease-free water 
(Promega), and quality of the RNA was checked on a 2.2
 
M formaldehyde/MOPS 1.2% 
agarose gel. Total RNA from human brain was purchase at BD Biosciences, Palo Alto, 
US. RT-PCR (Access RT-PCR System, Promega) was performed with 1 µg of total RNA 
with the following primers (Table 2.1): CYP46A1 (RTCYP46f and RTCYP46r); human 
β-actin (hACTINf and hACTINr), rat β-actin (rACTINf and rACTINr). Reaction 
conditions were as follows: 45
 
°C for 45 min, 94 °C for 2 min, followed by 35 cycles
 
of 
denaturation at (94 °C, 30 s), annealing (55 °C,
 
1 min), and extension (68 °C, 1 min), with 
a final extension
 
(68 °C, 7 min). 
 
2.3.7 Nuclear extracts 
Nuclear extracts were prepared as described by Schreiber and co-workers (Schreiber et 
al. 1989). Recombinant Sp proteins used in the gel mobility-shift assays were obtained by 
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transfecting 8 x 10
6
 SL2 cells with 10 µg of pPac-Sp1, pPac-Sp3FL and pPac-Sp4. Cells 
were seeded in 100mm plates and maintained for 48 h for nuclear extract preparation.  
 
2.3.8 Western blot analysis 
Twelve micrograms of nuclear protein were subject to 8% SDS-PAGE gels and 
electroblotted onto Immobilon P (Millipore, Bedfore, MA). After visualisation of the 
transferred proteins by amido black staining, the membranes were incubated with anti-
Sp1 (PEP-2), anti-Sp3 (D-20), or anti-Sp4 antibody (V-20) from Santa Cruz 
Biotechnology. Results were quantified using the Quantity One version densitometry 
analysis software (Bio-Rad Laboratories).  
 
2.3.9 Electroforetic mobility shift assay (EMSA) 
Double-stranded DNA probes and competitors were generated by annealing of 
complementary single-stranded oligonucleotides Sp-cons, SP-RE-A, SP-RE-B, SP-RE-C, 
mSP-RE-C, SP-RE-D, mSP-RE-D, SP-RE-E, SP-RE-F, SP-RE-G, SP-RE-H, SP-RE-I, 
and SP-RE-J (see Table 2.1). DNA (6 pmol) was end-labeled with γ32P dATP using T4 
polynucleotide kinase, and unincorporated nucleotides were removed by Sephadex G25 
filtration. The binding reactions were performed at 4 ºC in a total volume of 20 µl and 
contained: 2-5µg of nuclear extract, 10 mM of HEPES buffer, pH 8.0; 0.1 mM EDTA; 2 
mM DTT; 17.5% glycerol; 40 mM spermidine; 40 mM MgCl2; 0.5 µg of dIdC; 1 µg 
salmon sperm DNA; and 0.5-2 ng of oligonucleotide probe. In competition assays excess 
unlabeled oligonucleotide was pre-incubated (30 min), prior to incubation with each 
probe for additional 20 min. Super-shift reactions, were performed with 1 µl of anti-Sp1 
(PEP-2, Santa Cruz Biotechnology), of anti-Sp3 (D-20, Santa Cruz Biotechnology), or of 
anti-Sp4 antibody (V-20, Santa Cruz Biotechnology), which was added to the reaction 
media, that were kept on ice for 30 min before addition of the probe. Protein-DNA 
complexes were resolved on 5% non-denaturing PAGE gels (29:1 acrylamide: 
bisacrylamide) in 0.5 X Tris-borate buffer (45 mM Tris-borate, 1mM EDTA). The gels 
were eletrophoresed for 2 h 30 m, at 30 mA. 
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Table 2.1. Sequence of oligonucleotides used in this study: Putative Sp responsive 
elements in bold, mutated bases in small caps, and the position of the restriction site used 
in subsequent cloning are underlined. 
 
Oligonucleotide Cloning Mutagenesis EMSA RT-
PCR 
Sequence (5’→3’) 
hCYP46PromF2 X    GAGGTTCAAGGAAGCTGGAAAC
TGGGTTCCAGTCCTG 
hCYP46PromR2 X    GAGCCGACTCAGCTGTCAG 
120XmaIf X    AAACCCGGGGGAGGGCCCGG 
XhoIr X    TGACAGCTGAGTCGGCTCGAGC
CG 
RatCYP46promf X    CGGGGGCGGGTCCTGAGAGC 
RatCYP46promr X    CGGCTCGACCGACTAGCTGTCA
GC 
MD90CYP46  X   CATAACCCCGGCGGGttCttAGCC
GAGCGttCttGGAGGGTGCTGGG
TC 
MD120SPRE-C  X   GGACTGTGCGCCCTGttAtGtGTC
GGAGTCGCG 
MD120SPRE-D  X   CCCAAACCCGGGttAtGtCCCGG
AGCGCCGGAGC 
Sp-cons   X  ATTCGATCGGGGCGGGGCGAG
C 
SPRE-A   X  CCGAGCGGGCGGGGAGGGTG 
SPRE-B X  X  CGGCGGGGGCGGAGCCGAGC 
SPRE-C   X  CGCCCTGGGAGGGGTCGGAG 
mSPRE-C   X  CGCCCTGttAtGtGTCGGAG 
SPRE-D   X  AAACGGGGGAGGGCCCGGAG 
mSPRE-D   X  AAACGGGttAtGtCCCGGAG 
SPRE-F   X  AGGTTGGGGCGGAGCTCTGG 
SPRE-G   X  GGGCTGGGGCGGTGTGGAGG 
SPRE-H   X  TGCTCGGGGTGGGGCCTGGG 
SPRE-I   X  AGGTGGGGGCGGAGCCTGGG 
SPRE-J   X  CTGCTGGGGCGGACCTGAGT 
RTCYP46f    X TCA GTC ATC GTC ACG AGT CC 
RTCYP46r    X CTG GTC TCC ATC CCA AAA GC 
hACTINf    X GCA CCA CAC CTT CTA CAA 
TGA GC 
hACTINr    X AAT GTC ACG CAC GAT TTC 
CCG C 
rACTINf    X TATGGAGAAGATTTGGCACC 
rACTINr    X CCACCAATCCACACAGAGTA 
 
2.3.10 Statistical analysis 
Statistical analysis was performed using the Student’s t-test and the ANOVA one-way 
test with the Tukey HSD post-hoc test or the Tukey HSD for unequal N (Spjotvoll/Stoline 
test). All analysis was performed using the STATISTICA (data analysis software system), 
version 7.1 StatSoft, Inc. (2006). 
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2.4 Results 
2.4.1 Cloning of the 5´-upstream region of the human CYP46A1 gene 
A 4765bp fragment of the human CYP46A1 gene (between nucleotides -4828 and -64; 
+1 refers to the A of the initiation methionine), was identified with BLAST and amplified 
as described in section 2.3.1. 
As previously described, like in many neuronal genes, the CYP46A1 5’-flanking region 
was found to be GC-rich and lacking a typical CAAT or TATA boxes (Ohyama et al. 
2006). The most striking feature of the CYP46A1 proximal promoter was the presence of 
10 putative Sp-binding sites in the region encompassed by nucleotides -417 to -64 (Figure 
2.1 A). 
The CYP46A1 reporter plasmids and the parental pGL2basic vector were transfected 
into SH-SY5Y (human neuroblastoma) and into U118 (human glioma) cells, which 
express low levels of endogenous CYP46A1 (Ohyama et al. 2006), and into a cell line in 
which CYP46A1 mRNA is undetectable - HeLa (cervix adenocarcinoma) (Figure 2.1 B). 
Surprisingly, CYP46A1 reporter constructs presented high luciferase activities even in the 
cell lines where CYP46A1 mRNA could not be detected (Figure 2.1 B). Significant 
differences were found between the luciferase activities of the different constructs, 
namely in SH-SY5Y cells (ANOVA one-way test: F = 242.3, df = 5, p < 0.001). Post-hoc 
comparisons revealed that significant differences were found between reporter constructs 
pGL2 and 0.09pGL2 (Tukey HSD p < 0.001), and between 0.09pGL2 and 0.12pGL2 
(Tukey HSD p < 0.05), suggesting that basal proximal promoter is located between 
nucleotides -236 and -64. 
Since the CYP46A1 proximal promoter has several GC boxes which could represent 
binding sites for the Sp family of transcription factors, we have investigated whether Sp 
family members are important in the regulation of this gene.  
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2.4.2 Basal activity of the CYP46A1 promoter 
SH-SY5Y cells were transfected with the 1.2pGL2 construct and treated with different 
dosages of Sp binding inhibitor mithramycin A. Mithramycin A has been shown to inhibit 
the ability of Sp to bind to DNA and thus act as a transcriptional inhibitor of gene 
expression (Chatterjee et al. 2001, Ray et al. 1989). Treatment with mithramycin A 
resulted in a significant reduction of CYP46A1 promoter activity in a dose-dependent 
manner (ANOVA one-way test: F = 14.47, df = 3, p < 0.001) (Figure 2.2). Addition of 
25, 75 and 125 nM mithramycin A for 24 h decreased the promoter activity to 71.8%, 
46.9% and 21.7% respectively, as compared to untreated 1.2pGL2. The post-hoc 
comparisons revealed that significant differences were found between the untreated cells 
Figure 2.1. Functional deletion analysis of the human CYP46A1 gene promoter. A) Nucleotide 
sequence of the human CYP46A1 5' flanking region (- 417 to -64; +1 refers to the A of the initiation 
methionine). Putative Sp binding sites are underlined. B) Basal transcriptional activity of the human 
CYP46A1 promoter in different cell lines. Progressive 5’ deletion constructs were transiently transfected 
into HeLa, U118 and SH-SY5Y cell lines. Transfections were carried out using 0.5 µg of the CYP46A1 
reporter construct or the empty pGL2 vector. Normalized luciferase activities were expressed as mean 
values ± SD of duplicates for a minimum of three experiments.  
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and cells treated with 75 and 125 nM of mithramycin A (Tukey HSD: 75 nM, p < 0.05; 
125 nM, p < 0.01). 
 
 
 
 
 
 
 
 
2.4.3 Identification of Sp-responsive sequences in the CYP46A1 gene promoter 
To further examine the role of Sp proteins in CYP46A1 gene transcription we have 
investigated the individual role of Sp1, Sp3 and Sp4 transcription factors, employing 
Drosophila SL2 cells. These cells lack endogenous Sp factors and therefore allow 
investigation of gene regulation without interference of endogenous Sp proteins (Dennig 
et al. 1995). 
Over-expression of the ubiquitously expressed Sp1 or Sp3 significantly increased the 
luciferase reporter gene activity of all the CYP46A1pGL2 recombinants (Figure 2.3 A1). 
The strongest transactivation levels, 18 and 24 fold were attained in the presence of the 
0.12pGL2 and 0.2pGL2 constructs respectively (Student’s t-test, p <0.001). Deletion of 
the DNA segments -236 to -152 and -152 to -64 significantly reduced transactivation by 
Sp1 (ANOVA one-way test:  F = 72.48, df = 4, p < 0.001) and Sp3 (ANOVA one-way 
test: F = 72.48, df = 4, p < 0.001). The post-hoc comparisons revealed that significant 
differences were found between pGL2 and each of the other reporter constructs (Tukey 
Figure 2.2. CYP46A1 promoter activity is repressed by mithramycin A. Transfections were carried 
out in SH-SY5Y cells using 0.5 µg of the 1.2pGL2 reporter construct or the empty pGL2 vector. Two 
hours after transfection, cells were treated with vehicle or with 25, 75, or 125 nM of mithramycin A. 
Cells were harvested 24 h after the treatment and the resultant luciferase activity was measured. The 
normalized luciferase activity of cells transfected with pGL2 or 1.2pGL2 and vehicle-treated was set to 
100%, and the activities of treated samples calculated and plotted as a percentage of this value. Results 
were expressed as mean ± SD of duplicates for a minimum of three experiments (†p < 0.05; *p < 0.001, 
significant differences due to mithramycin A treatment). 
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HSD for unequal N: 0.09pGL2 p < 0.05, 0.12pGL2 p < 0.001; 0.2pGL2, p <0.001; 
0.3pGL2, p <0.001), and between 0.09pGL2 and each of the other reporter constructs 
(Tukey HSD for unequal N: 0.12pGL2 p < 0.001; 0.2pGL2, p <0.001; 0.3pGL2, p 
<0.001). Moreover, transactivation of the 0.3pGL2 was shown to be dose-dependent with 
the Sp1 and Sp3 expression vector (Figure 2.3 A2).  
 
 
 
 
 
 
 
 
 
The activation potential of the brain-enriched Sp4 protein was likewise assessed in 
SL2 cells and the results showed that the CYP46A1 promoter was also highly 
transactivated by this transcription factor (15-fold activation) (Figure 2.3 B). 
Nevertheless, in contrast with what was found for Sp1 and Sp3, no significant differences 
Figure 2.3. Effect of over-expressing Sp proteins on the human CYP46A1 promoter in Sp-deficient 
Drosophila SL2 cells. Transactivation of the CYP46A1pGL2 reporter constructs by the ubiquitous Sp1 
and Sp3 proteins. Co-transfection of 0.5 µg of the CYP46A1pGL2 reporter constructs with empty vector 
or with 0.025 µg (A1) or with increasing concentrations of pPacSp1 or pPacSp3 (0.0125–0.05 µg) (A2). 
Transactivation of the CYP46A1pGL2 reporter constructs by the brain-enriched Sp4 protein. 
Transfection of 0.5 µg of the CYP46A1pGL2 reporter constructs with empty vector or with 2 µg of 
pPacSp4 (B1), or with increasing concentrations of pPacSp4 (0.5–2 µg) (B2). Normalized luciferase 
activities were expressed as mean values ± SD of fold induction of duplicates for a minimum of three 
experiments (†p < 0.05; *p < 0.001). 
A1 A2 
B1 B2 
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in the Sp4 activation levels were obtained between the different promoter deletion 
constructs. These results are in agreement with those of Hagen and co-workers (Hagen et 
al. 1992), which found that Sp4 is not able to act synergistically through adjacent binding 
sites. Moreover, transactivation of the 0.3pGL2 was also shown to be dose-dependent 
with the Sp4 expression vector (Figure 2.3 B2).  
 
2.4.4 Functional cooperation among members of the Sp family in the activation of 
the CYP46A1 
To investigate the combinatorial mechanisms of Sp proteins transcriptional regulation 
of the CYP46A1 gene we transiently co-transfected SL2 cells with the 0.12pGL2 
construct plus different combinations of Sp1, Sp3 and Sp4 expression vectors (Figure 
2.4). The results showed that significant synergistic enhancement of transcriptional 
activation could be obtained upon co-expressing either Sp4-Sp1 (32-fold) or Sp4-Sp3 
(38-fold). This important functional difference revealed the brain-enriched Sp4 protein as 
an important player in the regulation of the CYP46A1 gene by Sp proteins. 
 
 
 
 
 
 
 
 
Figure 2.4. Sp4 functionally synergizes with Sp1 and Sp3 in activating the CYP46A1 promoter. Co-
transfection of 0.5 µg of the 0.12pGL2 reporter construct with empty vector or different combinations of 
pPacSp1, pPacSp3, and pPacSp4 expression vectors in SL2 cells. Normalized luciferase activities were 
expressed as mean values ± SD of fold induction of duplicates for a minimum of three experiments (†p < 
0.05; §p < 0.01). 
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2.4.5 Characterization of the Sp binding sequences in the CYP46A1 promoter region 
We used gel mobility-shift assays with the goal of identifying active Sp binding sites 
within the CYP46A1 locus. First, oligonucleotides encompassing the putative Sp 
responsive elements in -417 to -64 region of the CYP46A1 promoter were synthesized. 
These were named Sp-RE-A, Sp-RE-B, and so forth (see Table 2.1 and Figure 2.1 A). 
HeLa cells nuclear extracts were used to characterize the binding activities of each Sp-RE 
site by electrophoretic mobility shift assay.  
The specificity of the complex(es) formed when a Sp consensus oligonucleotide (Sp-
cons) was used as a probe were verified by means of a supershift assay using an anti-Sp1 
antibody (Figure 2.5 A: arrowhead). All Sp-RE oligonucleotides were able to compete for 
Sp1 binding to the Sp-cons, although with different affinities. Indeed, oligonucleotides 
Sp-RE-A, Sp-RE-C, Sp-RE-G, and Sp-RE-J were not able to completely prevent the 
formation of the Sp1/ Sp-cons complex at a 100-fold molar excess. The Sp1/ Sp-cons 
complex was not competed by an unrelated DNA sequence (Figure 2.5 A). 
In order to prove that the Sp transcription factors were able to bind to the different Sp-
REs, Sp1, Sp3, and Sp4 transcription factors were over-produced in SL2 cells, and the 
nuclear extracts used to characterize their binding activities to Sp-RE-A, Sp-RE-B, Sp-
RE-C, and Sp-RE-D (Figure 2.5 B). Results have confirmed that the four binding sites 
were able to bind to each of the different Sp proteins, even though with apparently 
different affinities. 
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Figure 2.5. Characterization of the binding activities to Sp-RE sites. (A) EMSA was performed using 
HeLa cell nuclear extracts and a radiolabeled double-stranded oligonucleotide corresponding to the Sp 
consensus (Sp1-cons) as a probe. Competition experiments were performed by adding a 10- or 100-fold 
excess of unlabeled doublestranded oligonucleotides corresponding to cold-self, a non-specific tubulin 
sequence, and Sp-RE-A, -B, -C, -D, -F, -G, -H, -I and -J. Supershift experiments were performed using an 
anti-Sp1 antibody. (B) EMSA was performed with nuclear extracts of SL2 cells over-expressing Sp1, 
Sp3, and Sp4 proteins, using as probes radiolabeled double-stranded oligonucleotides corresponding to 
sites Sp-RE-A, -B, -C and -D. 
A 
B 
Chapter 2  
 
56 
 
2.4.6 Functional analysis of Sp binding sites in CYP46A1 promoter by site directed 
mutagenesis 
The functional relevance of sites Sp-RE-A, Sp-RE-B, Sp-RE-C, and Sp-RE-D for 
CYP46A1 promoter activation was investigated by individual or combined mutagenesis of 
each site in the 0.09pGL2 and 0.12pGL2 constructs, followed by transfection into SH-
SY5Y cells (Figure 2.6). As shown in Figure 2.6 A, individual or combined mutation of 
the four Sp-RE sites significantly reduced the activity of the 0.09pGL2 and 0.12pGL2 
constructs (ANOVA one-way test: F = 32.19, df = 8, p < 0.001). The post hoc 
comparisons revealed no significant differences between the individual mutation of Sp-
RE-C or Sp-RE-D sites, although protein–DNA binding reactions suggested different 
affinities of each of these sites for binding to Sp1/Sp3 (Figure 2.6B).  
Combined mutation of Sp-RE-A and Sp-RE-B, or Sp-RE-C and Sp-RE-D, reduced the 
promoter activity to approximately 30–40% of the wt, while mutation of the four Sp-RE 
sites, reduced activity to approximately 15% of the wt.  
The effectiveness of the introduced mutations in impairing Sp binding was tested by 
gel-shift competition assays with HeLa nuclear extracts and mutated oligomers. As 
demonstrated in Figure 2.6 B, the mutated oligonucleotides did not effectively compete 
with a Sp consensus probe for the binding to Sp1/Sp3 nuclear proteins. 
Finally, we have co-transfected SL2 cells with the 0.12pGL2 mutants and pPac-Sp1, 
pPac-Sp3, and pPac-Sp4 expression vectors (Figure 2.6 C). As expected, results of 
individual or combined mutation of the four Sp-RE sites significantly reduced 
transactivation by Sp3 and Sp1 (ANOVA one-way test: F = 32.19, df = 8, p < 0.001). 
Nevertheless, the introduced mutations did not significantly reduce transactivation by Sp4 
(data not shown), suggesting that other transcription factors might serve as a docking 
factor for Sp4. Taken together, these results strongly indicate that all four Sp-RE sites are 
functional elements of the CYP46A1 promoter. 
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  Figure 2.6. Mutational analysis of the Sp binding sites in the CYP46A1 promoter using the 
0.12pGL2 reporter plasmid altered by site-directed mutagenesis. (A) SH-SY5Y cells were transfected 
with 0.5 µg of wild-type (0.12pGL2 wt) or the different mutated promoter reporter plasmids (mAB, mC, 
mD, mABC, mCD mABCD). The normalized luciferase activity of the 0.12pGL2 wt was set to 100%, 
and the activities of the mutant plasmids were calculated and plotted as a percentage of this value. Results 
were expressed as mean values ± SD of duplicates for a minimum of three experiments. (B) EMSA was 
performed using HeLa cell nuclear extracts and a radiolabeled double-stranded oligonucleotide 
corresponding to the Sp-RE-C and Sp-RE-D as a probe. Competition experiments were performed by 
adding a 10- or 100-fold excess of unlabeled doublestranded oligonucleotides corresponding to Sp 
consensus (Sp cons), a non-specific tubulin sequence, cold-self and mutated Sp-RE-C or -D. Super-shift 
experiments were performed using an anti-Sp1 and anti-Sp3 antibodies. (C) SL2 cells were co-transfected 
with 0.5 µg of wild-type (0.12pGL2 wt) or the different mutated promoter reporter plasmids (mAB, mC, 
mD, mABC, mCD, mABCD) and with 0.025 µg of pPac-Sp1 or pPac-Sp3 expression vector). The 
normalized luciferase activity of the 0.12pGL2 wt construct transactivated by Sp1 or Sp3 was set to 
100%, and the activities of the mutant plasmids were calculated and plotted as a percentage of this value. 
A 
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2.4.7 Conservation among species of the Sp responsive elements in the CYP46A1 
promoter 
We have cloned a 168 bp fragment of the rat CYP46A1 proximal promoter (-226 to -
54; +1 refers to the A of the initiation methionine), into the pGL2-basic vector (rat- 
CYP46A1pGL2), in order to assess if the Sp-responsive region was functionally 
conserved among species (Figure 2.7).  
To investigate the individual role of Sp1, Sp3 and Sp4 transcription factors in the 
activation of the rat CYP46A1 promoter we have over-expressed these proteins in SL2 
cells transfected with the ratCYP46A1pGL2 reporter construct. A significant increase in 
the luciferase reporter activity was observed for samples transfected with pPac-Sp1, pPac-
Sp3 and pPac-Sp4, demonstrating the functionality of the orthologous Sp-RE sites in rat 
CYP46A1 promoter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Transactivation of the rat CYP46A1 promoter by Sp proteins in Sp-deficient Drosophila 
SL2 cells. (A) Comparison of the rat (R) and human (H) proximal promoter of the CYP46A1 genes. 
Putative Sp binding sites are underlined. Vertical dashed lines indicate sequence similarities. Numbers 
represent nucleotide positions relative to the first codon. (B) The ratCYP46A1pGL2 reporter (0.5 µg) was 
co-transfected with 0.025 µg of pPacSp1, 0.025 µg of pPacSp3, 1 µg of pPacSp4 or empty vector. 
Normalized luciferase activities were expressed as mean values ± SD of fold induction of duplicates for a 
minimum of three experiments. 
A B 
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2.4.8 Sp binding activity in primary cultures of cortical neurons and astrocytes 
To determine which Sp proteins bind to the Sp-REs sites of the CYP46A1 promoter in 
primary cultures of rat cortical neurons and astrocytes, specific antibodies against Sp 
proteins were added to the DNA-binding reactions using nuclear extracts from primary 
cell cultures (Figure 2.8). 
In rat cortical neurons supershift analysis revealed that Sp3 and Sp4 were the major 
components of the complexes formed with the Sp-RE-D probe. Similar results were 
obtained with Sp-RE-B and Sp-RE-C (data not shown). Indeed, anti-Sp3 antibody, 
retarded complexes II and III, while the anti-Sp4 antibody retarded complex I. The anti-
Sp1 antibody was unable to retard or deplete any of the complexes. In astrocytes nuclear 
extracts, the Sp proteins that bound the Sp-RE-D probe were Sp1 (complex I) and Sp3 
(complex III). In this case, addition of the anti-Sp4 was unable to retard or deplete any of 
the complexes. 
 
 
 
 
 
 
 
Figure 2.8. Sp proteins binding activity to the Sp-RE sites of the CYP46A1 proximal promoter in 
nuclear extracts from primary cortical neurons and astrocytes. EMSA was performed using 5 µg of 
primary cortical neurons and astrocytes nuclear extract proteins and a radiolabeled double-stranded 
oligonucleotide corresponding to site Sp-RE-D as a probe. Super-shift experiments were performed with 
an anti-Sp1, -Sp3 and -Sp4-specific antibodies. 
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2.4.9 Correlation between Sp protein levels and CYP46A1 mRNA 
The transactivation results obtained in SL2 cells transfected with different 
combinations of Sp1, Sp3, and Sp4 expression vectors have shown a significant 
synergistic enhancement of transcriptional activation by Sp4 when co-expressed with 
either Sp1 or Sp3. Moreover, supershift analysis revealed that Sp3 and Sp4 were the 
major components of the complexes formed with the Sp-RE probes in cortical neurons. 
These results suggested that CYP46A1 expression levels may depend on the cell-specific 
differences in the expression levels of Sp proteins. Therefore, we have also determined 
the accumulation of the CYP46A1 mRNA in HeLa, U118, SH-SY5Y, and PC12 cells, as 
well as in primary cultures of rat cortical neurons and astrocytes. Total RNA from human 
brain and rat cortex were used as positive controls (Figure 2.9 A). In parallel, we have 
assessed the relative concentrations of Sp1, Sp3, and Sp4 protein levels (Figure 2.9 B).  
RT-PCR analyses have shown that the human-derived cell lines present undetectable 
(HeLa) or extremely low levels of CYP46A1 mRNA (U118, SH-SY5Y). These results 
were confirmed by real-time quantitative RT-PCR (data not shown). As expected, the 
highest CYP46A1 mRNA levels were detected in primary cultures of rat cortical neurons 
(Figure 2.9 A). Although in vivo Cyp46a1 was reported to be expressed only in neurons 
(Lund et al. 1999), we could detect high levels of CYP46A1 mRNA in primary cultures 
of rat astrocytes. 
As expected, western blot analysis exhibited distinctive levels of Sp1, Sp3, and Sp4 
proteins in the different cells tested (Figure 2.9 B). Interestingly, an inverse correlation 
could be found between the Sp1/total Sp ratio and the CYP46A1 mRNA levels. These 
results were in agreement with our in vitro results which showed that the highest 
transactivation of the CYP46A1 proximal promoter was achieved upon co-transfection of 
Sp3 and Sp4 expression vectors. On the other hand, the only cell line where CYP46A1 
mRNA was undetectable (HeLa) presented the lowest levels of Sp4. Nevertheless, there 
was no correlation between the levels of Sp4 and CYP46A1 mRNA in continuous cell 
lines, which suggests that other transcription factors or epigenetic modifications of this 
GC-rich promoter might also be important for CYP46A1 basal expression levels. 
Role of Sp proteins in CYP46A1 transcription 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5 Discussion 
In this study, we have performed an analysis of the human CYP46A1 promoter to 
identify DNA elements and transcription factors that regulate basal expression of this 
Figure 2.9. Correlation between CYP46A1 mRNA level with Sp family protein abundance in 
various cells types. (A) RT-PCR performed on total RNA isolated from HeLa, U118, SH-SY5Y, and 
PC12 cells, from primary cultures of rat cortical neurons and astrocytes, and from human brain and rat 
cortex. Reactions were performed in parallel under identical conditions using primers targeting the 
CYP46A1 mRNA, and the β-actin transcript as a control. Amplification products were separated in 
ethidium bromide- labeled agarose gel eletrophoresis. (B) Nuclear extracts were isolated from HeLa, 
U118, SH-SY5Y, and PC12 cells and from primary cultures of cortical neurons and astrocytes. Nuclear 
proteins (12.5 µg) were subjected to SDS-PAGE (8%), transferred to PVDF membranes, and the 
membranes were incubated with a specific anti-Sp1, -Sp3 and -Sp4 antibody. Protein loading control 
using Amido Black staining of the membrane is shown in the bottom panel. The results shown are 
representative of those obtained in three independent cultures.  
A 
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gene. Deletion analysis revealed that a region spanning from -236 to -64 (+1 refers to the 
A of the first codon) is indispensable for basal expression of this TATA-less promoter 
activity. This GC-rich promoter region, which comprises consensus binding elements for 
Sp proteins and other zinc finger proteins as Egr-1 and Egr-2 transcription factors, is 
sufficient for high activity level in neuroblastoma cells. 
Our data suggest that the neuronal-specific expression of CYP46A1 is regulated by 
positive regulatory elements rather than by a discrete repressive element, such as the 
neuronal restrictive silencer element (REST) that has been described to regulate cell type 
specificity of many neuronal genes (Ballas & Mandel 2005). Indeed, treatment of SH-
SY5Y cells with mithramycin A, resulted in a significant reduction of promoter activity, 
suggesting a role of Sp family of transcription factors in CYP46A1 regulation. This 
chemotherapeutic drug has been used extensively as a tool to study Sp-dependent 
transcriptional responses, since it was shown to globally inhibit binding of Sp 
transcription factors to their cognate sites (Ray et al. 1989, Blume et al. 1991, Chatterjee 
et al. 2001). 
Sp1 is generally considered a transcriptional activator, although an inhibitory region 
has recently been mapped in its extreme amino terminus (Bouwman & Philipsen 2002, 
Lee et al. 2005). Sp3 can function as an activator or a repressor depending on its isoform, 
PTMs and the sequence context of a given cis-element (Suske 1999, Bouwman & 
Philipsen 2002, Li et al. 2004, Sapetschnig et al. 2004). Sp3 has four isoforms that are the 
products of differential translational initiation (Sapetschnig et al. 2004). The short forms 
of Sp3 lack the subdomain A of the transactivation domain and act as repressors or weak 
activators. Although Sp3 is a transcription activator, it has also been described to reduce 
Sp1-dependent transcription of promoters containing adjacent Sp-binding sites by 
competing with Sp1 for promoter occupancy (Yu et al. 2003). Yet, there are promoters 
for which Sp3 activates rather than represses transcription (Gartel et al. 2000, Sowa et al. 
1999). Despite the different roles of Sp1 and Sp3, they are generally thought to compete 
for the same binding sites. Previous studies have shown that both Sp1 and Sp3 are 
associated in situ with the GC boxes of a variety of promoters (Chan et al. 2004, Lee et 
al. 2004, Liu et al. 2004, Stoner et al. 2004, Zelko & Folz 2004, de Leon et al. 2005, Sun 
et al. 2005a). 
In this study, we have shown that the CYP46A1 promoter is highly transactivated by 
Sp1, Sp3 and Sp4. Moreover, we have identified a critical role of four repeated GC boxes 
in the regulation of CYP46A1 promoter activity and in DNA– protein complex formation. 
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These GC-boxes were demonstrated to be both required and sufficient for high levels of 
promoter activity in neuroblastoma cells. Moreover, Sp1, Sp3, and Sp4 are able to bind to 
the four Sp-RE elements in the CYP46A1 promoter. Combined mutation of Sp-RE-A and 
B, or Sp-RE-C and -D, reduced the promoter activity to approximately 30–40% of the wt, 
while only the mutation of the four Sp-RE sites, reduced activity to approximately 15% of 
the wt, and impaired transactivation by Sp proteins. Although we cannot rule out a role 
for other GC box-binding transcription factors, Sp3 and Sp4 were the major components 
of the protein–DNA complexes observed in extracts of primary cortical neurons, 
suggesting that these factors are essential for the activity of these GC boxes in neurons. 
Moreover, significant synergistic enhancement of the promoter transcriptional activation 
was obtained upon co-expressing Sp4 with Sp3. 
Our studies suggest that Sp proteins contribute not only to control the level of 
CYP46A1 expression but also to regulate the cell-type specificity. Since Sp1 and Sp3 are 
ubiquitously expressed, it may seem surprising that such transcription factors may 
contribute to the neuronal-specific expression of CYP46A1. Nevertheless, growing 
evidences suggest a role of Sp proteins in the cell-specific expression of several neuronal 
genes, namely cyclin-dependent kinase 5 (Ross et al. 2002b), N-methyl-D-aspartate 
receptor (Liu et al. 2004), secretin (Lee et al. 2004), superoxide dismutase 2 (Mao et al. 
2006), neurogranin (Gui et al. 2006), and neurotrophin-3 (Ishimaru et al. 2007). 
Moreover, Sp proteins have been shown to be mediators of cyclooxygenase-2 induction 
by oxidative stress in primary neurons (Lee et al. 2006), and other results have suggested 
the need for Sp proteins as mediators of the transcriptional responses triggered by nerve 
growth factor (Yan & Ziff 1997, Billon et al. 1999, Sobue et al. 2005). Thus, the four Sp-
RE boxes and their corresponding binding proteins may play an important role in 
regulating both the level of expression and cell-type specificity of the CYP46A1 gene. 
Our results suggest that CYP46A1 expression level will depend on the cell-specific 
differences in Sp proteins levels. We have found an inverse correlation between the 
Sp1/total Sp ratio and the CYP46A1 mRNA levels. Moreover, the ratios of Sp proteins 
present in the neuronal versus non-neuronal cells correlate well with their relative 
contributions to the Sp-RE binding activity. Indeed, these results are in agreement with 
our in vitro studies which show that the highest transactivation of the CYP46A1 proximal 
promoter is achieved upon co-transfection of Sp3 and Sp4 expression vectors. 
Unfortunately, a good human cell model for the study of the human CYP46A1 expression 
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has not yet been found, which prevented us to confirm Sp3 and Sp4 binding to the human 
promoter by chromatin immunoprecipitation assays. 
It is interesting to notice that CYP46A1 has been recently described to be expressed in 
vivo in neurons of the neural retina (Bretillon et al. 2007), cells where Sp4 is also 
expressed in high levels (Lerner et al. 2005). Nevertheless, we have not found any 
correlation between Sp4 levels and CYP46A1 mRNA in the continuous cell lines, which 
suggests that PTMs that may affect Sp protein activity, other transcription factors, or 
epigenetic modifications of the CYP46A1 promoter, might also be important for basal 
expression of this gene. Indeed, posttranslational modifications might be affecting Sp1 
and Sp3 gene regulation in the human neuroblastoma cell line, since PTMs, such as 
phosphorylation, glycosylation, ubiquitinylation, acetylation, ribosylation (Bouwman & 
Philipsen 2002), and SUMOylation (Spengler et al. 2005, Spengler & Brattain 2006) have 
been described to affect Sp protein function. However, little is known about Sp4 PTM 
that may affect its function.  
Preliminary results from Ohyama and co-workers (Ohyama et al. 2006), revealed a 
potential for oxidative stress regulation of CYP46A1. Indeed, these authors have shown 
that when exposing SH-SY5Y cells to the organic hydroperoxide tert-butylhydroperoxide, 
the reporter promoter activity was stimulated ~2-fold. Interestingly, Sp1 and Sp3 have 
been described as neuronal oxidative stress-induced transcription factors (Ryu et al. 2003, 
Lee et al. 2006). Sp1 and Sp3 protein levels and function have also been described to be 
altered in neurodegenerative diseases that have been linked to oxidative stress and defects 
in cholesterol homeostasis, such as in Huntington’s and Alzheimer’s Disease (Dunah et 
al. 2002, Blalock et al. 2004, Qiu et al. 2006, Santpere et al. 2006). Moreover, Sp1 has 
been described to play an important role in regulating genes involved in the amyloid 
cascade (BACE1, BACE2, Tau) (Sun et al. 2005b, Heicklen-Klein & Ginzburg 2000, 
Christensen et al. 2004). 
Of interest is the observation that many LXR target genes, involved in lipid 
metabolism and reverse cholesterol transport, present functional Sp binding elements in 
the promoter. The combination of LXREs and Sp sites has been identified and 
characterized on the promoter of the cholesterol ester transfer protein gene (Le Goff et al. 
2003, Luo & Tall 2000), ABCA1 (Thymiakou et al. 2007), apoE  (Zannis et al. 2001), 
and lipoprotein lipase (Yang & Deeb 1998, Zhang et al. 2001). Thus, the cross-talk 
between LXR activation and members of the Sp family of transcription factors seems to 
play an important role in the modulation of lipid metabolism.  
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In conclusion, we have demonstrated the importance of Sp family of transcription 
factors as major regulators of CYP46A1 basal expression. Although, all Sp proteins are 
transactivators of the CYP46A1 promoter, neuronal differentiation may differentially 
modify the interaction and function between individual Sp factors and the cis-elements 
herein characterized, and, thus set up the brain-specific expression of the CYP46A1 gene. 
These findings may imply that cell-type specificity of transcription factors in the CNS 
may include a unique aspect of neurons: the substitution of Sp1 by Sp4. 
Since, 24OHC has been described as exerting an unique modulatory effect on amyloid 
precursor protein processing by increasing the alpha-secretase activity as well as the α- / 
β-secretase activity ratio (Famer et al. 2007), it is consequently possible that 
transcriptional regulators such as Sp proteins may serve as modifiers in 
neurodegenerative pathogenesis. 
Therefore, the identification of CYP46A1 as a target gene of Sp proteins can help to 
elucidate the molecular events involved in the regulation of gene expression in the central 
nervous system, but also in processes associated with neurodegenerative disorders. 
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3.1 Abstract 
CYP46A1 is a neuron-specific cytochrome P450 that plays a pivotal role in 
maintaining cholesterol homeostasis in the CNS. However, despite its importance, the 
molecular mechanisms underlying human CYP46A1 expression are still poorly 
understood, partly due to the lack of a cellular model that expresses high levels of 
CYP46A1 mRNA. Our previous studies demonstrated that Sp transcription factors 
control the level of CYP46A1 expression, and are most probably responsible for cell type 
specificity. Herein, we have differentiated Ntera2/clone D1 (NT2) cells into post-mitotic 
neurons, and identified for the first time a human cell model that expresses high levels of 
CYP46A1 mRNA. Immunocytochemistry and western blot analysis revealed a decrease 
in the ubiquitous Sp1 protein levels, concomitant with the increase in CYP46A1 mRNA 
levels. This decrease was correlated with changes in the ratio of Sp proteins associated to 
the CYP46A1 proximal promoter in the context of native chromatin. Indeed, by ChIP 
analysis a 50% decrease in the Sp1 protein recruited to the proximal promoter of this gene 
was detected. To examine if the increase in the (Sp3+Sp4)/ Sp1 ratio was observed at the 
level of other Sp-regulated neuronal promoters, we have selected four genes known to be 
expressed in the human brain, MOR, reelin, GRIN1 and GRIN2A, and analyzed the Sp1, 
Sp3 and Sp4 binding pattern to these promoters, in undifferentiated NT2 and in post-
mitotic neurons. ChIP data pointed to the fact that, contrary to what we initially 
hypothesize, the dissociation of Sp1 from promoter regions is not a common feature 
amongst neuronal Sp-regulated genes, since we could not identify any conserved patterns 
in the recruitment of Sp. Our results, suggest that binding of Sp proteins to DNA in a 
neuronal chromatin environment is highly dependent on promoter context, implying that 
although the Sp1 levels are significantly decreased after neuronal differentiation, Sp1-
dependent transactivation of specific neuronal promoter is most likely to occur. 
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3.2 Introduction 
Cholesterol metabolism in the central nervous system (CNS) is distinct from that in 
other tissues. No uptake of cholesterol from the plasma to the brain occurs, as the blood 
brain barrier (BBB) prevents the diffusion of large molecules at the tight junctions of 
brain capillary endothelial cells (Bjorkhem & Meaney 2004). Thus, virtually all the 
cholesterol necessary to the good functioning of the CNS is synthesized in situ (Dietschy 
& Turley 2004), and is efficiently recycled. To maintain cholesterol homeostasis the brain 
relies on a unique catabolism pathway, the conversion of cholesterol into 24(S)-
hydroxycholesterol (24OHC) (Bjorkhem & Meaney 2004), which is thought to be the 
most important mechanism of cholesterol turnover (Bjorkhem et al. 1997). The enzyme 
responsible for the conversion of cholesterol into 24OHC was found to be the neuronal 
specific cytochrome P450 46A1 (CYP46A1) (Lund et al. 1999). 
The CYP46A1 gene is localized in chromosome 14q32.1, encompasses 15 exons and 
14 introns and encodes the cholesterol 24-hydroxylase (Lund et al. 1999). Unlike other  
cytochrome P450 sterol hydroxylases that are predominantly expressed in the liver (Xie et 
al. 2003), CYP46A1 is highly expressed in neurons of several brain regions and also in 
neurons of the neural retina (Lund et al. 1999, Bretillon et al. 2007).  
Despite the pivotal role of CYP46A1 in the maintenance of brain cholesterol 
homeostasis, only recently the structural and functional characterization of the human 
CYP46A1 5’ flanking region was described (Ohyama et al. 2006, Milagre et al. 2008). 
Unlike what is common in other P450 genes, there is no substrate-dependent 
transcriptional regulation of CYP46A1 expression, and treatment of SH-SY5Y 
neuroblastoma cells with a broad spectrum of endogenous and exogenous compounds 
also did not result in any significant change in CYP46A1 promoter activity (Ohyama et al. 
2006). In our previous studies we have mapped a promoter region
 
indispensable for basal 
expression of this gene that responds to the ubiquitous specificity protein (Sp)1 and Sp3 
transcription factors, as well as the brain-enriched Sp4. Our results suggested that the 
cell-type specific expression of Sp transcription factors, namely the substitution of Sp1 by 
Sp4 in neurons, is responsible for the basal expression of the CYP46A1 gene (Milagre et 
al. 2008). Moreover, we have also demonstrated the importance of these transcription 
factors in the CYP46A1 response to the epigenetic modifiers trichostatin A and 5’-Aza-2’-
deoxycytidine (Nunes et al. 2010, Milagre et al. 2010), reinforcing the importance of the 
different Sp transcription factors in the regulation of CYP46A1. 
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Comparison of the human and rat CYP46A1 promoter sequences revealed significant 
differences, upstream of the core promoter (Milagre et al. 2008), suggesting that results 
from studies in rat primary cortical neurons may not reflect what happens in human brain. 
Therefore the lack of a cellular model that expresses high levels of human CYP46A1 
mRNA has limited the insight into the molecular mechanisms underlying the expression 
of this gene, namely the validation of our initial hypothesis that a shift in the ratio 
between Sp proteins recruited to the CYP46A1 promoter, favouring the neuronal enriched 
Sp4, would be responsible for an increase in CYP46A1 expression. Interestingly, Steve 
Barger has also put forward the hypothesis that the substitution of the ubiquitous Sp1 by 
Sp4 in neuronal cells, would be responsible for cell-type specificity expression in the 
CNS (Mao et al. 2006).  
Herein we aimed to confirm if an alteration in the ratio of Sp proteins recruited to the 
CYP46A1 promoter in human post-mitotic neurons, would be responsible for the 
neuronal-specific expression of this gene, and to analyze if such a switch, with important 
implications on the control of neuronal gene expression, also occurs in the promoters of 
other Sp-regulated genes, expressed in neurons. We have used the Ntera2/clone D1 (NT2) 
human teratocarcinoma cell line that can be induced by retinoic acid to differentiate into 
human postmitotic neurons (NT2N) and other cell types of neuronal lineage (Guillemain 
et al. 2000), and demonstrated for the first time a significant increase in CYP46A1 
mRNA levels that was concomitant with the decrease in the levels of Sp1 associated with 
the proximal promoter of this gene. Nevertheless, we did not identify any conserved 
alteration in the Sp protein binding patterns to the other neuronal Sp-regulated gene 
promoters analyzed, suggesting that Sp transcription factors DNA binding and 
transcriptional activity is highly dependent on the neuronal chromatin context, reinforcing 
the knowledge that Sp transcription factors act as part of complex networks in neuronal 
gene regulation. 
 
3.3 Methods 
3.3.1 Cell Culture 
NT2 testicular embryonal carcinoma cells were cultured as previously described 
(Cheung et al. 1999, Megiorni et al. 2005), with minor modifications. Briefly, NT2 cells 
were maintained in high glucose DMEM (Sigma Aldrich Inc., St Louis, MO, USA) 
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supplemented with 10 % heat inactivated fetal bovine serum (GIBCO, Rockville, MD, 
USA), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin (Sigma), 
at 37 °C in a humidified 5 % CO2 atmosphere. To obtain NT2 neurons (NT2N), cells 
were seeded at 1x10
6
 cells/ml in 100 mm bacterial grade Petri-dish to initiate cell 
aggregation and 10 µM all-trans retinoic acid (RA) (Sigma) was added in the following 
day. Medium was changed every 3 days and cells were maintained in RA-containing 
medium for 3 weeks. Afterwards, the cells were seeded in poly-D-lysine and Matrigel
®
 
(PDL-MG) coated tissue culture grade Petri dishes and maintained in high glucose 
DMEM supplemented with 5% FBS (Hyclone, Logan, UT, USA), 100 units/ml penicillin, 
100 µg/ml streptomycin and mitotic inhibitors [1 µM cytosine D-arabinofuranoside, 10 
µM fluorodeoxyuridine and 10 µM uridine (all from Sigma)]. 
 
3.3.2 Antibodies 
The antibodies used in western blot, immunocytochemistry (ICC) and chromatin 
immunoprecipitation (ChIP) are listed in Table 3.1. 
 
Table 3.1 – List of the antibodies used in western blot, immunocitochemistry and 
chromatin immunoprecipitation (ChIP). 
Protein Clone/ Reference Source Assay 
Sp1 PEP-2 Santa Cruz Biotechnology 
Western Blot, ICC, 
ChIP 
Sp3 D-20 Santa Cruz Biotechnology 
Western Blot, ICC, 
ChIP 
Sp4 V-40 Santa Cruz Biotechnology 
Western Blot, ICC, 
ChIP 
TUJ-1 MMS-435P Covance ICC 
Nestin AB5922 Millipore ICC 
MAP2 MAB3418 Millipore ICC 
NF200 N4142 Sigma ICC 
 
3.3.3 Immunocytochemistry 
Cells were washed with ice-cold PBS, fixed in 4 % paraformaldehyde / PBS, pH 7.4, 
permeabilized with 0.1 % Triton X-100
®
 in PBS, and then treated with blocking solution 
(10 % FBS, 0.05 % Triton X-100
®
 in PBS). Incubation with specific primary antibodies 
was performed overnight at 4ºC in a humidified chamber, followed by incubation with 
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FITC-conjugated goat anti-rabbit IgG antibody (Sigma) for 1 hour at room temperature. 
Finally, cells were rinsed with PBS, mounted in fluorescent mounting medium containing 
5 µg/ml Höechst dye 33258 (Sigma). Fluorescence was visualized using a Leica DC 100 
camera (Leica, Wetzlar, Germany) adapted to an Axioskop
®
 microscope (Zeiss, 
Göttingen, Germany) and photographed by using Image Manager 50 software (Leica). 
Control experiments for non-specific binding were performed in parallel by omission of 
the primary antibody. 
 
3.3.4 Expression Analysis 
Total cell RNA was extracted using Trizol Reagent (Invitrogen Carlsbad, CA, USA) 
following manufacturer’s instructions. Real-Time PCR analysis for CYP46A1 mRNA 
levels was performed as previously described (Nunes et al. 2010). Real-Time PCR 
analysis for reelin, GRIN1, GRIN2A and MOR was performed using SYBR green Master 
Mix in an ABI 7300 sequence detection system (Applied Biosystems, Foster City, CA, 
USA) and specific primers (Table 2) for reelin, GRIN1, GRIN2A and MOR. Results 
presented are from three individual experiments and each sample was assayed in 
triplicate. mRNA levels were normalized to the level of β-actin, and are presented as fold 
change from controls, using the 

Ct method (CYP46A1, reelin, MOR and GRIN2A) or 
using the standard curve method and expressed as fg of target mRNA per ng of β-actin 
mRNA (GRIN1). Six candidate genes (β-actin, GAPDH, 18s, ATPb5, UBC, eIF4A2) 
were analyzed with the Norm Finder algorithm (Andersen et al. 2004) and β-actin was 
found to be the most stable single gene to be used as an endogenous control, in the 
experimental conditions used. 
 
3.3.5 Western blot analysis 
Cells were harvested and lysed in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 1% Triton-X 100) containing 1 mM dithiothreitol and a protease inhibitor mixture 
(Roche Diagnostics GmbH, Penzberg, Germany). After incubation at 4 ºC, for 30 
minutes, samples were sonicated four times for 4 seconds each, on ice, followed by 
centrifugation at 14,000 rpm for 30 min. Proteins were subject to 7.5% SDS-PAGE gels 
and electroblotted onto Immobilon P (Millipore, Bedford, MA, USA). After visualization 
of the transferred proteins by amido black staining, the membranes were incubated with 
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specific antibodies. Results were quantified using the Quantity One version densitometry 
analysis software (Bio-Rad Laboratories Inc., Hercules, CA, USA). 
 
3.3.6 Chromatin immunoprecipitation 
NT2 cells (1 x 10
7
) were fixed with 1% formaldehyde for 10 min at room 
temperature. After cross-linking, the reaction was quenched with 0.125 M of glycine for 
10 min at room temperature. Cells were washed twice with ice-cold PBS, pelleted by 
centrifugation, resuspended in 1 ml of cell lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 
0.5% Igepal and 1 x protease inhibitor cocktail), and incubated 30 min at 4ºC. After 
centrifugation the nuclei were resuspended in nuclei lysis buffer (50 mM Tris-HCl pH 
8.1, 10 mM EDTA, 1% SDS and 1 x protease inhibitor cocktail) and incubated for 10 min 
on ice. The soluble chromatin with a size range of 0.5 kb to 0.9kb was prepared by 
sonication. After centrifugation to remove cell debris, chromatin was pre-cleared [1 h at 
4ºC with a 50% gel slurry of protein A/G – agarose beads saturated with salmon sperm 
DNA and bovine serum albumin (Upstate)], diluted in IP dilution buffer (0.01% SDS, 
0.5% Triton X-100, 2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 100 mM NaCl and 1 x 
protease inhibitor cocktail), and 10% of the supernatant was used as input. The diluted 
chromatin was incubated overnight at 4°C with the antibodies of interest and the immune 
complexes were recovered by 1 h incubation at 4ºC with a 50% gel slurry of protein A/G 
– agarose beads (Upstate). The precipitated complexes were washed sequentially with 
low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 
mM NaCl and 1 x protease inhibitor cocktail), high salt buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 500 mM NaCl and 1 x protease inhibitor 
cocktail), LiCl buffer (1 mM EDTA, 10 mM Tris-HCl pH 8.1, 250 mM LiCl, 1% Igepal, 
1% deoxycholic acid and 1 x protease inhibitor cocktail) and twice with Tris – EDTA 
buffer (1 mM EDTA and 20 mM Tris-HCl pH 8.1), and extracted twice with freshly 
prepared elution buffer (100 mM NaHCO3 and 1% SDS) with mild vortexing. The cross-
linking between DNA and proteins was reversed by incubation with 0.3 M NaCl, 
overnight at 67ºC, in the presence of RNase A. Samples were then digested with 
proteinase K at 45ºC for 1 h. DNA was purified using QIAquick PCR purification kit 
(Qiagen). The recovered DNA was analyzed by real-time PCR with SYBR green Master 
Mix in an ABI 7300 sequence detection system (Applied Biosystems). The real-time 
PCRs were performed using primers that covered CYP46A1 proximal promoter region as 
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previously described (Nunes et al. 2010), or primers for the proximal promoter regions of 
reelin, GRIN1, GRIN2A and MOR (Table 3.2).   
 
Table 3.2 – List of primers used in qPCR and qChIP 
Gene Primer name / 
TaqMan Assay 
Sequence (5’→ 3’) / Source q 
PCR  
RT-
PCR 
Ch
IP 
Referen-
ce 
CYP46A1 CYP46A1 
HS00198510_M1 
 
qChIP+1rCYP46f 
qChIP+1rCYP46f 
Applied Biosystems 
 
 
5’ gcggacctgagtctgaagag 3’ 
5’ aatcacaactccgcttctgg 3’ 
x  
x 
(Nunes et 
al. 2010) 
β Actin ACTB 
HS99999_M1 
 
qPCRHuACTINf 
qPCRHuACTINr 
 
hACTINf 
hACTINr 
Applied Biosystems 
 
 
5’-ctggaacggtgaaggtgaca-3’ 
5’-aagggacttcctgtaacaatcca-3’ 
 
5’-gcaccacaccttctacaatgagc-3’ 
5’-aatgtcacgcacgatttcccgc-3’ 
x 
 
 
 
x 
 
 
 x 
 
(Milagre 
et al. 
2008) 
neuroD 
hNeuroDFwd 
hNeuroDRev 
5’-gccccagggttatgagactatcact-3’ 
5’-ccgacagagcccagatgtagttctt-3’ 
x   
(Megiorni 
et al. 
2005) 
reelin qPCRReelinFwd 
qPCRReelinRev 
 
 
qCHIPReelinFwd 
qCHIPReelinRev 
5’-gcaccagccaaaggacttca-3’ 
5’-gttgccaccagcgcagtaa-3’ 
 
 
5’- ccgggacacgtgtggcggcg-3’ 
5’-ggcgagaagaagggcggacggg-3’ 
x  
x 
(Haas et 
al. 2002) 
 
(Kundako
vic et al. 
2009) 
GRIN1 qPCRGRIN1Fwd 
qPCRGRIN1Rev 
 
 
qCHIPGRIN1Fwd 
qCHIPGRIN1Rev 
5’-ccaggcggagagacagagaa-3’ 
5’-ctccttgcatgtcccatcact-3’ 
 
 
5’-gagcttcagccatccttcaa-3’ 
5’-ccttttccagagccttaccc-3’ 
x  
x 
(Bullock 
et al. 
2008) 
 
(Stadler et 
al. 2005) 
GRIN2A qPCRGRIN2Afwd 
qPCRGRIN2ARev 
 
 
qCHIPGRIN2AFwd 
qCHIPGRIN2ARev 
5’-atgggaaaaggtgggcaagt-3’ 
5’- cctccagggtgacgatgct-3’ 
 
 
5’-gctcctcccttgaccatgta-3’ 
5’-accagaagaggtgagccaga-3’ 
x  
x 
(Bullock 
et al. 
2008) 
 
(Stadler et 
al. 2005) 
MOR qPCRMORFwd 
qPCRMORRev 
 
qCHIPMORFwd 
qCHIPMORRev 
5’-ctgggtcaacttgtcccact-3’ 
5’-tggagtagagggccatgatc-3’ 
 
5’-actccttggatcgctttgc-3’ 
5’-cctcccaccttagtagttcaca-3’ 
x  
x 
(Bedini et 
al. 2010) 
 
(Liu et al. 
2009) 
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3.3.7 Statistical Analysis 
Statistical analysis was performed using the Student’s t-test, Kruskal-Wallis test with 
Dunn’s post-hoc test and the ANOVA one-way test with the Tukey HSD post-hoc test or 
the Tukey HSD for unequal N (Spjotvoll/Stoline test). All analysis was performed using 
the STATISTICA (data analysis software system), version 9.1 StatSoft, Inc. (2010) or 
Prism 5.0 software (GraphPad Software). 
 
3.4 Results 
3.4.1 Differentiation of the NT2 cell line 
The first protocols for neuronal differentiation of NT2 cells were very time 
consuming and laborious taking up to 2 months before NT2 neurons could be obtained 
(Andrews 1984, Pleasure et al. 1992). Therefore in the last decade there has been an 
effort to develop a differentiation culture system with reduced differentiation time. 
Indeed, cell aggregate methods for NT2 neuronal differentiation that rely on the use of a 
high concentration of RA, together with the influence of cell-cell adhesion in freely 
floating aggregates have been described (Megiorni et al. 2005, Paquet-Durand et al. 2003, 
Horrocks et al. 2003).  
The differentiation process is divided into two stages: the differentiation stage, in 
which NT2 cells are treated with RA for 21 days, and the replate stage, in which the NT2 
cells are replated in PDL-MG coated tissue culture grade petri dishes and treated with 
mitotic inhibitors for 1 week; herein we have named the days of RA treatment NT2 d0, d1 
and so forth until d21, and the 7
th
 day after replating as NT2N R7d. 
In order to assess if RA treatment was inducing the differentiation of the aggregate 
culture, we tested the expression of the basic helix-loop-helix transcription factor 
involved in neuronal differentiation (NeuroD) by RT-PCR in the first days of 
differentiation (Figure 3.1 A). Our results show an increase in NeuroD mRNA levels two 
days after addition of RA, which was in accordance with previous reports (Jain et al. 
2007, Megiorni et al. 2005, Przyborski et al. 2003).  
To confirm neuronal differentiation we assessed the presence of cytoskeletal markers 
both in immature precursors and mature neurons by immunofluorescence (Figure 3.1 B). 
NT2 d0 precursor cells express the intermediate filament nestin, a typical marker for 
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neuronal precursors (Figure 3.1 B), while displaying only faint immunoreactivity to the 
antibody against type III β-tubulin (TUJ-1). The replate in PDL-MG coated surfaces and 
the incubation with mitotic inhibitors, in the absence of RA, led to the decrease of 
proliferating NT2 precursor cells. Indeed, NT2N R7d neurons already displayed 
immunoreactivity for microtubule-associated protein 2 (MAP-2), neurofilament 200 
(NF200), and TUJ-1, and extensive neuritic networks. Counterstaing with Höechst dye 
revealed the presence of a few epitheloid cells (large nuclei) that do not have positive 
staining for the neuronal markers (Figure 3.1 B).  
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Analysis of neuronal markers during differentiation of NT2 cells. NT2 cells were treated 
with retinoic acid (RA) for 21 days. The cells were then replated on culture plates coated with PDL-MG 
and maintained for 1 week in the absence of RA and in the presence of mitosis inhibitors (NT2N). A) 
NeuroD mRNA levels, during NT2 differentiation, were determined by RT-PCR. β-actin was used as a 
control. B) Immunodetection of the neuronal markers TUJ-1, MAP2, Nestin and NF200. The results 
shown are representative of those obtained in at least three independent cultures. Scale bar = 100 µm. 
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3.4.2 CYP46A1 mRNA levels during NT2 neuronal differentiation 
After having confirmed that NT2N cells express several markers of post-mitotic 
neurons, we determined the CYP46A1 mRNA levels throughout differentiation (Figure 
3.2). We observed a 10.4 fold increase in CYP46A1 mRNA levels at NT2N R7d, when 
compared with the NT2 d0 cells (ANOVA one-way test:  F = 5.4, df = 5, *p < 0.001), 
demonstrating the up-regulation of this gene after neuronal differentiation.  
 
 
 
 
 
3.4.3 Expression pattern of other Sp regulated genes in undifferentiated and 
differentiated NT2 cells 
Afterwards we have also evaluated the mRNA levels of other genes expressed in 
neuronal cells and previously described has being regulated by Sp proteins, in 
undifferentiated (NT2 d0) and in differentiated NT2 (NT2N R7d) cells. We have chosen 
the µ opioid receptor gene (MOR) that has been shown to be highly regulated at the level 
of transcription (Xu & Carr 2001), reelin that codes for a serine protease involved in 
synaptic plasticity (Chen et al. 2005), and GRIN1 and GRIN2A that code for N-methyl-
D-aspartate (NMDA) receptors subunits, essential for  synaptic plasticity (Harris et al. 
1984) (Figure 3.3). We observed low mRNA levels of reelin and MOR in undifferentiated 
cells, but these significantly increased in NT2N cells, by 36.7- and 6.5- fold (Student’s t-
Figure 3.2. CYP46A1 mRNA expression analysis during differentiation of NT2 cells. Real-time PCR 
analysis of steady-state mRNA transcript levels in NT2 cells during differentiation. mRNA levels were 
normalized to the level of β-actin, expressed as fold change relative to undifferentiated cells and represent 
means ± SEM from at least three individual experiments (*p < 0.001).  
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test, †p < 0.01 and §p < 0.05), respectively. Furthermore, GRIN1 mRNA was not 
detected in undifferentiated cells whereas in NT2N R7d it was readily detected. In 
contrast, we did not observe any significant variation on the mRNA levels of GRIN2A. 
These data demonstrate the up-regulation of genes, other than CYP46A1, that have been 
described as targets of Sp proteins, during differentiation of NT2 cells into human 
neurons.  
 
 
 
 
 
 
3.4.4 Sp transcription factors levels during differentiation of NT2 cells into neurons 
We evaluated by immunocytochemistry and western blot if the protein levels of the 
different Sp transcription factors were altered during differentiation of NT2 cells (Figure 
3.4), since Sp1 and Sp3 are described as being expressed in all mammalian cell types, 
while Sp4 expression is mainly restricted to the brain (Suske 1999).  
Figure 3.3. mRNA expression analysis of  MOR, reelin, GRIN1 and GRIN2A in  NT2 d0 and NT2N 
R7d cells. Real-time PCR analysis of steady-state mRNA transcript levels in undifferentiated and 
differentiated NT2 cells. Values were normalized to the internal standard β-actin and expressed as fg of 
target mRNA per ng of β-actin mRNA (GRIN1) or as fold change relative to undifferentiated cells 
(reelin, MOR and GRIN2A) and represent means ± SEM from at least three individual experiments (§p < 
0.05; †p <  0.01; *p < 0.001). 
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Figure 3.4. Sp protein levels during differentiation of NT2 cells. A) Immunodetection of the Sp 
transcription factors Sp1, Sp3 and Sp4 in NT2 d0 and NT2N R7d cells. B) Western blot analysis of the Sp 
proteins levels during NT2 neuronal differentiation. Nuclear extracts were subjected to SDS-PAGE, 
transferred to PVDF membranes and the membranes were incubated with specific anti -Sp1, -Sp3 and -
Sp4 antibodies. Protein loading control using Amido Black staining of the membrane is shown in the 
bottom panel. The results shown are representative of those obtained in three independent cultures. Data 
represent means ± SEM and are expressed as fold change relative to control cells (§p < 0.05). Scale bar = 
100 µm. 
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Immunocytochemistry demonstrated that although all the Sp transcription factors 
were present in both the undifferentiated NT2 d0 and the differentiated NT2N R7d cells, 
Sp1 and Sp3 levels seemed to slightly decrease. Since it is difficult to quantitatively 
analyze immunostaining in cells with marked morphological differences such as those 
seen in the undifferentiated and differentiated cells, we further evaluated the different Sp 
protein levels by western blot analysis. We confirmed a decrease in protein levels of 
ubiquitous Sp1 during the differentiation of NT2 cells into neurons. In fact, Sp1 decreases 
to about 50% in NT2N R7d cells (Kruskal-Wallis test, §p < 0.05), when compared with 
undifferentiated NT2 d0. However, we did not observe any significant change in Sp3 
levels throughout differentiation, nor in the levels of the brain enriched Sp4. These results 
show that there is a shift in the ratio of Sp1/Sp3/Sp4 nuclear levels after neuronal 
differentiation of NT2 cells. 
 
3.4.5 Recruitment of Sp transcription factors to the GC-rich proximal promoters of 
CYP46A1 and other Sp-regulated genes in NT2 d0 and NT2N R7d cells 
To further understand if the decrease in Sp1 protein levels observed in NT2N cells 
lead to a modification in the multiprotein complex bound to the CYP46A1 promoter, we 
performed ChIP assays. We detected Sp1, Sp3 and Sp4 associated to the CYP46A1 
proximal promoter region (Figure 3.5), both in NT2 d0 and in NT2N R7d cells. 
Moreover, we observed a significant decrease in the binding of the Sp1 transcription 
factor to the proximal promoter of CYP46A1, after neuronal differentiation (Student’s t-
test, §p <0.05), whereas the levels of both Sp3 and Sp4 association remained unchanged. 
These data confirmed our previous results, showing that Sp proteins are recruited to the 
CYP46A1 proximal promoter in human cells that express high levels of CYP46A1 
mRNA. Furthermore, these results also indicate that there is a shift in the ratio of the 
Sp1/Sp3/Sp4 transcription factors bound to the CYP46A1 proximal promoter region in the 
differentiated cells, which is in agreement with our previous hypothesis (Milagre et al. 
2008).  
Subsequently, we performed ChIP assays to determine the association of Sp proteins 
to the proximal promoters of the reelin, MOR, GRIN1 and GRIN2A genes, before and 
after NT2 differentiation. Our results showed that both Sp1 and Sp3 were present in the 
region spanning from -220 to +70 of the reelin promoter in undifferentiated cells 
(Student’s t-test, †p < 0.01 and §p < 0.05, respectively), whereas Sp1 was significantly 
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dissociated from the promoter region in NT2N R7d cells, since there were no longer 
significant differences between the chromatin recovered with the anti-Sp1 antibody, and 
that recovered with IgG. Moreover, we observed that Sp4 was recruited to the reelin 
promoter (Student’s t-test, §p < 0.05) in post-mitotic neurons. In contrast, the anti-Sp1 
antibody was the only capable of immunoprecipitating the region spanning from -346 to -
227 of the MOR promoter (Student’s t-test, †p < 0.01) and only in NT2N cells. By 
analyzing the recruitment of Sp proteins to the GRIN1 promoter, we could detect all of 
the studied Sp transcription factors associated with the -89 to +19 region of this gene in 
the undifferentiated cells (Student’s t-test, *p < 0.001 for Sp1 and Sp3 and †p < 0.01 for 
Sp4), whereas after differentiation the levels of the Sp1 and Sp3 bound to the promoter 
significantly decreased (Student’s t-test, †p < 0.01 and §p < 0.05, respectively), and Sp4 
could no longer be detected.  
Lastly, we have also analyzed recruitment of Sp factors to the GRIN2A promoter, 
although we did not detect and increase in GRIN2A mRNA in NT2N cells. Interestingly, 
we could also observe an alteration in the Sp proteins associated with the -222/ -118 
region. Our results revealed that neuronal differentiation did not induce an alteration in 
the binding of Sp1 to the GRIN2A promoter region, while association Sp3 was detected 
only in the NT2N R7d cells (Student’s t-test, §p < 0.05). Sp4 was never found to be 
associated with GRIN2A promoter. Our data demonstrate that the replacement of Sp1 by 
Sp4 after neuronal differentiation is not a common feature amongst the studied promoters, 
highlighting the involvement of other regulatory mechanisms. 
 
3.5 Discussion 
Cholesterol 24-hydroxylase is a neuron specific cytochrome P450 that plays a 
pivotal role in the maintenance of brain cholesterol homeostasis. Although increasing 
evidence suggests that upregulation of CYP46A1 may be a therapeutic strategy in 
Alzheimer’s Disease treatment (Hudry et al. 2009), due to the lack of an appropriate cell 
model system that expresses high levels of human CYP46A1, the unraveling of the 
regulatory mechanisms governing its neuronal specific expression has been impaired. 
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Figure 3.5. Recruitment of Sp transcription factors to the proximal promoter of CYP46A1 and 
other Sp-regulated genes in NT2 and NT2N cells. Recruitment of Sp transcription factors to the 
proximal promoter of CYP46A1, reelin, MOR, GRIN1 and GRIN2A. Chromatin from NT2 d0 and NT2N 
R7d was prepared and precipitated with antibodies directed against -Sp1, -Sp3, -Sp4. After DNA 
recovery, the precipitates were evaluated by real-time PCR. Results are expressed as fold change over 
IgG and represent means of at least three independent experiments ± SEM (§p < 0.05; †p < 0.01; *p < 
0.001). 
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To overcome this problem, herein we have induced neuronal differentiation of human 
NT2 cells. Post-mitotic NT2 neurons have been widely characterized and numerous 
studies have shown that, after RA treatment, these cells express several neuronal markers 
such as MAP1 and 2, Tau, synaptophysin and chromogranin (Pleasure et al. 1992), as 
well as neuropeptides, neurotrophic factors, neurotransmitters and neurotransmitter 
receptors (Guillemain et al. 2000, Llanes et al. 1995, Zigova et al. 2000, Sodja et al. 
2002). Herein we show that CYP46A1 mRNA levels are significantly increased after 
differentiation of NT2 cells into post-mitotic neurons, and to our knowledge, this is the 
first report of a human neuronal cell line that expresses high levels of CYP46A1 mRNA. 
Our previous work, pointed to Sp transcription factors as major regulators of 
CYP46A1 basal expression (Milagre et al. 2008). Combination of Sp1, Sp3 and Sp4 
overexpression studies in Drosophila SL2 cells, and systematic promoter mutagenesis 
identified Sp3 and Sp4 binding to four GC-boxes as required and sufficient
 
for high levels 
of promoter activity. Moreover, EMSA demonstrated that the transcription factors Sp1, 
Sp3 and Sp4 bind to the GC-boxes on the CYP46A1 proximal promoter, and that Sp3 and 
Sp4 were the major
 
components of the protein-DNA complexes observed in primary rat 
cortical extracts. Thus, it was our hypothesis that Sp1, Sp3, and Sp4 functionally interact 
with the CYP46A1 endogenous promoter, and that a shift that would increase the 
(Sp3+Sp4)/ Sp1 ratio would result in the transcriptional activation this gene. Indeed, it is 
well documented that changes in the relative levels of Sp1/Sp3/Sp4 are one of the 
mechanisms by which the Sp transcription factors regulate gene expression (Lee et al. 
2004, Magee et al. 2005, Mao et al. 2006). Analysis of the expression levels of Sp 
proteins during the differentiation process revealed that there is a 50 % decrease in Sp1 
protein levels in NT2N post-mitotic neurons, while the levels of Sp3 and Sp4 remained 
unchanged. Interestingly, we did not detect any significant decrease in Sp1 mRNA levels 
(data not shown). Moreover, we only detected the decrease in Sp1 protein after addition 
of mitotic inhibitors (cytosine D-arabinofuranoside, fluorodeoxyuridine and uridine) to 
the cell culture. We have also detected a decrease of Sp1 protein levels when we treated 
SH-SY5Y neuroblastoma cells with the DNMT inhibitor, 5’-Aza-2’-deoxycytidine 
(Milagre et al. 2010) (results discussed in Chapter 4), a drug that has also been shown to 
induce cell cycle arrest (Lavelle et al. 2003). Although Sp1 has been described to play an 
important role in mitosis, by activating the transcription of the genes encoding D-type 
cyclins, cyclin E, Cdk2, E2F-1 and c-Myc, which are key factors for progression through 
G1-phase and entry into S-phase (Wierstra 2008), it has not been thoroughly investigated 
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how mitotic inhibitors may affect Sp1 protein levels. Nevertheless, several evidences 
support the role of posttranslational modifications in the regulation of Sp1 stability during 
mitosis (Chuang et al. 2008, Spengler et al. 2008). Indeed, a shift between activator and 
repressor function is a common feature of transcription factors, and an aspect of this 
feature includes the coupling of ubiquitin / proteasome mediated degradation. 
Sp1 was one of the first transcription factors purified and cloned from mammalian 
cells (Dynan and Tjian, 1983), and it is generally considered as a factor that determines 
the core activity of promoter by a direct interaction with factors at the basal transcription 
machinery, including cooperation with several transcriptional activators, such as CRSP, 
p300/CBP, etc (Owen et al. 1998, Ryu et al. 1999). Corresponding to its function in the 
activation of many house-keeping genes, Sp1 is widely expressed in human tissues. An 
increasing amount of data, however, accumulates that Sp1-dependent transcription might 
also be involved in the regulation tissue-specific expression, namely of brain-specific 
genes (Chen et al. 2007, Xu & Carr 2001, Liu et al. 2003). Nevertheless, Mao and co-
workers have found that Sp1 protein is nearly absent in forebrain neurons, and have 
raised the question whether substitution of the ubiquitous Sp1 by the brain enriched Sp4 
in neuronal cells, underlies the cell-type specificity expression in the CNS (Mao et al. 
2007, Ishimaru et al. 2007).  
In order to understand if the shift observed in the ratio of the different Sp proteins in 
post-mitotic neurons was correlated with qualitative changes in the binding of these 
transcription factors to the CYP46A1 proximal promoter in the context of native 
chromatin, we performed ChIP using in NT2N cells, that express high levels CYP46A1 
mRNA, and compared the results with those obtained in undifferentiated NT2 d0 cells. 
ChIP assays provided strong evidence in support of a correlation between the increase in 
CYP46A1 mRNA levels, the decrease in Sp1 protein levels, and a 50% decrease in the 
Sp1 recruited to the proximal promoter of this gene.  
These results raised the question of why displacing Sp1 from the CYP46A1 promoter 
can up-regulate this gene. Although, our ChIP results strongly point to the dissociation of 
Sp1 from the proximal promoter, there was no overall increase of Sp3 and Sp4 binding to 
the promoter. This implies that either in undifferentiated NT2 cell, Sp1 is involved in the 
recruitment of HDAC or co-repressors complexes, or that the release of Sp1 in NT2N 
may induce a more favorable conformation of Sp3 and Sp4 to bind to associated co-
activators or brain-specific transcription factors. Another possibility is that a Sp1 free 
promoter favors the recognition of cis-acting sites by other transcription factors.  
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Indeed, Sp1 has been described to bind directly to HDAC1 and other co-repressors 
(Doetzlhofer et al. 1999, Zhang & Dufau 2002, Lagger et al. 2003, Bu & Gelman 2007), 
and to be implicated in the HDAC-dependent repression of the p21 (Lagger et al. 2003), 
Src-suppressed C kinase substrate (Bu & Gelman 2007), thymidine kinase (Doetzlhofer et 
al. 1999) and human telomerase reverse transcriptase (Hou et al. 2002) promoters. 
Surprisingly, we did not detect HDAC1 and 2 recruited to the CYP46A1 promoter in 
undifferentiated NT2 cells, nor did we detect a significant increase in promoter histone 
acetylation in NT2N cells (data not shown).  
On the other hand, our previous results showed that the highest activation of the 
CYP46A1 promoter was achieved by co-transfection of Sp3 and Sp4 (Milagre et al. 
2008), suggesting that Sp1 might be a less potent transcriptional activator of this gene. 
Nevertheless, direct interactions between Sp3 and Sp4 and other nuclear proteins cannot 
be excluded as a mechanism of CYP46A1 activation. Indeed, although there is little 
information about putative multimerization regions of Sp4 protein available for protein-
protein interactions in the DNA-bound state, this transcription factor has been shown to 
activate expression of photoreceptors-specific genes, by synergizing with Crx, and it has 
also been shown that Sp3 and possible Sp1 may inhibit this Sp4-mediated transcriptional 
activation (Lerner et al. 2005). 
It is commonly accepted that Sp1, Sp3 and Sp4 can have both positive and negative 
effects on DNA binding and transcriptional activity, and that this dichotomy is likely to 
reflect, at least in part its posttranslational modifications or the promoter context. Indeed, 
Sp4 has been described to have opposite effects on the regulation of neurotrophin-3 (NT-
3) and the high affinity NT-3 receptor TrkC promoters: overexpression of Sp4 reduced 
NT3 promoter activity and increased TrKC promoter activity whereas knockdown of Sp4 
increased expression of NT3 and reduced expression of TrKC (Ramos et al. 2009). 
Interestingly, it has been shown that in the human plasma membrane-associated sialidase 
locus, when Sp1 and Sp3 bind to a particular response element, they can promote 
transcription from transcription start site 1, while repressing the brain-specific 
transcription start site 0 (Yamaguchi et al. 2010).  
An alternative hypothesis is that an additional transcriptional regulator might be 
tethered to overlapping sites and/or Sp1 sites, once Sp1 levels are decreased. In fact, such 
a mechanism has been suggested in the case of the p14ARF promoter, where in vivo 
displacement of Sp1 at the overlapping sites by E2F1 requires a threshold E2F1 to 
overcome Sp1 occupation (Zhang et al. 2009). Probably this is not the case for CYP46A1, 
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since when we have used nuclear extracts from NT2N cells, the supershift analysis did 
not detected any proteins other than Sp proteins bound the GC-boxes, that we had 
previously identified has essential for basal promoter activity (data not shown).  
Since it would be interesting to analyse if an increase in the (Sp3+Sp4)/ Sp1 ratio was 
a common feature in the context of native chromatin in neuronal promoters other than 
CYP46A1, we have selected four genes – MOR, reelin, GRIN1 and GRIN2A, that have 
been shown to be expressed in the human brain (Bai & Kusiak 1995, Chen et al. 2002, 
Arvidsson et al. 1995) and to be regulated by Sp transcription factors (Traynelis et al. 
2010, Wei & Loh 2010, Levenson et al. 2008). Interestingly, at the reelin promoter we 
have detected a complete switch in binding between Sp1 and Sp4; indeed, we detected the 
association of Sp1 and Sp3, but not Sp4 in the undifferentiated cells, while only Sp3 and 
Sp4 are bound to the promoter in the NT2N post-mitotic neurons. Chen and co-workers 
had previously shown that induction of the reelin promoter with RA in NT2 cells was 
accompanied by higher amounts of Sp1 and Pax6 binding to the proximal promoter (Chen 
et al. 2007). Nevertheless, these authors have used NT2 cells treated just for six days with 
RA, and therefore, these results cannot be directly compared with the results we obtained 
with post-mitotic NT2N neurons.  
Analysis of Sp binding to the other selected gene promoters, MOR, GRIN1 and 
GRIN2A, revealed that, like in other cell types, binding of Sp proteins to DNA in a 
neuronal chromatin environment appears highly dependent on promoter context. Indeed, 
we could not identify any conserved alteration in the Sp binding patterns to the formerly 
mentioned promoter regions, nor did we detect the association of Sp4 in differentiated 
NT2N cells.  
Herein, we demonstrated a significant increase in CYP46A1 mRNA levels after 
neuronal differentiation of NT2 cells, which is accompanied by a decrease in the Sp1 
associated to the proximal promoter of this gene. Our data also point to the fact that, 
contrary to what we initially hypothesize, the dissociation of Sp1 from the promoter 
regions of neuronal Sp-regulated genes, is not a common feature, suggesting that although 
the Sp1 levels are significantly decreased after neuronal differentiation, Sp1-dependent 
transactivation of specific neuronal promoter is most likely to occur, and that there is still 
much to learn about the Sp protein regulatory functions in neurons 
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4.1 Abstract 
Brain cholesterol metabolism in the CNS is distinct from that in other tissues, since 
exchanges of cholesterol through the BBB do not occur. Cholesterol homeostasis is 
maintained by a series of interdependent processes involving synthesis, transport and 
catabolism, which are controlled by several proteins also expressed in other tissues. 
Nevertheless, brain cholesterol elimination depends on a neuronal-specific cytochrome 
P450, CYP46A1, and the lack of a cellular model that expresses high levels of this 
enzyme has limited the insight into how human post-mitotic neurons handle cholesterol. 
Herein, we aimed to assess if differentiated Ntera2/clone D1 (NT2) cells could be a useful 
model to study the cellular mechanisms involved in neuronal cholesterol homeostasis. We 
have shown that NT2N post-mitotic neurons express key genes involved in brain 
cholesterol synthesis, synthesis regulation and uptake, namely HMG-CoA synthase, 
HMG-CoA reductase, SREBP2 and LDLr. Moreover, the expression profiles observed 
during neuronal differentiation are in accordance with what is thought to occur in vivo, 
namely the decrease in the levels of cholesterol synthesizing enzymes. Furthermore, this 
is the first time that CYP46A1 protein and 24OHC have been detected in human neuronal 
cells in culture. CYP46A1 protein is upregulated in post-mitotic neurons, with a 
concomitant decrease in CYP27A1 protein levels. We observed an increase in the ratio 
between 24OHC and 27OHC levels throughout neuronal differentiation, which suggests 
that progenitor cells eliminate cholesterol in the form of 27OHC, while neurogenesis 
induces a change to the 24-hydroxylase-dependent elimination pathway. Moreover, 
CYP39A1 and CYP7B1, the enzymes responsible for metabolizing 24OHC and 27OHC, 
are also up-regulated in post-mitotic neurons, which can partly explain the lack of 
enzyme-product correlation through the differentiation process. Taken together, our 
results demonstrate that differentiated NT2 cells are a valuable cell model for the study of 
cholesterol homeostasis in human neurons. 
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4.2 Introduction 
Cholesterol plays an essential role in central nervous system (CNS) structure and 
function, being required for proper myelination, stabilization and organization of axonal 
microtubules, dendritic differentiation and synaptic plasticity (Saher et al. 2005, Fan et al. 
2001, Fan et al. 2002, Mauch et al. 2001). Since the blood-brain barrier (BBB) prevents 
uptake of cholesterol from the circulation, brain cholesterol is essentially synthesized in 
situ (Bjorkhem & Meaney 2004). Cholesterol synthesis in the developing CNS is 
relatively high, but declines to very low levels in the adult (Dietschy & Turley 2004). 
This is explained by a highly efficient recycling of brain cholesterol, which has an 
unusual long half-life that has been estimated to be at least 5 years (Bjorkhem et al. 
1998). Frank Pfrieger has put forward the hypothesis that neurons switch from production 
of cholesterol during the embryonic stage to rely constitutively on cholesterol delivery by 
astrocytes via lipoproteins after birth (Pfrieger 2003). Indeed, evidence for a cholesterol 
shuttle from astrocytes to neurons has been presented (Mauch et al. 2001), and results 
obtained from in vitro systems demonstrated that in rodents, neurons and glial cells 
present distinct profiles of biosynthetic enzymes, post-squalene precursors and cholesterol 
metabolites (Nieweg et al. 2009). Nevertheless, it is thought that due to the structural and 
functional specialization of brain regions, some neurons may depend entirely on an 
external cholesterol supply while others may be autonomous (Pfrieger 2003). Indeed, 
HMG-CoA reductase and 7- dehydrocholesterol reductase, are expressed in neurons 
throughout the adult mouse brain (Korade et al. 2007). In situ data provided by the Allen 
Brain Mouse Atlas, has revealed that the expression of cholesterol homeostasis genes are 
preferentially targeted to neuronal hippocampal pyramidal and granule layers (Valdez et 
al. 2010).  
Despite the efficiency of the cholesterol recycling machinery, the rate of cholesterol 
synthesis in the adult brain is larger than the rate of accumulation, therefore a mechanism 
by which excess cholesterol is excreted has to exist. The major mechanism of brain 
cholesterol elimination involves the conversion of cholesterol into 24(S)-
hydroxycholesterol (24OHC), which readily crosses the BBB (Lütjohann et al. 1996, 
Bjorkhem et al. 1997, Bjorkhem et al. 1998). The enzyme responsible for 24(S)-
hydroxylation of cholesterol is a cytochrome P450 - CYP46A1 - that is almost 
exclusively expressed in neurons (Lund et al. 1999, Bretillon et al. 2007). Interestingly, 
inactivation of Cyp46a1 resulted in a decrease of 24OHC levels in the brain (~60%), that 
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was associated with a selective reduction of cholesterol synthesis (~40%), suggesting a 
close relation between synthesis and metabolism of cholesterol in the CNS (Lund et al. 
2003). Another oxysterol that may be involved in brain cholesterol homeostasis is 
27-hydroxycholesterol (27OHC). There is a flux of 27OHC from the circulation into the 
brain of the same magnitude as the flux of 24OHC in the opposite route (Heverin et al. 
2005). Both oxysterols are potent suppressors of cholesterol synthesis and are ligands for 
LXR and , nuclear receptors which play an important role in lipid homeostasis in the 
CNS (Wang et al. 2002).  
Although several human derived neuroblastoma cell lines express cholesterol 
synthesizing enzymes, the lack of a cellular model that expresses high levels of CYP46A1 
enzyme has limited the insight of how human post-mitotic neurons handle cholesterol. 
Moreover, comparison of the human and rat CYP46A1 promoter sequences revealed 
significant differences, upstream of the core promoter (Milagre et al. 2008), suggesting 
that results from studies in primary cortical and hippocampal neurons isolated from 
mouse embryos may not reflect what happens in human brain.  
We have demonstrated that differentiation of Ntera2/clone D1 (NT2) cells by retinoic 
acid into post-mitotic neurons (NT2N), might be a good in vitro system to study cellular 
mechanisms involved in human neuronal cholesterol metabolism, since after 
differentiation we could observe a significant increase in CYP46A1 mRNA levels (results 
presented in Chapter 3). Herein we have examined cholesterol metabolites, the expression 
of sterol hydroxylases and of other genes important for cholesterol synthesis, catabolism 
and transport during the differentiation of NT2 cells into post-mitotic neurons. Our results 
demonstrate that the key players in maintaining cholesterol homeostasis in the brain are 
expressed in NT2N, and that there is a shift in the 24OHC / 27OHC ratio throughout 
neuronal differentiation.  
 
4.3 Methods 
4.3.1 Cell Culture 
NTERA-2cl.D1 testicular embryonal carcinoma cells (NT2) were cultured as 
previously described (Chapter 3, section 3.3.1). 
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4.3.2 Expression Analysis 
Total cell RNA was extracted using Trizol Reagent (Invitrogen Carlsbad, CA, USA) 
following manufacturer’s instructions. Real-Time PCR analysis for CYP46A1 mRNA 
levels was performed as described previously (Nunes et al. 2010). Real-Time PCR 
analysis for HMG-CoA Reductase, HMG-CoA Synthase, SREBP-2, LDLr, CYP7B1 and 
CYP39A1 was performed using SYBR green Master Mix in an ABI 7300 sequence 
detection system (Applied Biosystems) and specific primers (Table 4.1). Results 
presented were obtained from at least three individual experiments and each sample was 
assayed in triplicate. CYP46A1 and CYP27A1 mRNA levels were normalized to the level 
of β-actin and expressed as pg of CYP mRNA per ng of β-actin mRNA. HMG-CoA 
Reductase, HMG-CoA Synthase, SREBP-2 LDLr, CYP7B1 and CYP39A1 were 
normalized to the level of β-actin as fold change from controls, using the Ct method.  
 
Table 4.1 – List of primers used for qPCR.  
Gene Primer / TaqMan Assay Sequence (5’→ 3’) / Source 
CYP46A1 CYP46A1  HS00198510_M1 Applied Biosystems Ref:4331182 
CYP27A1 CYP27A1 HS01026016_M1 Applied Biosystems Ref:4331182 
β Actin ACTB HS99999_M1 Applied Biosystems Ref:4310881E-060521 
HMGCoA 
Reductase 
HuHMGCoARedf 
HuHMGCoARedr 
5’-ATAGGAGGCTACAACGCCCAT-3’ 
5’-TTCTGTGCTGCATCCTGTCC-3’ 
HMGCoA  
Synthase 
HuHMGCoASynf 
HuHMGCoASynr 
5’-GGCACAGCTGCTGTCTTCAAT-3’ 
5’-ACCAGGGCATACCGTCCA T-3’ 
SREBP2 HuSREBP2f 
HuSREBP2r 
5’-CAGCTGCACATCACAGGGAA-3’ 
5’-GTACATCGGAACAGGCGGAT-3’ 
LDLr HuLDL-Rf 
HuLDL-Rr 
5’-CAGATATCATCAACGAAGC-3’ 
5’-CCTCTCACACCAGTTCACTCC-3’ 
CYP7B1 qPCRHuCYP7B1f 
qPCRHuCYP7B1r 
5’-CAGCCTAATCTGCCTAGAAAGCAGC-3’ 
5’-CGCACACAGTAGTCCCCGGTC-3’ 
CYP39A1 qPCRHuCYP39A1f 
qPCRHuCYP39A1r 
5’-CCAGTGTCCTGCAAGGTGGTTTGC-3’ 
5’-GCTGGGGGACACCCACCAAAT-3’ 
β Actin qPCRHuACTINf 
qPCRHuACTINr 
5’-CTGGAACGGTGAAGGTGACA-3’ 
5’-AAGGGACTTCCTGTAACAATCCA-3’ 
 
 
4.3.3 Western blot analysis 
Mitochondrial and microsomal extracts were prepared as described previously with 
minor modifications (Mast et al. 2010). In brief, confluent cells were washed with cold 
PBS containing 1 mM Pefabloc and centrifuged at 200 g for 10 minutes. The supernatants 
were discarded, the pellets resuspended in 6 volumes (v/v) of homogenization buffer (50 
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mM Tris-Cl (pH7.4), 250 mM sucrose, 5 mM MgCl2, 1 mM Pefabloc, 1 mM DTT and 
protease inhibitor cocktail), incubated on ice for 2 minutes and homogenized in a glass 
homogenizer. The crude homogenate was centrifuged at 1000 g for 15 minutes. The 
supernatant was collected and kept in a separate tube on ice. The pellet was resuspended 
and centrifuged again at 1000 g for 15 minutes. The supernatants were combined and 
centrifuged at 10000 g for 20 minutes. The supernatant was collected and kept in a 
separate tube on ice and the pellet was further resuspended in 3 volumes (V/V) of 
homogenization buffer and centrifuged. The resulting pellet containing the mitochondrial 
fraction was resuspended in an appropriate volume of homogenization buffer, whereas the 
combined supernatants were further centrifuged at 100000 g for 60 minutes. The resulting 
pellets containing the microsomal fraction were resuspended in an appropriate volume of 
homogenization buffer. All steps were carried out at 4ºC. Mitochondrial and microsomal 
extracts were subject to 10% or 12.5% SDS-PAGE gels and electroblotted onto 
Immobilon P (Millipore, Bedford, MA, USA). After visualization of the transferred 
proteins by amido black staining, the membranes were incubated with specific antibodies. 
Results were quantified using the Quantity One version densitometry analysis software 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). 
 
4.3.4 Sterol extraction and gas chromatography - mass spectrometry (GC-MS) 
analysis  
Total sterols from cell pellets and culture medium were extracted and analyzed by 
isotope dilution–mass spectrometry using deuterium-labeled oxysterols as internal 
standards, as previously described (Dzeletovic et al. 1995).  
 
4.3.5 Statistical Analysis 
Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-
hoc test or the ANOVA one-way test with the Tukey HSD post-hoc test or the Tukey 
HSD for unequal N (Spjotvoll/Stoline test). All analysis was performed using the 
STATISTICA (data analysis software system), version 9.1 StatSoft, Inc. (2010) or Prism 
5.0 software (GraphPad Software). 
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4.4 Results 
4.4.1 Expression pattern of genes involved in cholesterol synthesis, transport and 
catabolism during NT2 neuronal differentiation 
In order to evaluate if the NT2 cell culture system could be a useful system to study 
the cellular mechanisms involved in human neuronal cholesterol metabolism, we have 
examined by real-time PCR the mRNA levels of genes involved in cholesterol synthesis, 
transport and elimination, during NT2 neuronal differentiation (Figure 4.1). Our results 
show a significant decrease of both HMG-CoA synthase and HMG-CoA reductase 
mRNA levels during NT2 differentiation (ANOVA one-way test: F = 48.78, df = 3, p < 
0.001 and ANOVA one-way test: F = 13.8, df = 3, p < 0.01, respectively). Post-hoc 
comparisons revealed significant differences between NT2 d0 and all the analysed time-
points for HMG-CoA synthase (Tukey HSD, p < 0.001) and for HMG-CoA reductase 
(Tukey HSD, p < 0.05 for NT2 d21; p < 0.01 for NT2N R7d and NT2NR15d). These 
data suggest that human NT2 cells suppress cholesterol biosynthesis during neuronal 
differentiation; nevertheless we did not observe any significant difference on the mRNA 
levels of SREBP2, a transcription factor that regulates the expression of several genes 
closely related to cholesterol metabolism. LDLr mRNA levels significantly decrease 
during RA administration (ANOVA one-way test: F = 32.83, df = 3, p < 0.001), whereas 
in post-mitotic neurons the mRNA levels of this receptor tend to increase, reaching levels 
similar to those of NT2d0. 
The analysis of sterol 27-hydroxylase (CYP27A1) and cholesterol 24-hydroxylase 
(CYP46A1), revealed that CYP27A1 mRNA levels were significantly induced by RA 
treatment, reaching a peak at d21 (ANOVA one-way test: F = 43.42, df = 3, p < 0.001; 
Tukey HSD, p < 0.001), and then gradually decrease. Indeed, post-hoc comparisons 
revealed significant differences between NT2 d21 and both NT2N R7 and R15d (Tukey 
HSD, p < 0.001), although the mRNA levels do not reach those observed at NT2 d0. As 
expected, mRNA levels for the neuronal specific CYP46A1 significantly increase 
throughout differentiation (ANOVA one-way test: F = 20.04, df = 3, p < 0.001). 
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4.4.2 CYP46A1 and CYP27A1 protein levels during NT2 neuronal differentiation 
To confirm that the increase in CYP27A1 and CYP46A1 mRNA levels are reflected 
at the protein level, we performed western blot analysis of mitochondrial and microsomal 
extracts (respectively) obtained from cells collected at different time points of the 
Figure 4.1. mRNA expression analysis of sterol hydroxylases and other key genes in cholesterol 
homeostasis during differentiation of NT2 cells. Real-time PCR analysis of steady-state mRNA 
transcript levels in NT2 cells during differentiation. Values were normalized to the internal standard β-
actin. Data represent means ± SEM from at least three individual experiments. CYP46A1 and CYP27A1 
mRNA levels were normalized to the level of β-actin and expressed as pg of CYP mRNA per ng of β-
actin mRNA. HMG-CoA Reductase, HMG-CoA Synthase, SREBP-2 and LDLr were normalized to the 
level of β-actin as fold change from controls (§p < 0.05; †p < 0.01; *p < 0.001). 
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differentiation (Figure 4.2). We observed that, CYP46A1 protein can only be detected at 
the final stages of NT2 differentiation, and that the increase in CYP46A1 protein levels 
occurs concomitantly with the increase in mRNA levels. CYP27A1 protein is readily 
detected at NT2 d0 and the levels of this enzyme slightly decrease at NT2N R15d 
(Kruskal-Wallis test, p < 0.05).  
 
 
 
 
 
 
 
 
4.4.3 Quantification of cholesterol metabolites during NT2 neuronal differentiation 
We measured the levels of cholesterol metabolites extracted from the medium and 
cellular fraction throughout the differentiation process of the NT2 cells by GC-MS 
analysis. Oxysterols can be formed by the action of specific enzymes or by auto-oxidation 
of the cholesterol molecule. 24OHC and 27OHC have been demonstrated to be 
enzymatically formed by specific sterol hydroxylases, CYP46A1 and CYP27A1, 
respectively, whereas there is little or no evidence that these can be products of 
cholesterol auto-oxidation (Bjorkhem & Diczfalusy 2002, Schroepfer 2000). Our analysis 
revealed measurable levels of both 24OHC (0.13 ± 0.02 ng of 24OHC/µg of total cell 
cholesterol in cell pellets and 0.29 ± 0.2 ng of 24OHC/µg of total cell cholesterol from 
Figure 4.2. CYP46A1 and CYP27A1 protein levels during differentiation of NT2 cells. A) Western 
blot analysis of CYP46A1 and CYP27A1 protein levels in NT2 cells during neuronal differentiation. 
Mouse brain microsomes were used as a positive control, for the CYP46A1 western blot. Microsomal and 
mitochondrial extracts were subjected to SDS-PAGE, transferred to PVDF membranes, and incubated 
with specific antibodies. Protein loading control using Amido Black staining of the membrane is shown 
in the bottom panel. B) Quantification of CYP27A1 protein levels. Data represent means ± SEM and are 
expressed as fold change relative to control cells (§p < 0.05). The results shown are representative of 
those obtained in three independent cultures. 
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the medium) and 27OHC (0.65 ± 0.07 ng of 27OHC/µg of total cell cholesterol extracted 
from cell pellets and 2.3 ± 1.0 pg of 27OHC/µg of total cell cholesterol, from the 
medium) at d0 of differentiation (Figure 4.3). We observed that, although there is a 
significant increase in mRNA and protein levels of CYP46A1, the levels of 24OHC 
extracted from cell pellets and secreted to the medium were not altered (Figure 4.3). The 
levels of 27OHC extracted from cell pellets (Figure 4.3A) significantly decreased in the 
replate stages to levels lower than the control (0.29 ± 0.09 ng and 0.12 ± 0.03 ng of 
27OHC/µg of total cell cholesterol in NT2N R7d and NT2N R15d, respectively; ANOVA 
one-way test: F = 51.89, df = 3, p < 0.001). The levels of 27OHC secreted to the medium 
(Figure 4.3B) were not altered at NT2 d21 (2.4 ± 0.87 pg of 27OHC/µg of total cell 
cholesterol), but also decreased in the replate stages to levels significantly lower than 
those observed at the NT2 d0 (0.46 ± 0.12 and 0.2 ± 0.05 pg of 27OHC/µg of total cell 
cholesterol in NT2N R7d and R15d, respectively) (ANOVA one-way test: F = 109.67, df 
= 3, p < 0.001).  
 
 
 
Figure 4.3. Oxysterol levels during NT2 neuronal differentiation. Levels of oxysterols extracted from 
cell pellets (A) and medium (B) were determined at day 0 (NT2 d0) and day 21 (NT2 d21) of RA 
treatment, and at day 7 (NT2N R7d) and day 15 (NT2N R15d) after cells were replated in PDL-MG 
coated plates, as described in materials and methods. Data are expressed as ng oxysterol/ µg total 
cholesterol (A) and pg secreted oxysterol/ hour/ total cholesterol (B) and represent mean values ± SD of 
at least three independent experiments (§p < 0.05; †p < 0.01; *p < 0.001). 
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4.4.4 Shift in the 24OHC / 27OHC levels during NT2 neuronal differentiation 
Reflecting what happens in the adult brain in physiological conditions, where only a 
small production of 27OHC occurs in CNS (Bjorkhem et al. 2010), our results showed an 
increase in the ratio between 24OHC and 27OHC during neuronal differentiation (Figure 
4.4). Indeed, in the cellular fraction the 24OHC/ 27OHC ratio increased from 
approximately 0.2 at d0 to 1 at NT2N R15d (ANOVA one-way test: F = 20.24, df = 3, p 
< 0.001), and the ratio between both oxysterols secreted to medium increased from 
approximately 0.12 to 1.39 (ANOVA one-way test: F = 21.82, df = 3, p < 0.001). 
 
 
 
 
 
 
4.4.5 Expression pattern of genes involved in oxysterol metabolism during NT2 
neuronal differentiation 
We have demonstrated a lack of enzyme-product correlations when we compared the 
changes in 27OHC levels with the changes in CYP27A1 protein levels. Indeed, although 
we did observe a decrease in CYP27A1 in NT2N R15d, this decrease was far from being 
as drastic as the decrease observed in 27OHC levels. Moreover, the increase in CYP46A1 
mRNA/ protein levels was also not correlated with an increase in 24OHC levels. Since 
CYP7B1 and CYP39A1 are known to metabolize 27OHC and 24OHC, respectively, we 
have investigated the expression levels of these enzymes. We observed that both CYP7B1 
as well as CYP39A1 mRNA levels significantly increased at NT2 d21 (Figure 4.5) 
Figure 4.4. Ratio between 24- and 27- hydroxycholesterol during NT2 neuronal differentiation. The 
ratios of 24OHC and 27OHC extracted from cell pellets (A) and medium (B) were calculated at day 0 
(NT2 d0) and day 21 (NT2 d21) of RA treatment, and at day 7 (NT2N R7d) and day 15 (NT2N R15d) 
after cells were replated in PDL-MG coated plates, as described in materials and methods. Data represent 
mean values ± SD of at least three independent experiments (§p < 0.05; †p < 0.01; *p < 0.001). 
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(ANOVA one-way test: F = 16.16, df = 3, p < 0.001 and ANOVA one-way test: F = 
49.40, df = 3, p < 0.001). Afterwards, mRNA levels start to decrease to levels that are 
still significantly higher than control levels.  
 
 
 
 
 
 
 
4.5 Discussion 
A large effort has been made in the last decade to unravel the mechanisms underlying 
cholesterol metabolism in the brain. There are significant quantitative and qualitative 
differences in cholesterol homeostasis in rodents, when compared to humans (Dietschy & 
Turley 2004, Dietschy & Turley 2001, Heverin et al. 2005). Thus, a better understanding 
of cholesterol homeostasis and the consequences of its deregulation in neurodegenerative 
disorders would be greatly enhanced by human cellular models, where the key players 
involved in the control of brain cholesterol synthesis, transport and catabolism are 
expressed.  
Our work has focused on the characterization of NT2 post-mitotic neurons as a 
model for the study of human CNS cholesterol homeostasis. In this work, we have 
assessed the expression profiles of several genes coding for key enzymes involved in 
cholesterol synthesis (HMG-CoA synthase and HMG-CoA reductase) and synthesis 
regulation (SREBP2), uptake (LDLr) and catabolism (CYP27A1 and CYP46A1), during 
neuronal differentiation. The rate limiting enzymes in cholesterol biosynthesis - HMG-
CoA synthase and HMG-CoA reductase - are downregulated during NT2 differentiation, 
Figure 4.5. mRNA expression analysis of CYP7B1 and CYP39A1 during differentiation of NT2 
cells. Real-time PCR analysis of steady-state mRNA transcript levels in NT2 cells during differentiation. 
Data represent means ± SEM from at least three individual experiments. Values were normalized to the 
internal standard β-actin and are represented as fold change from controls (§p < 0.05; †p < 0.01; *p < 
0.001).  
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which is in agreement with the decreased cholesterol synthesis known to occur in the 
adult brain (Dietschy & Turley 2004). Moreover, we detected high mRNA levels of 
SREBP2, a key transcriptional regulator of genes involved in cholesterol metabolism, 
namely HMG-CoA synthase, HMG-CoA reductase and LDLr. Indeed, in depleted 
cholesterol conditions, SREBP2 suffers proteolytic processing, the active peptides are 
translocated to the nucleus and enhance gene transcription (Brown & Goldstein 1997). It 
is however well established that, although cholesterol levels control SREBP activity, 
fluctuations in cellular cholesterol do not alter SREBP transcription (Goldstein & Brown 
1990). Therefore, the fact that we did not detect any significant change in SREBP2 
mRNA levels throughout differentiation of NT2 cells was not unexpected. No significant 
differences were detected between LDLr mRNA levels in NT2 d0 and NT2 R15d, which 
is in agreement with what is described in vivo; in fact, Hanaka and co-workers have 
shown that LDLr mRNA levels in the adult brain are similar to those observed in the 
embryonic brain (Hanaka et al. 2000).  
Sterol hydroxylases also play an important role in the maintenance of cholesterol 
homeostasis, since they can convert cholesterol into oxysterols which are side chain 
oxidized sterols that have the ability to pass cell membranes at a much faster rate than 
cholesterol itself (Bjorkhem & Diczfalusy 2002). Moreover, oxysterols can act as 
important ligands to various receptors involved in lipid metabolism (Schroepfer 2000). 
CYP27A1 is a ubiquitously expressed cytochrome P450 that is able to convert cholesterol 
into 27OHC (Babiker et al. 1997, Russell 2000). It has been shown that mutations in the 
CYP27A1 gene, that prevent the formation of 27OHC, cause cerebrotendinous 
xanthomatosis a disease that is characterized by the accumulation of cholesterol 
metabolites in the brain and peripheral tissues (Russell 2000), which has a deleterious 
effect on cognition (Kim et al. 2009b). On the other hand, CYP46A1 is a brain-specific 
cytochrome P450 that was found to be responsible for the conversion of cholesterol to 
24OHC (Lund et al. 1999). This is thought to be the major mechanism by which excess 
cholesterol is excreted from the brain (Bjorkhem et al. 1997). In fact, mice with a 
disruption in this gene exhibit severe deficiencies in spatial, associative, and motor 
learning and have impaired hippocampal long-term potentiation (Kotti et al. 2006). Here, 
we have confirmed our previously results, and show that if NT2N cells are left in culture 
with mitotic inhibitors for two weeks, CYP46A1 mRNA reaches slightly higher levels 
than those previously observed at NT2N R7d, which is reflected in a pronounced increase 
in protein levels. CYP27A1 mRNA levels significantly increase at NT2 d21, and then 
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start to decrease to levels slightly above the control. Indeed, CYP27A1 has been 
previously described as a RAR/ RXR-target gene in myeloid cells (Szanto et al. 2004, 
Quinn et al. 2005). Nevertheless, we did not observe a significant increase in CYP27A1 
protein levels at NT2 d21, but instead we observed a significant decrease at NT2N R15d, 
when compared with undifferentiated cells. These results suggest that undifferentiated 
cells may dependent upon the CYP27A1 elimination pathway whereas, post-mitotic 
neurons depend on cholesterol efflux in the form of 24OHC.  
Since there was such a marked modulation in CYP27A1 and CYP46A1 levels 
throughout the differentiation process, we also investigated the levels of their products - 
27OHC and 24OHC. Surprisingly, we observed that there is no change in the levels of 
24OHC, both in the cell pellets and in the medium. In contrast, the levels of 27OHC 
secreted to the medium and in cells pellets decreased in NT2N R15d to levels lower than 
those observed at the NT2 d0.  
Although the levels of CYP46A1 do not correlate with the 24OHC detected in either 
cell pellets or the medium, there is a significant shift in the ratio between 24OHC and 
27OHC that favours 24OHC in the final stages of differentiation of the NT2 cells into 
neurons. This may reflect what happens in the adult brain in non-pathological conditions 
where only a small production of 27OHC occurs in CNS (Bjorkhem et al. 2010), while 
the majority of 24OHC in the organism is produced in the brain (Lütjohann et al. 1996). 
One may speculate that neurogenesis leads to a higher utilization of the CYP46A1 
pathway to eliminate cholesterol in the form of 24OHC, whereas the multipotent 
progenitor cells eliminate cholesterol in the form of 27OHC.  
The lack of enzyme-product correlation observed when we compared the changes in 
24OHC and 27OHC levels with the changes in CYP46A1 and CYP27A1 protein levels, 
led us to examine the expression patterns of CYP39A1 and CYP7B1, enzymes involved in 
the metabolism of these two oxyterols. In vivo, 27OHC can be metabolized by CYP7B1 
to 7α-hydroxy-3-oxo-4-cholestenoic acid and can also be further metabolized by 
CYP27A1 to 3β-hydroxy-5-cholestenoic acid (Bjorkhem et al. 2009). CYP39A1 which is 
also expressed in the brain (Shafaati et al. 2009) is the enzyme responsible for 
metabolizing 24OHC (Li-Hawkins et al. 2000). The observed expression profile of 
CYP7B1 has a parallel profile to CYP27A1, however little is known about the 
transcription regulation of CYP7B1. Nevertheless, there is a significant increase in 
CYP7B1 in NT2N cells that may explain the observed decrease in 27OHC levels. 
CYP39A1 levels are also significantly increased in post-mitotic neurons, which may 
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account for the lack of enzyme-product correlation observed for CYP46A1. Indeed, it has 
been suggested that induction of CYP39A1 may lead to the production of 7α-24OHC and 
mask any increase in 24OHC content (Shafaati et al. 2009).  
Alternatively, CYP46A1 has been shown to further metabolize 24OHC into 24,27-
dihydroxycholesterol, binding to 24OHC with an higher affinity than to cholesterol (Mast 
et al. 2003). Therefore, such an effect would mask any increase in the production of 
24OHC, and it would be extremely relevant to quantify 24,27-dihydroxycholesterol in 
NT2N cells. Furthermore, the fact that the decrease in 27OHC occurs concomitantly with 
the increase in CYP46A1, and due to the broad substrate specificity of CYP46A1 (Mast 
et al. 2003), it is feasible that, not only 24OHC is converted to the 24,27-
dihydroxycholesterol, but also that 27OHC in excess could be further metabolized by the 
highly expressed CYP46A1 in post-mitotic neurons. Due to its physiologic relevance, we 
are currently investigating the hypothesis that 27OHC can be a substrate for CYP46A1.  
Herein we show that NT2N post-mitotic neurons express several genes involved in 
brain cholesterol synthesis and synthesis regulation, uptake and catabolism. Furthermore, 
this is the first time CYP46A1 protein and 24OHC have been detected in human neuronal 
cells in culture. More importantly, our results indicate that during neurogenesis there 
seems to be a shift in the cholesterol elimination pathways, from a 27-hydroxylation-
dependent pathway to a 24-hydroxylation-dependent pathway. Taken together, our results 
suggest differentiated NT2 as a good experimental cell system for the study of cholesterol 
homeostasis in the human neurons. 
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5.1 Abstract 
The major mechanism of brain cholesterol elimination is the conversion of 
cholesterol into 24(S)-hydroxycholesterol by CYP46A1, a neuron-specific cytochrome 
P450. Since increasing evidence suggests that upregulation of CYP46A1 may be relevant 
for the treatment of Alzheimer’s disease, we aim to identify the molecular mechanisms 
involved in CYP46A1 transcription. Our previous studies demonstrated the role of Sp 
transcription factors in basal expression and histone deacetylase (HDAC) inhibitor-
dependent derepression of CYP46A1. Here, we show that the demethylating agent 5’-
Aza-2’-deoxycytidine (DAC) is a CYP46A1 inducer and that pre-treatment with DAC 
causes a marked synergistic activation of CYP46A1 transcription by trichostatin A. 
Surprisingly, bisulfite sequencing analysis revealed that the CYP46A1 core promoter is 
completely unmethylated in both human brain and non-neuronal human tissues where 
CYP46A1 is not expressed. Therefore, we have investigated Sp expression levels by 
western blot and real-time PCR, and their binding patterns to the CYP46A1 promoter, by 
electrophoretic mobility shift assay and chromatin immunoprecipitation assays, after 
DAC treatment. Our results showed that DAC decreases not only Sp1 and Sp3 protein 
levels, but also the binding activity of Sp3 to the +1 region of the CYP46A1 locus. 
Concomitantly, HDAC1 and HDAC2 were also significantly dissociated from the 
promoter. In conclusion, DAC induces CYP46A1 gene expression, in a DNA methylation-
independent mechanism, decreasing Sp3/HDAC binding to the proximal promoter. 
Furthermore, by affecting the expression of the Sp3 transcription factor in neuronal cells, 
DAC might affect not only brain cholesterol metabolism, but also the expression of many 
other neuronal genes. 
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5.2 Introduction 
DNA methylation and histone modifications are major epigenetic events that regulate 
gene expression. Therefore, in recent years, emphasis has been put on the clinical 
application of epigenetic drugs, namely DNA methyltransferase (DNMT) and histone 
deacetylase (HDAC) inhibitors. Despite the substantial evidence on the effect of these 
drugs on the regulation of tumor suppressor genes, little is known about how the cross-
talk between DNA methylation and histone acetylation affects transcription of genes 
involved in the pathophysiology of neurodegenerative disorders. 
The cholesterol 24-hydroxylase (CYP46A1) is a cytochrome P450 enzyme, 
exclusively expressed in neurons (Lund et al. 1999), and responsible for the conversion of 
cholesterol to 24(S)-hydroxycholesterol (24OHC). This represents the major pathway of 
cholesterol elimination from the brain, since this oxysterol can traverse the blood brain 
barrier, enter circulation, and be cleared by the liver (Russell et al. 2009). The importance 
of CYP46A1 in the normal functioning of the central nervous system (CNS) has been 
highlighted by studies on Cyp46a1 knock-out mice. Despite having a normal 
development when compared to the wild type littermates, Cyp46a1
-/-
 mice have a 
decrease in brain cholesterol synthesis and exhibit severe deficiencies in spatial, 
associative and motor learning, and hippocampal long-term potentiation (LTP) (Kotti et 
al. 2006).  
Due to its importance in the maintenance of brain cholesterol homeostasis, growing 
evidences suggest that an increase in CYP46A1 expression could be beneficial in 
neurodegenerative disorders, especially in Alzheimer’s disease (AD). CYP46A1 up-
regulation may increase cholesterol clearance, either by increasing cholesterol 
hydroxylation and 24OHC formation (Wang et al. 2008b) or by increasing ABCA1 and 
APOE expression in a liver X receptors (LXR) dependent mechanism (Fukumoto et al. 
2002, Whitney et al. 2002). Moreover, activation of LXR has been reported to attenuate 
the neuroinflammatory response of primary mixed glial cultures to fibrillar amyloid β 
(Aβ) (Zelcer et al. 2007). Overexpression of CYP46A1, or treatment with 24OHC has 
also been shown to increase the α-secretase activity as well as the α/β-secretase activity 
ratio (Famer et al. 2007, Prasanthi et al. 2009). Importantly, a recent study has 
demonstrated that in vivo overexpression of CYP46A1 before or after the onset of 
amyloid plaques significantly reduces Aβ pathology in mouse models of AD (Hudry et al. 
2009). 
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Taken together, these data clearly highlight the importance of understanding the 
molecular mechanisms that govern human CYP46A1 expression. Our previous work has 
demonstrated that human CYP46A1 promoter reporter constructs present high luciferase 
activity in cell lines where CYP46A1 mRNA could not be detected and that these 
recombinants are strongly transactivated in vitro not only by the brain-specific Sp4, but 
also by ubiquitous Sp1 and Sp3 (Milagre et al. 2008). These facts suggest that CYP46A1 
gene transcription might be regulated by epigenetic modifications, such as DNA 
methylation and/or histone modifications. Indeed, our previous studies have shown that 
inhibition of HDACs activity by trichostatin A (TSA), valproic acid and sodium butyrate 
causes a potent induction of human CYP46A1 expression (Nunes et al. 2010). Moreover, 
our results suggested that induction of CYP46A1 by TSA is correlated with a local shift in 
Sp1/ Sp3/ Sp4 ratio bound to the CYP46A1 proximal promoter, which favored the 
detachment of HDAC1 and HDAC2 as well as the recruitment of histone 
acetyltransferases and RNA polymerase II (Nunes et al. 2010).  
The DNMT inhibitor 5’- Aza - 2’- deoxycytidine (DAC) is a potent inhibitor of 
genomic and promoter methylation, by inhibiting DNMT activity, through irreversible 
binding of DNMTs to DAC substituted DNA (Creusot et al. 1982, Christman et al. 1985). 
It is generally accepted that DAC and TSA synergistically affect gene expression, by a 
mechanism that depends on promoter demethylation induced by DAC and subsequent 
reinforcement by histone acetylation induced by TSA. Nevertheless, several studies have 
suggested that DAC can also affect gene transcription by a mechanism independent of 
promoter demethylation (Soengas et al. 2001, Scott et al. 2006).  
Here we show that the treatment of SH-SY5Y neuroblastoma cells with DAC 
enhances TSA-dependent induction of the CYP46A1 gene, by decreasing Sp3/ HDAC 
binding to the promoter, in a DNA demethylation-independent manner. 
 
5.3 Methods 
5.3.1 Source of human samples  
In accordance with the Institutional Medical Ethics Committee, all tissue specimens 
were collected after patient’s informed consent. Human stomach specimens were 
obtained from individuals who underwent diagnostic stomach endoscopy, but whose 
results were negative for any stomach-associated pathology (Hospital de Santa Maria, 
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Lisboa, Portugal). Peripheral blood samples were obtained from healthy volunteers 
recruited from faculty staff by advertisement and used to prepare lymphocytes. Frozen 
human brain samples (cortices) were obtained from the Institute of Neuropathology, 
IDIBELL (Hospital Universitari de Bellvitge, University of Barcelona, Hospitalet de 
LLobregat, Barcelona, Spain). Those samples were control brains with no neurological 
abnormalities, cognitively-screened in life and with no neuropathological abnormalities. 
 
5.3.2 Antibodies 
The antibodies used in chromatin immunoprecipitation (ChIP), electrophoretic 
mobility shift assay (EMSA), and western blot are listed in Table 5.1.  
Table 5.1. List of the antibodies used in western blot, electrophoretic mobility shift assay 
(EMSA), andchromatin immunoprecipitation (ChIP).  
Protein Clone/ Reference Source Assay 
Sp1 39058 
Active Motif, Inc. 
(Rixensart, Belgium) 
ChIP 
Sp1 PEP-2 
Santa Cruz Biotechnology, Inc. 
(Santa Cruz) 
EMSA, western blot 
Sp3 D-20 
Santa Cruz Biotechnology Inc. 
(Santa Cruz) 
ChIP, EMSA, western 
blot 
Sp4 V-40, 
Santa Cruz Biotechnology Inc. 
(Santa Cruz) 
ChIP, EMSA, western 
blot 
HDAC1 05-100 
Upstate Biotechnology 
(Lake Placid, NY, USA) 
ChIP, western blot 
HDAC2 05-814 
Upstate Biotechnology 
(Lake Placid, NY, USA) 
ChIP,western blot 
RNA 
polymerase II 
05-623 
Upstate Biotechnology 
(Lake Placid, NY, USA) 
ChIP 
 
5.3.3 Cell Culture and treatment 
SH-SY5Y (human neuroblastoma) and HeLa (cervix adenocarcinoma) cell lines were 
maintained as previously described (Milagre et al. 2008). The optimal concentration of 
DAC was determined by performing dose response assays in both cell lines. 
Subsequently, all cells were treated with 5 M DAC or/ and 0.25 M TSA for the 
indicated time points or with vehicle (water or ethanol, respectively). Cell culture medium 
was changed every 24 hours. 
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5.3.4 mRNA analysis 
Total RNA from treated or untreated cells was isolated using Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) following manufacturer’s instructions. 1.5 µg of RNA 
was reversed transcribed using SuperScript II reverse-transcriptase kit with random 
hexamer primers (Invitrogen), and first strand DNA from 150 ng of RNA was used as a 
template in quantitative real-time PCR (qPCR) with an ABI PRISM 7300 sequence 
detection system (Applied Biosystems, Foster City, CA, USA). The cycling program was 
set as follows: denature at 95 ºC for 10 min, followed by 40 cycles of 95 ºC for 15 sec and 
60 ºC (for CYP46A1, Sp3 and β-actin) or 63 ºC (for Sp1 and Sp4) for 1 min. The 
Taqman® gene expression assay and the primers used in this study are described in table 
5.2. Results presented were obtained from three individual experiments and each sample 
was assayed in triplicate. CYP46A1 mRNA levels were normalized to the level of β-actin 
and expressed as pg of CYP46A1 mRNA per ng of β-actin mRNA. Sp1, Sp3 and Sp4 
mRNA levels were normalized to the level of β-actin and expressed as fold change from 
controls, using the 

Ct method. Four candidate genes were analyzed with the Norm 
Finder algorithm (Andersen et al. 2004) and β-actin was found to be the most stable 
single gene to be used as an endogenous control. 
 
5.3.5 Genomic DNA isolation and bisulfite sequencing analysis 
Tissue genomic DNA was isolated using the Puregene Cell and Tissue kit (Gentra 
Systems, Minneapolis, MN, USA). Genomic DNA from SH-SY5Y cells was isolated 
using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA), according to the 
manufacturer’s instructions. A PCR product encompassing the proximal promoter region 
was amplified from genomic DNA, in vitro methylated with SssI methylase or mock 
methylated and used as methylated or unmethylated control, correspondingly. Bisulfite 
sequencing analysis was performed using 1µg of genomic DNA with the EZ DNA 
Methylation Kit (Zymo Research, Orange, CA, USA). 
Bisulfite modified DNA was PCR amplified using two pairs of primers that covered 
a 557bp region of CYP46A1 proximal promoter containing the 438bp CpG island (Table 
5.2), amplifying the +1 to +177 and the -380 to +21 region of the CYP46A1 promoter. 
The PCR products were then cloned into the pCR®2.1 vector (Invitrogen) and 24 
colonies of each reaction were purified and analyzed by sequencing. 
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5.3.6 Nuclear Extracts 
Nuclear extracts were prepared as described by Schreiber and co-workers (Schreiber et 
al. 1989), subjected to 7.5% SDS-PAGE gels and electroblotted onto Immobilon P 
(Millipore, Bedford, MA, USA). After visualization of the transferred proteins by amido 
black staining, the membranes were incubated with specific antibodies. Results were 
quantified using the Quantity One densitometry analysis software (Bio-Rad Laboratories 
Inc., Hercules, CA, USA). 
 
Table 5.2. Sequence of primers used in this study.  
Gene Primer / 
TaqMan Assay 
Sequence (5’→ 3’) / Source Assay 
CYP46A1 
CYP46A1 
HS00198510_M1 
Applied Biosystems qPCR 
β Actin 
ACTB 
HS99999_M1 
Applied Biosystems qPCR 
Sp1 
qPCRSp1fwd 
qPCRSp1Rev 
5’-gcctccagaccattaacctcagt -3’ 
5’- gctccatgatcacctggggcat -3’ 
qPCR 
Sp3 
Sp3qPCRfwd2 
Sp3qPCRRev2 
5’-gctggtatacagctacatccaggag -3’ 
5’-caccactgagctgccactcttc -3’ 
qPCR 
Sp4 
qPCRSP4Fwd 
qPCRSP4Rev 
5’- gcagcggcgatggctacaga -3’ 
5’- agggctgagagtcctgggagc -3’ 
qPCR 
β Actin 
qPCRHuACTINf 
qPCRHuACTINr 
5’-ctggaacggtgaaggtgaca-3’ 
5’-aagggacttcctgtaacaatcca-3’ 
qPCR 
CYP46A1 (+1 
to +177) 
bCYP46p1F 
bCYP46p1R 
5′-gatttgagtttgaagaggtgg -3′ 
5′-caacaacaaccc(g/a)aaactcataac-3′ 
Bisulfite 
sequencing 
CYP46A1 
(-380 to +21) 
bCYP46p2F 
bCYP46p2R 
5’- ggagttatgagttt(c/t)gggttgttg -3’ 
5’-tatccccaaacccccaatccc-3’ 
Bisulfite 
sequencing 
 
5.3.7 Electroforetic Mobility Shift Assay 
EMSA was performed as previously described (Milagre et al. 2008). Briefly, 2-5 µg 
NE were incubated with γ32P-labeled oligonucleotide probe harboring sites SP-RE-B or 
SP-RE-D. For supershift assays, 1 µl of each specific antibody were pre-incubated with 
the NE for 30 min before the addition of probe. Protein-DNA complexes were resolved 
on 5 % native polyacrylamide gels and visualized by autoradiography. 
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5.3.8 Chromatin immunoprecipitation 
ChIP assays were performed as previously described in Chapter 3 (Section 3.3.6). 
The recovered DNA was analyzed by real-time PCR with SYBR green Master Mix in an 
ABI 7300 sequence detection system (Applied Biosystems). Real-time PCR was 
performed using primers that covered different regions of the promoter as previously 
described (Nunes et al. 2010).  
 
5.3.9 Statistical analysis 
Statistical analysis was performed using the Student’s t-test and the ANOVA one-
way test with the Tukey HSD post-hoc test or the Tukey HSD for unequal n 
(Spjotvoll/Stoline test). All analysis was performed using the STATISTICA (data 
analysis software system), version 7.1 StatSoft, Inc. (2006). A value of p < 0.05 was 
considered significant. 
 
5.4 Results 
5.4.1 DAC activates the transcription of human CYP46A1 gene and acts 
snergistically with TSA 
In our previous studies we have characterized the molecular mechanisms involved in 
the CYP46A1 response to HDAC inhibitors (Nunes et al. 2010). In this study, we aimed 
to elucidate if another epigenetic mechanism, namely DNA methylation, is involved in 
the tissue specific expression of the human CYP46A1 gene. With this purpose, we 
investigated the effect of the demethylating agent DAC on the expression of the human 
CYP46A1 gene. SH-SY5Y and HeLa cells were treated with increasing concentrations of 
DAC for 96 h or with 5 M DAC for increasing periods of time, and CYP46A1 
expression was quantified by real-time PCR (qPCR) (Figure 5.1). The kinetics of 
CYP46A1 mRNA accumulation in SH-SY5Y treated with 5 M DAC showed that 
mRNA levels started to increase significantly 72 h after DAC treatment (ANOVA one-
way test: F = 21.29, df = 3, p < 0.001; Tukey HSD for unequal N, p < 0.01), reaching a 
maximum 96 h after treatment (Tukey HSD for unequal N, p < 0.001) (Figure 5.1 A). 
Moreover, treatment with 2.5 M or 5 M DAC for 96 h significantly increased the 
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CYP46A1 mRNA levels, when compared with untreated cells (ANOVA one-way test: F 
= 10.89, df = 3, p < 0.01; Tukey HSD for unequal N, p < 0.01) (Figure 5.1 B). In 
contrast, in HeLa cells treated with 5 M DAC for 96 h, CYP46A1 mRNA levels 
remained undetected (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since we have previously shown that TSA leads to an up-regulation of CYP46A1 
expression in SH-SY5Y cells (Nunes et al. 2010), the coordinated effects of the 
Figure 5.1. DAC increases CYP46A1 mRNA levels and potentiates the TSA-dependent induction of 
CYP46A1 expression in SH-SY5Y cells. Real-time PCR analysis of CYP46A1 steady-state mRNA 
transcript levels in SH-SY5Y cells treated with 5 µM DAC for the indicated time points (A), with 
increasing concentrations of DAC for 96 hours (B), and with 5 µM DAC for 96 hours, 0.25 µM TSA for 
16 h, or with both (C). Values were normalized to the internal standard β-actin. Data represent means ± 
SEM of at least three independent experiments and were expressed as pg of CYP46A1 mRNA per ng of 
β-actin mRNA (§p < 0.05; †p < 0.01; *p < 0.001). 
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demethylating agent, DAC, with the HDAC inhibitor, TSA, were further evaluated (Fig. 
1C). Pre-treatment with the DNA demethylating agent caused marked synergistic 
activation of the CYP46A1 gene by TSA, resulting in a significant increase of the 
CYP46A1 mRNA levels when compared with DAC or TSA treated cells (Fig 1B) 
(ANOVA one-way test: F = 154.1, df = 3, p < 0.001; Tukey HSD for unequal N, p < 
0.001 and p < 0.05, respectively).These results demonstrate that CYP46A1 gene 
transcription was significantly induced by DAC treatment in SH-SY5Y cells, and that 
pre-treatment with this DNA demethylating agent caused marked synergistic activation of 
the CYP46A1 gene by TSA. 
 
5.4.2 Methylation status of the CYP46A1 promoter in SH-SY5Y cells and different 
human tissues 
Since DAC led to the derepression of CYP46A1 expression in SH-SY5Y, we 
evaluated the methylation status of the proximal promoter in this cell line as well as in 
human brain, lymphocytes and stomach samples. Analysis of the 5’ flanking region of the 
CYP46A1 gene (-0.3 kb) and its first exon by a CpG island searcher program (EMBOSS 
CpGPlot) indicated that the proximal promoter region of this gene is located in a 
predicted CpG island that encompasses nucleotides -300 to +138 relative to the ATG start 
codon (+1). This island (all values are observed/expected) was defined based on its size 
(438bp/ >200bp), GC content (79%/ 50%) and CpG dinucleotide frequency (0,81/ >0,6) 
(Gardiner-Garden & Frommer 1987). The DNA methylation status of the CYP46A1 
promoter region was assessed by bisulfite sequencing analysis and surprisingly, our 
results showed that the CYP46A1 promoter region was completely unmethylated not only 
in human brain, but also in SH-SY5Y cells and human tissues where CYP46A1 is not 
expressed (Figure 5.2). As positive controls, we used an in vitro methylated or 
unmethylated PCR product amplified from genomic DNA, corresponding to the 
CYP46A1 proximal promoter region (Figure 5.2). In parallel, we have also assessed the 
methylation status of the pyruvate dehydrogenase 2 gene promoter, which we have 
previously shown to be methylated in somatic tissues (data not shown) (Pinheiro et al. 
2010).These data demonstrated that, as expected, the CYP46A1 promoter is completely 
unmethylated in the human brain, where CYP46A1 is highly expressed.  
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Figure 5.2. Bisulfite sequencing of CYP46A1 promoter region in SH-SY5Y cells and different 
human tissues. Bisulfite-treated DNA was PCR amplified using primers spanning the CpG island 
containing the proximal promoter region of CYP46A1. PCR products were cloned, and multiple clones 
were sequenced and analyzed for their methylation status. A) Map of CYP46A1 proximal promoter region 
showing location of CpG sites (vertical dashes) and primers used for bisulfite sequencing (arrows). 
Bisulfite sequencing results are shown for human brain (B), SH-SY5Y cells (C), human lymphocytes (D), 
human stomach (E), and in vitro methylated DNA as a control (F). Open and filled circles indicate 
unmethylated and methylated CpG sites, respectively. The CpG sites are mapped in reference to the 
translation start site.  
 
Chromatin-Modifying Agents Increase Transcription of CYP46A1 
 
 
117 
 
Surprisingly, our data also showed that the same region is also completely 
unmethylated in human tissues where CYP46A1 mRNA cannot be detected, suggesting 
that DNA methylation of the proximal promoter does not play a role in the regulation of 
CYP46A1 tissue specific expression. Interestingly, the CYP46A1 gene responded to DAC 
treatment, in SH-SY5Y cells, even though the promoter is already completely 
unmethylated in these cells. However, we cannot exclude that methylation might be 
affecting an enhancer or other regulatory element not yet identified, outside of the 
CYP46A1 core promoter. 
 
5.4.3 Treatment with the demethylating agent DAC causes a shift in the Sp protein 
levels ratio  
The fact that CYP46A1 was induced by DAC treatment in SH-SY5Y cells, even 
though the proximal promoter was completely unmethylated, led us to investigate if the 
expression levels of the Sp transcription factors, previously described as key regulators of 
CYP46A1 (Milagre et al. 2008), were being affected by this drug. In fact, 72 h after 
treatment with 5 M DAC, we could observe a significant decrease in the protein levels 
of Sp1 and the different Sp3 isoforms (ANOVA one-way test: F = 14.8, df = 4, p < 0.001; 
Tukey HSD for unequal N, p < 0.05; and ANOVA one-way test: F = 20.62, df = 4, p < 
0.001; Tukey HSD for unequal N, p < 0.01, respectively) (Figure 5.3 A and B). The 
levels of both Sp1 and Sp3 remained low 96 h after treatment. In contrast, the brain 
specific Sp4 protein levels were not affected upon treatment with 5 M DAC.  
Interestingly, in HeLa cells where DAC treatment did not affect CYP46A1 
expression, the levels of Sp1, Sp3 and Sp4 protein were also not affected by this DNA 
demethylating agent (Figure 5.3A). To further understand the mechanisms by which DAC 
treatment was affecting the Sp expression levels, we assessed the mRNA levels of the 
different Sp transcription factors by real-time PCR, after DAC treatment. Our results 
showed that DAC treatment did not significantly alter the mRNA levels of Sp1, Sp3 or 
Sp4 (Figure 5.3 C). 
Our results showed that Sp1 and Sp3 protein levels were significantly decreased by 
treatment with DAC and this decrease was concomitant with the increase in CYP46A1 
mRNA levels. 
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Figure 5.3. Treatment with DAC affects Sp transcription factors protein levels. SH-SY5Y or HeLa 
cells were treated with 5 M DAC for the indicated time points. A and B) Nuclear extracts were 
subjected to SDS-PAGE, transferred to PVDF membranes, and the membranes were incubated with 
specific anti -Sp1, -Sp3 and -Sp4 antibodies. The HDAC 2 levels were determined as a loading control. 
C) Real-time PCR analysis of Sp1, Sp3 and Sp4 steady-state mRNA transcript levels. Values were 
normalized to the internal standard β-actin. All results shown are representative of those obtained in at 
least three independent cultures. Data represent means ± SEM and are expressed as fold change relative 
to control cells (§p < 0.05; †p < 0.01; *p < 0.001).  
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5.4.4 Recruitment of Sp proteins to the CYP46A1 promoter after treatment with 
DAC alone or in combination with TSA  
Afterwards, we have investigated whether the decrease in Sp1 and Sp3 protein levels 
was correlated with changes in the different Sp protein binding activities to the Sp 
response elements in the CYP46A1 proximal promoter, or to the formation of novel DNA-
protein complex(es) after DAC treatment. We have incubated nuclear proteins isolated 
from SH-SY5Y cells treated with 5 M DAC for different time points, with the Sp-RE-B 
and Sp-RE-D probes, which we had already shown to have a high affinity for the different 
Sp proteins (Milagre et al. 2008). The EMSA results showed a time-dependent decrease 
in the total nuclear proteins capable of binding to the Sp-RE-B probe after DAC treatment 
(Figure 5.4 A). Similar results were obtained with the Sp-RE-D probe (data not shown). 
In agreement with our previous results (Nunes et al. 2010), Sp3 was the major component 
of these protein complexes, and the composition of the complexes formed with nuclear 
extracts prepared from cells treated with 5 M DAC for 72 h did not greatly differ from 
those formed with nuclear extracts prepared from control cells (Figure 5.4 B). 
 Since we have previously demonstrated that the total nuclear proteins capable of 
binding to the Sp-RE-B probe decreased after TSA treatment (Nunes et al. 2010), we 
decided to analyze the effect of treatment with 5 M DAC for 72 h, 0.25 M TSA for 6 
hours, or the combined treatment, in the binding activities of Sp proteins to the Sp-RE-B 
element. As expected, TSA treatment led to a decrease in total nuclear proteins capable of 
binding to the probe, when compared with the vehicle-treated cells (Figure 5.4 C). 
Interestingly, when we used nuclear proteins prepared from cells treated with DAC alone 
or in combination with TSA, we could observe a decrease in Sp protein binding to the Sp-
RE-B element when compared with TSA-treated cells. Nevertheless, treatment with both 
the DNA demethylating agent and the HDAC inhibitor does not elicit a further decrease 
in Sp proteins binding affinity, when compared with DAC alone (Figure 5.4 C). 
These results show that DAC not only decreases Sp1 and Sp3 levels but also 
decreases the binding activity of these transcription factors to the Sp-RE elements in the 
CYP46A1 proximal promoter.  
 
 
 
 
Chapter 5 
 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further understand if the multiprotein complexes bound to the proximal promoter 
were being affected by the treatment with DAC alone or in combination with TSA, we 
performed ChIP assays. We have previously shown that in untreated and TSA-treated 
Figure 5.4. DAC affects Sp protein binding to the SP-RE-B site of the CYP46A1 proximal promoter 
in human neuroblastoma cells. EMSA were performed using nuclear extracts (NE) of SH-SY5Y cells 
and a radiolabeled double-stranded oligonucleotide corresponding to the Sp-RE-B site as a probe. A) The 
probe was incubated with NE prepared from cells treated with vehicle or with 5 µM DAC for the 
indicated time points. B) Super-shift (SS) experiments were performed using NE of cells treated with 
vehicle or with 5 µM DAC for 72 hours, and anti-Sp1 and -Sp3 antibodies. C) The probe was incubated 
with NE prepared from cells treated with vehicle or with 5 µM DAC for 72 hours, 0.25 M TSA for 6 
hours or both. Autoradiograms are representative of three independent experiments. 
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SH-SY5Y cells, both the ubiquitous Sp1 and Sp3 as well as the brain enriched Sp4 were 
present in the CYP46A1 +1 region of the promoter (Nunes et al. 2010). Since our results 
show that Sp protein levels were affected by DAC treatment, the binding of these proteins 
to the promoter region was determined (Figure 5.5). Confirming our previous results, in 
untreated SH-SY5Y cells, Sp1, Sp3 and Sp4 were present in the +1 region (Figure 5.5 A 
and B). In agreement with our EMSA results, we observed a significant decrease in the 
binding of the Sp3 transcription factor to the proximal promoter, 72 h after treatment with 
5 M DAC (ANOVA one-way test: F = 5.50, df = 3, p < 0.01; Tukey HSD for unequal 
N, p < 0.01). DAC treatment of SH-SY5Y cells did not affect the binding of any of the 
other Sp transcription factors to the GC-rich proximal promoter region of the CYP46A1 
gene (Figure 5.5 B), suggesting that, although DAC induces a decrease in Sp1 levels, this 
decrease is not reflected in the binding of this transcription factor at the promoter level. 
We further examined the binding of HDACs to the CYP46A1 promoter. HDAC1 and 
HDAC2 were significantly dissociated from the +1 promoter region, 72 h after DAC 
treatment, since there were no longer significant differences between the chromatin 
recovered with the anti-HDAC1 and 2 antibodies, and that recovered with IgG (Figure 5.5 
B). 
We further analyzed the recruitment of Sp3 and RNA polymerase II (RNA pol II) to 
the CYP46A1 promoter in cells treated with either TSA or with the combined treatment of 
DAC and TSA. As previously demonstrated, TSA did not induce an overall decrease in 
Sp3 binding to the +1 region (Nunes et al. 2010) but in cells treated with DAC and TSA 
the Sp3 association to the proximal promoter was diminished by approximately 50%, a 
decrease similar to the one obtained after DAC treatment (Figure 5.6).  
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These results are in agreement with our EMSA results, where treatment with both the 
DNA demethylating agent and the HDAC inhibitor did not elicit a further decrease in Sp 
proteins binding affinity, when compared with DAC alone (Figure 5.4). Furthermore, we 
were expecting to detect a correlation between recruitment of RNA pol II and CYP46A1 
mRNA levels. Nevertheless, although we have confirmed our previous results, showing a 
significant recruitment of RNA pol II after TSA treatment, DAC alone did not alter RNA 
pol II association to the proximal promoter, and pre-treatment with DAC did not further 
enhance the TSA-dependent recruitment.  
 
 
Figure 5.5. Decrease of Sp3 and HDAC binding to the CYP46A1 proximal promoter after DAC 
treatment. Chromatin from SH-SY5Y cells treated with 5 µM DAC for the indicated time points (A), or 
for 72h (B) was prepared and immunoprecipitated with anti-Sp1, -Sp3, -Sp4, -HDAC1, -HDAC2 and -
RNA pol II antibodies.  After DNA recovery, the precipitates were evaluated by real-time PCR. All 
results are expressed as percentage of total input and represent means ± SEM of at least three independent 
experiments (§p < 0.05; †p < 0.01; *p < 0.001). 
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5.5 Discussion 
CYP46A1 is a key player in the maintenance of cholesterol homeostasis in the brain. 
Increasing evidence suggests that upregulation of CYP46A1 may benefit AD treatment. 
Indeed, injection of a adeno-associated vector encoding CYP46A1 in the brain of AD 
transgenic mice, before or after the onset of amyloid deposits, can significantly reduce  
Aβ pathology in vivo (Hudry et al. 2009).  Furthermore, in vitro overexpression of 
CYP46A1, or treatment with 24OHC increases α-secretase activity as well as α/β-
secretase activity ratio (Famer et al. 2007, Prasanthi et al. 2009). 
HDAC inhibitors are the only compounds known to up-regulate the expression of 
CYP46A1 gene (Shafaati et al. 2009, Nunes et al. 2010). In the present study, we have 
identified DAC, a Food and Drug Administration approved drug that effectively passes 
the blood brain barrier (Chabot et al. 1983), as an inducer of the CYP46A1 gene and 
characterized the molecular mechanisms involved in the potentiation of TSA-dependent 
CYP46A1 induction by this DNMT inhibitor. To explore the involvement of DNA 
methylation and histone modifications in CYP46A1 gene silencing, we first treated 
different cell lines with DAC and TSA. Synergistic derepression of the CYP46A1 gene by 
DAC and TSA or derepression with DAC alone was observed in SH-SY5Y 
neuroblastoma cells, but was absent in HeLa cells. In addition, we investigated the DNA 
Figure 5.6. Recruitment of Sp3 and RNA pol II to the GC-rich region of the CYP46A1 proximal 
promoter, after combined treatment with DAC and TSA. Chromatin from SH-SY5Y cells treated 
with 5 µM DAC for 72h, 0.25 M TSA for 6 hours or both, was prepared and immunoprecipitated with 
anti-Sp3 and -RNA pol II antibodies. After DNA recovery, the precipitates were evaluated by real-time 
PCR. All results are expressed as percentage of total input and represent means ± SEM of at least three 
independent experiments (§p < 0.05; †p < 0.01; *p < 0.001, relative to vehicle treated cells). 
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methylation profile of the CpG island that contains the CYP46A1 proximal promoter 
region, covering the Sp-binding sites previously shown to be important for CYP46A1 
basal expression. Surprisingly, the bisulfite sequencing analysis revealed that the 
CYP46A1 core promoter is completely unmethylated, even in human tissues where 
CYP46A1 is not expressed, which suggests that DNA methylation of the proximal 
promoter does not play a role in the regulation of CYP46A1 tissue specific expression. 
We have previously demonstrated that the effect of TSA on CYP46A1 mRNA levels was 
virtually instantaneous, detectable by immediate localized histone hyperacetylation 
(Nunes et al. 2010), which is in favor of an unmethylated promoter. Moreover, by ChIP 
analysis we could not detect any association of DNMT1 or MeCP2 to the CYP46A1 
promoter in untreated SH-SY5Y cells (data not shown). Nevertheless, we cannot exclude 
that DNA demethylation may reactivate an unidentified transcription factor that controls 
CYP46A1 expression, or that methylation of an enhancer or other regulatory element not 
yet identified, outside of the CYP46A1 core promoter, can interfere with its expression. 
The mechanism underlying DAC-mediated relieve of CYP46A1 repression in 
neuroblastoma cells is not clearly known. DAC had been previously reported to induce 
the expression of unmethylated silenced genes (Zhu et al. 2001, Soengas et al. 2001, 
Scott et al. 2006). Interestingly, two of these genes p19
INK4d
 and p21
WAF1/Cip
 are also Sp-
regulated genes (Yokota et al. 2004, Kim et al. 2003). Therefore, we have investigated Sp 
expression levels, and binding patterns to the CYP46A1 promoter, by western blot, real-
time PCR, EMSA and ChIP analysis, after DAC treatment. DAC treatment decreased not 
only Sp1 and Sp3 protein levels, but also the binding activity of Sp3 to the +1 region of 
the CYP46A1 locus. An effect of DAC and 5-aza cytidine on the expression levels of Sp 
proteins had been previously reported. Indeed, treatment of MCF-7L breast and GEO 
colon cancer cells with 5-aza cytidine led to down-regulation of Sp3, but up-regulation of 
Sp1 (Ammanamanchi & Brattain 2001, Periyasamy et al. 2000). Interestingly, in HeLa 
cells, where CYP46A1 mRNA levels were not induced by DAC, Sp protein levels were 
also not affected. Our results also revealed that, although affecting protein levels of both 
Sp1 and Sp3, DAC treatment did not alter mRNA levels of the different Sp transcription 
factors. Interestingly, DAC affects levels of specific proteins by rapidly inducing 
degradation by the proteasomal pathway (Cecconi et al. 2009, Patel et al. 2010). 
Concomitant with the decrease in Sp3 binding to the CYP46A1 +1 region, ChIP 
experiments also revealed that HDAC1 and HDAC2 were significantly dissociated from 
the promoter. DAC had already been reported to relieve p21
WAF1
 repression in acute 
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myeloid leukemia cells by a mechanism that involved release of HDAC1 (Scott et al. 
2006). The decrease in Sp3 binding induced by DAC is in agreement with our previous 
results, which showed that the decrease of Sp3 at particular responsive elements induced 
by TSA, namely at the Sp-RE-B site, could locally shift the Sp1/ Sp3/ Sp4 ratio, and 
favor the detachment of HDAC1 and HDAC2 from the CYP46A1 promoter (Nunes et al. 
2010). Sp3 has been demonstrated to physically interact with specific repressor 
complexes, namely with HDACs and mSin3A (Zhang & Dufau 2002, Clem & Clark 
2006, Sun et al. 2002). Loss of Sp3 binding induced by DAC, which might be required 
for HDAC association, may facilitate TSA-induced acetylation of the histone tail and the 
maintenance of the open configuration of the local chromatin, suggesting that this drug 
can directly induce regional chromatin remodeling, independently of its effects on DNA 
methylation. Although DAC treatment did not induce an enrichment of RNA pol II at the 
CYP46A1 promoter, as we would expect, we can hypothesize that in a HDAC-free 
promoter, recruitment of basal transcriptional machinery is facilitated. It would have been 
interesting to monitor by ChIP, phosphorylation of specific serine residues in the 
carboxy-terminal domain to further assess initiating, productive and elongating RNA pol 
II.  
The use of drugs that modify the epigenome has been recently highlighted in brain 
disorders, namely in AD. In the Tg2576 mouse model of AD, 4-phenylbutyrate reversed 
spatial memory deficits by normalizing Tau hyperphosphorylation in the hippocampus, 
without affecting Aβ levels (Ricobaraza et al. 2009). Moreover, in the AβPP23 transgenic 
mouse model of AD, low doses of valproic acid significantly reduced Aβ plaque number 
and improved memory deficits (Qing et al. 2008). The importance of histone acetylation 
for synaptic plasticity and memory formation has also been demonstrated. Environmental 
enrichment caused chromatin modification through increased histone-tail acetylation, and 
reinstated learning and memory even after significant neurodegeneration had taken place 
in CK-p25 transgenic mice (Fischer et al. 2007). In a follow-up study, mice 
overexpressing HDAC2, but not HDAC1, exhibited decreased dendritic spine density, 
synaptic number and synaptic plasticity, and impaired memory formation (Guan et al. 
2009). Conversely, Hdac2 knockout mice showed memory improvement, while the 
symptoms induced by HDAC2 overexpression, were partially reverted by treatment with 
the HDAC inhibitor vorinostat.  
Nevertheless, some caveat is necessary when exploring the potential use of 
epigenetic drugs in neurodegeneration. First of all, it has to be considered that the 
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development of neurodegenerative diseases is often very slow and the onset not precisely 
defined. The side-effects related to the use of epigenetic drugs for long periods of time 
that cover the period of Mild Cognitive Impairment, is not yet known. One of the major 
concerns deals with the possible negative effect that epigenetic drugs could exert on 
cancer. It is largely known that changes in methylation patterns of oncogenes and 
oncosuppressor genes are associated to cancer onset and development. For this reason, the 
use of compounds potentially able to modulate the epigenome should be tested, 
considering the possible altered regulation of a wide number of genes. Wide-analysis 
approaches like ChIP-arrays, RNA micro-arrays and proteomics assays could represent 
the obvious road to disclose potential “side-effects” of epigenetic drugs. In this regard, we 
have already the indication that epigenetic modulation does not necessarily involve the 
whole genome. In fact, the use of a macro-array representative of about 600 genes 
expressed in CNS has shown that only 1-2% of such genes were modulated by altered 
DNA methylation status (Cavallaro et al. 2006). A second aspect that should be 
considered deals with the efficacy of DAC administration and CYP46A1 induction versus 
different AD features, like Aβ production and aggregation, and cognitive impairment. To 
this purpose, the use of cell cultures and AD transgenic animal models will be necessary, 
but the findings presented in this paper help to elucidate the mechanisms underlying the 
effects of epigenetic regulation on cholesterol metabolism and represent a platform for the 
development of a possible epigenetic intervention in AD. 
In summary, the fact that DAC has been approved by the Food and Drug 
Administration to treat myelodysplastic syndrome, that it effectively passes the BBB, and 
in light of the recent interest on the use of HDAC inhibitors as a therapeutic avenue for 
neurodegenerative disorders, it is of the utmost importance to characterize the molecular 
mechanisms by which these epigenetic drugs can affect the expression of neuronal 
specific genes. In this study, we have shown that DAC is a CYP46A1 inducer, which can 
further potentiate the TSA-dependent increase in CYP46A1 gene expression, by a DNA 
methylation independent mechanism, inducing a decrease in Sp3/ HDAC binding to the 
promoter of this neuronal specific gene. Furthermore, affecting the expression of the Sp3 
transcription factor, specifically in neuronal cells, DAC might not only affect brain 
cholesterol metabolism, but potentially affect the expression of many other neuronal 
genes. 
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The original studies presented in this thesis elucidate, for the first time, key 
mechanisms and factors involved in the regulation of the human CYP46A1 gene. We 
show that the Sp transcription factors are key regulators of CYP46A1 expression and are 
involved in the DAC-mediated derepression of CYP46A1, in a proximal promoter 
methylation-independent mechanism. Furthermore, our results suggest that progenitor 
cells eliminate cholesterol in the form of 27OHC, while neurogenesis induces a shift to 
the cholesterol 24-hydroxylase-dependent elimination pathway. 
In the first part of our studies we have cloned and characterized the human CYP46A1 
promoter. We found it to be highly GC rich and identified a region spanning from 
nucleotides -236/-64 that encompasses four essential GC boxes, which is indispensable 
for basal expression of this TATA-less gene. In addition we have shown that the Sp 
transcription factors Sp1, Sp3, and Sp4 regulate the cholesterol 24-hydroxylase gene 
expression, and that there is an increase in the ratio of (Sp3+Sp4)/ Sp1 proteins bound to 
the proximal promoter Sp-response elements in vitro, when using nuclear extracts 
prepared from primary rat cortical neurons. Actually, the hypothesis that a substitution of 
Sp4 by Sp1 would be a mechanism of gene regulation in neurons, had previously been put 
forward by Steve Barger (Mao et al. 2006). By performing ChIP analysis we were able to 
determine that indeed Sp1 is dissociated from the CYP46A1 proximal promoter region 
after differentiation of human NT2 cells into post-mitotic neurons, however the levels of 
both Sp3 and Sp4 remain unchanged. Thus, although we failed to see a substitution of 
Sp1 by Sp4, we confirmed our in vitro findings, by detecting Sp3 and Sp4 as the major 
proteins bound to the proximal promoter of CYP46A1 in human post-mitotic neurons.  
The fact that the different Sp proteins bind to similar response elements and can 
modulate transcription by protein-protein interactions, raises the question of whether the 
displacement of Sp1 can cause a shift in the conformation of the promoter region, that 
leads to the differential recruitment of co-activators/ co-repressors or even components of 
the core initiation machinery. Indeed, it was recently described that a switch in specific 
subunits of the ATP-dependent chromatin remodeling complexes must be exchanged 
during the transition from neuronal progenitors to post-mitotic neurons. This switch 
involves the exchange of the subunits BAF45a and BAF53a of the neural-progenitor-
specific Brg/ Brahma associated factor (BAF) complex, for the homologous BAF45b and 
BAF53b subunits within neuron-specific BAF (nBAF) complex in post-mitotic neurons 
and preventing the subunit switch impairs neuronal differentiation (Lessard et al. 2007). 
The BAF53b subunit and the nBAF complex have been shown to be essential for an 
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evolutionarily conserved program of post-mitotic neural development and dendritic 
morphogenesis (Lessard et al. 2007, Wu et al. 2007). Since, Sp1 has been shown to 
interact with the BAF complex in vivo and to increase the BAF-mediated activation of the 
interferon-stimulated gene factor 3 promoter (Liu et al. 2002), one may speculate that 
such a switch, along with the dissociation of Sp1 transcription factor from the promoter, 
could be important in prompting the expression of neuron-specific genes, such as 
CYP46A1.  
Bioinformatic analysis has shown the existence of two putative RE1 sites upstream of 
the CYP46A1 proximal promoter (unpublished data). REST has been shown to inhibit the 
Sp1-dependent transcriptional activation of target genes, in non-neuronal cells (Myers et 
al. 1998, Plaisance et al. 2005, Park et al. 2007). Furthermore, it has been widely 
described that REST interacts with several chromatin-modifying proteins such as HDACs 
(reviewed in Ooi & Wood 2007), and our group and others have shown the importance of 
HDACs on the repression of CYP46A1 transcription in non-neuronal cells (Shafaati et al. 
2009, Nunes et al. 2010). As such, one may speculate that the repressor REST can play a 
role in controlling the tissue-specific expression of this gene. 
Since replacement of Sp1 by Sp4 might have important effects on neuronal gene 
expression, and consequently on the differentiation of post-mitotic neurons, we have 
assessed the binding pattern of Sp transcription factors to the promoters of other Sp-
regulated genes expressed in neurons. In the reelin locus we could indeed detect a 
substitution of Sp1 by Sp4, at the proximal promoter region; however, we failed to detect 
any conserved binding pattern of Sp proteins, after neuronal differentiation, at the 
promoters of the other genes analyzed. For instance, in the GRIN1 promoter, after 
neuronal differentiation, we no longer detected Sp4 association, while in the MOR 
promoter we observed the recruitment of Sp1. Although, in contrast with what initially 
hypothesized, these results are not completely unexpected, since all of the genes studied 
have different promoter arrangements with regard to the Sp response elements (Wendel & 
Hoehe 1998, Liu et al. 2003, Mejia-Guerra & Lareo 2005, Chen et al. 2007), and the 
majority of studies point to the major importance of the promoter context in Sp-dependent 
tissue-specific gene expression (Faraonio et al. 1994, Liu et al. 2003, Ross et al. 2002b, 
Yamaguchi et al. 2010). Indeed, our results reinforce the notion that binding of Sp 
proteins to DNA greatly depends on promoter context suggesting that, in the neuronal 
chromatin environment, Sp1-dependent transactivation of specific neuronal promoters is 
Concluding Remarks 
 
133 
 
most likely to occur, despite the significant decrease in Sp1 levels after neuronal 
differentiation.  
Brain cholesterol elimination depends on the neuronal expression of CYP46A1 and 
the lack of a cellular model that expresses high levels of this enzyme has limited the 
insight into how human post-mitotic neurons handle cholesterol. We have shown that 
cholesterol synthesizing enzymes are decreased in NT2N cells, and most importantly that 
the cholesterol 24-hydroxylase expression is up-regulated, which reflects what is thought 
to occur in vivo. Although the complexity of brain structure and diversity of cell 
populations cannot be mimicked by an in vitro system, the NT2 cell model is a widely 
accepted surrogate of mature neurons of the human CNS (Llanes et al. 1995, Freemantle 
et al. 2002, Deb-Rinker et al. 2005). Furthermore, the use of original human tissues is 
limited because of availability and ethical concerns, taking into account the differences in 
cholesterol homeostasis between rodents and humans (Dietschy & Turley 2001, Dietschy 
& Turley 2004, Heverin et al. 2005) and given our results, we believe that the NT2 cell 
model can be a valuable in vitro model to study neuronal cholesterol metabolism and to 
test potential therapeutic agents that can modulate CYP46A1 expression. 
To our knowledge this was the first time that CYP46A1 protein and 24OHC have 
been detected in human neuronal cells in culture. Moreover, concomitantly with the 
increase in CYP46A1 protein, we observed a decrease in CYP27A1 protein levels, and an 
increase in CYP39A1 and CYP7B1, the enzymes responsible for metabolizing 24OHC 
and 27OHC. Interestingly, we have also shown that RA-induced transition from 
progenitors to fully differentiated neural phenotype, induces a shift in the cholesterol 
catabolic pathway utilized by these cells, suggesting that progenitor cells eliminate 
cholesterol in the form of 27OHC, while post-mitotic neurons depend on cholesterol 24-
hydroxylation. CYP46A1 expression increases after birth reaching steady-state levels that 
are maintained through adulthood. However, nothing is known about CYP27A1 
expression in the developing brain, and it would be interesting to investigate if the shift in 
the utilization of the sterol-hydroxylases also occurs in vivo.  
The lack of enzyme-product correlation observed when we compared the changes in 
24OHC and 27OHC levels with the changes in CYP46A1 and CYP27A1 protein levels, 
led us to hypothesize that CYP46A1 can further metabolize 27OHC. It has been shown 
that CYP46A1 presents broad substrate specificity and that the substrate-binding pocket 
of this enzyme is large and capable of accommodating structurally diverse substrates of 
different sizes (Mast et al. 2003). Moreover, CYP46A1 has been shown to further 
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metabolize 24OHC into 24,27-dihydroxycholesterol, binding to 24OHC with an higher 
affinity than to cholesterol (Mast et al. 2003). Our results do not show an increase in 
24OHC concomitant with the increase in CYP46A1 protein, but show a correlation 
between the decrease in 27OHC and the increase in CYP46A1. Therefore, it is possible 
that, not only 24OHC is converted to 24,27-dihydroxycholesterol, but also that 27OHC in 
excess could be further metabolized by CYP46A1, in post-mitotic neurons. Indeed, we 
are currently addressing this issue by over-expressing CYP46A1 in human embryonic 
kidney 293 cells, and trying to detect an increase in the levels of 24,27-
dihydroxycholesterol, after addition of exogenous 27OHC.  
If we can prove that 27OHC is a substrate for CYP46A1, this has important 
physiological consequences. Although a flux of 27OHC from the plasma to the brain has 
been demonstrated, the levels of this oxysterol in the brain are extremely low (Heverin et 
al. 2004, Heverin et al. 2005). 27OHC has been shown to be metabolized by CYP7B1 to 
7α-hydroxy-3-oxo-4-cholestenoic acid in vitro, which can rapidly traverse an in vitro 
model of the BBB (Meaney et al. 2007). Furthermore, by measuring the concentrations in 
the internal jugular vein and in the brachial artery of healthy volunteers, a net flux of this 
metabolite from the brain into blood circulation has been demonstrated, which is 
consistent with this being an important terminal metabolite of 27OHC in the brain. 
However, the magnitude of the flux of 7α-hydroxy-3-oxo-4-cholestenoic acid from the 
brain is much lower than could be expected if this was the only metabolite of 27OHC 
leaving the brain (Meaney et al. 2007). If it is confirmed that CYP46A1 metabolizes 
27OHC, it is possible that this activity towards 27OHC is responsible for the discrepancy 
observed by Meaney and co-workers (2007).  
We have previously shown that TSA, an HDAC inhibitor can up-regulate CYP46A1 
expression, by affecting the histone acetylation levels at the proximal promoter (Nunes et 
al. 2010). Moreover, bioinformatic analysis of the 5’ flanking region predicted that the 
proximal promoter region of CYP46A1 is located in a CpG island. We have hypothesized 
that a cross-talk between DNA methylation and HDAC/ HAT dependent-chromatin 
modifications could be involved in the cell-specific expression of this gene. Treatment of 
neuroblastoma cells with the demethylating agent DAC, showed a time- and dose-
dependent derepression of CYP46A1. Furthermore, pre-treatment with DAC, 
synergistically enhanced the TSA mediated up-regulation, pointing to the possibility that 
indeed an epigenetic program could be involved for the tissue-specific expression of 
CYP46A1. Surprisingly, bisulfite sequencing analysis demonstrated that the core 
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promoter is completely unmethylated, even in human tissues where CYP46A1 is not 
expressed, which suggests that DNA methylation of the proximal promoter does not play 
a role in the regulation of CYP46A1 tissue-specific expression. Interestingly, Sp1 binding 
to DNA regulatory elements has been shown to protect CpG islands from methylation 
(Brandeis et al. 1994, Macleod et al. 1994). Since ChIP analysis demonstrated that Sp1, 
Sp3 and Sp4 are bound to the proximal promoter in untreated cells, where CYP46A1 
mRNA is barely detected, it is possible that CYP46A1 proximal promoter is protected 
from CpG methylation by this mechanism. Interestingly, DAC has been reported to 
induce the expression of other unmethylated silenced Sp-regulated genes (Kim et al. 
2003, Yokota et al. 2004, Scott et al. 2006). Nevertheless, we cannot exclude that 
methylation of an enhancer or other regulatory element not yet identified, outside of the 
CYP46A1 core promoter, can interfere with CYP46A1 expression, or that DNA 
demethylation may reactivate an unidentified transcription factor that controls CYP46A1 
expression.  
DAC has been approved by the Food and Drug Administration to treat 
myelodysplastic syndrome and has been shown to effectively traverse the BBB. However, 
the characterization of the molecular mechanisms by which DAC can affect the 
expression of neuronal specific genes in a DNA methylation-independent manner, is not 
well known. We observed that DAC treatment decreased Sp1 and Sp3 protein levels. 
Interestingly, DAC has been shown to affect the levels of specific proteins by inducing 
degradation by the proteasomal pathway (Cecconi et al. 2009, Patel et al. 2010). 
Moreover, we observed a decrease in the binding activity of Sp3 and HDAC1 and 2, to 
the +1 region of the CYP46A1 locus. This decrease in Sp3 is in agreement with previous 
results from our laboratory (Nunes et al. 2010), where we show that a decrease of Sp3 
induced by TSA, favors the detachment of both HDAC1 and 2 from the CYP46A1 
proximal promoter. In fact Sp3 has been demonstrated to physically interact with HDACs 
(Sun et al. 2002, Zhang & Dufau 2002). Loss of Sp3 binding induced by DAC, which 
may be required for HDAC association, may facilitate the TSA-induced derepression of 
CYP46A1, suggesting that DAC can directly induce regional chromatin remodeling, 
independently of its effects on DNA methylation. It would be of great interest to 
understand if, in neuronal cells, DAC treatment induces Sp1 and Sp3 degradation by the 
proteasomal pathway, and if these effects associated with inhibition of HDAC activity are 
sufficient to induce CYP46A1 expression, or if additional neuron-specific factors are also 
necessary to up-regulate this gene.  
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The fact that, so far the only compounds known to up-regulate the expression of the 
CYP46A1 gene are TSA and DAC, drugs that can modify the epigenome, raises the 
question of the use of these agents in the clinic. Several studies have shown that only a 
small subset of genes display altered expression profiles after treatment with this type of 
drugs (Marks et al. 2000, Glaser et al. 2003, Karpf et al. 2004, Shafaati et al. 2009). 
However, it is of the utmost importance to assess both in vitro and in vivo the various 
molecular players and pathways involved in the CNS proper functioning that are affected 
by these drugs, both in normal and in different pathophysiological conditions. For 
instance, although valproate is widely used as a mood stabilizer, a recent clinical trial 
demonstrated significant worsening of agitation and aggression in AD patients receiving 
valproate when compared to placebo (Herrmann & Lanctot 2007). Whether the 
pharmacological manipulation of the epigenome will provide successful therapeutic 
outcomes remains unclear, particularly because current treatments are unable to modulate 
specific genomic regions, and this may increase the risk of off-target responses.  
Our results also raise another unanswered question, regarding the correlation between 
an alteration in the ratio of Sp proteins that are bound to the CYP46A1 promoter and the 
up-regulation of this gene. Indeed, after neuronal differentiation Sp1 is dissociated from 
the promoter, whereas after treatment with DAC it is Sp3 binding that is decreased. 
Although Sp4 binding remains unchanged, our results imply that the shift in the ratio of 
the Sp proteins bound to the promoter is not the single event leading to an increase in 
CYP46A1 expression. In agreement, specific knockdown of Sp3 with siRNAs was not 
sufficient to potentiate TSA-mediated upregulation of CYP46A1 (Nunes et al. 2010). Sp 
proteins suffer a wide range of PTMs, which modulate the activity of these transcription 
factors (reviewed in Wierstra 2008). Phosphorylation is one of the major modifications 
described to regulate Sp proteins transcriptional activity. In fact, Sp1 has been shown to 
be phosphorylated by at least nine kinases, and two phosphatases have also been shown to 
regulate its phosphorylation levels. Interestingly, both DAC and TSA are known to 
activate signaling pathways, which modulate the activity of specific kinases and 
phosphatases (Brush et al. 2004, Wang et al. 2008a, Simboeck et al. 2010, Takano et al. 
2010), which in turn can target Sp proteins. Furthermore, it has been shown that TSA can 
induce changes in Sp proteins PTMs, without affecting Sp binding to the promoter of 
target genes (Zhang et al. 2006, Zhang et al. 2008). Moreover, it has been shown that Sp3 
is regulated by SUMOylation (Sapetschnig et al. 2002, Ross et al. 2002a) and this 
modification leads to local heterochromatic gene silencing (Stielow et al. 2008). 
Concluding Remarks 
 
137 
 
SUMOylation has been shown to be important in both neuronal development (Shalizi et 
al. 2006) and in neurological disorders such as AD (reviewed in Martin et al. 2007). In 
order to thoroughly dissect the underlying mechanisms that lead to an increased CYP46A1 
expression it would be of great interest to study the signaling pathways activated by DAC 
and TSA treatment and during neuronal differentiation, which can induce changes in Sp 
transcription factors PTMs and differentially regulate their transcriptional activity.  
In conclusion, the results presented in this thesis are a significant contribution to the 
definition of the regulatory circuits that control human CYP46A1 expression and may 
prove useful in unraveling potential therapeutic agents and approaches that can modulate 
CYP46A1 expression, and thus control brain cholesterol metabolism in different 
pathophysiological conditions.  
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